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SUMMARY 
The objective of this thesis is to explore the usage trend, clinical efficacy and cost 
effectiveness of various bisphosphonates for management of osteoporosis to be 
used in Singapore based on reported literature.   
 
Firstly, the usage trend of bisphosphonates in KK Hospital is explored 
retrospectively from usage data.  Among patients with a bone mineral density 
(BMD) scan done in KK Hospital, alendronate was prescribed to about 45% who 
were not osteoporotic, and less than 30% of patients defined as osteoporotic 
received a bisphosphonate.  These results indicated suboptimal use of alendronate. 
 
To explore the clinical efficacy of bisphosphonates, a meta-analysis of randomised, 
placebo controlled trials was performed for each of the bisphosphonate in order to 
determine their safety and efficacy profile.  Results of the pooled efficacy and 
safety data were then applied to a cost-effectiveness analysis as well as a decision 
analytic model to allowing for comparison between the agents. 
 
From the meta-analysis of lumbar vertebral and femoral neck BMD results, 
alendronate had the highest improvement in BMD at one, two and three years.  
There were insufficient data available for tiludronate, pamidronate and ibandronate 
for three years of usage or more. 
 
Among the other 4 agents (alendronate, clodronate, etidronate and risedronate), 
etidronate was the most cost effective agent when compared for either lumbar 
  xi 
vertebral or femoral neck bone mineral density, even with various one-way 
sensitivity analysis being applied.  Alendronate ranked second, followed by 
risedronate and then clodronate.  With the decision analytic model, the arm with no 
treatment provided the lowest expected value of treatment for all one-, two- and 
three-year models, followed by etidronate.  The marginal values between 
risedronate and alendronate were minimal, ranking third and fourth respectively.  
Clodronate was ranked the last among the agents. These results showed that from 
the public health prospective, it would not be cost-effective to provide prophylactic 
treatment for all postmenopausal women using bisphosphonates. 
 
In patients who require the use of bisphosphonate, the analyses suggests etidronate 
to be the choice of treatment for prevention of osteoporotic fractures and 
alendronate as an alternative for patients who can afford its higher price.   
  1 
CHAPTER 1: INTRODUCTION – IMPACT OF OSTEOPOROSIS 
1  
1.1 Introduction to Osteoporosis 
Osteoporosis is a systemic skeletal disease of low bone mass, characterised by reduced 
cortical thickness and density (number as well as size) of the trabeculae in cancellous 
bones throughout the body.  This condition predisposes patients to an increased risk of 
fractures, such as vertebral compression fractures and traumatic fractures of hip or wrists 
due to falls. 
 
The World Health Organisation (WHO) issued the following guideline to classify 
conditions of low bone mineral density (BMD) in 1994 1-3 
• Normal - a BMD value more than 1 standard deviation (SD) below the young 
adult mean in the population. This classifies 84.1% of the young adult population 
as normal and 15.9% as abnormal. 
• Osteopenia (Low bone mass) - a BMD value between 1 and 2.5 SD below the 
young adult mean. This classifies 15.2% of the young adult population as 
osteopenic.  
• Osteoporosis - a BMD value less than 2.5 SD of the young adult mean. This 
classifies 0.6% of the young adult population as osteoporotic  
• Severe Osteoporosis (or Established Osteoporosis) - a BMD value more than 2.5 
SD below the young adult mean and the presence of one or more fragility 
fractures.  
 
  2 
 
 
Osteoporosis may be classified in 2 broad categories depending on etiology. 4, 5 
• Primary 
 Type 1 : Postmenopausal osteoporosis manifested in postmenopausal women, 
characterised by disproportionate loss of cancellous bone 
 Type 2 : Age-associated osteoporosis, which affects both cancellous and 
cortical bone as a result of senile decline in bone mass 
• Secondary 
 Osteoporosis with an identifiable cause of bone mass loss eg. glucocorticoid 
induced osteoporosis, or by a disease such as hyperthyroidism or myeloma 
 
Osteoporosis is a chronic condition which increases the risks of fractures.  Unlike men, 
whose BMD gradually decrease with age, women at menopause experience a significant 
reduction in circulating estrogen levels in the body, resulting in a sharp drop in the BMD 
over a period of a few years after menopause. 6-8  Hence, traditionally, there has been more 
focus put on the study of interventions for osteoporosis in women. 
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1.2 Incidence of osteoporosis in Singapore 
There are a number of factors which may predispose an increasing proportion of women 
in Singapore to postmenopausal osteoporosis. 
 
Firstly, Singapore sees a trend of increase in life expectancy with improved healthcare 
standards.  The Ministry of Health 2001 Annual Report estimates an average increase of 
25% in life expectancy of women from 1956 to 2000 (from 65.2 to 80.0 years). 9  This 
results in an increase in both the proportion of women living past menopause as well as 
the average number of years in which they live past menopause.  It has been shown that 
the incidence of fracture among women increases with age.  One study in Australia 
estimated the proportion of women expected to sustain a fracture to increase from 1.9% of 
the population under 55 years to 49.1% of women over 89 years of age. 10 
 
Secondly, the average level of daily physical activity in Singapore has reduced with 
lifestyle changes and progress in society, with changes such as improved transportation 
systems, higher proportion of white collar workers and increasing employment of 
household maids etc.  In a survey in 1998, only 20 to 30 percent of the local population 
between 40 to 70 years of age exercise regularly, with women having a consistently lower 
percentage as compared to men. 11  There have been many studies correlating exercise and 
bone stress with reducing risks of osteoporosis as well as reports of higher rates of 
osteoporosis in “developed” as compared to “developing” countries. 12-17  Hence, a general 
reduction in exercise may lead to an increased proportion of the population being prone to 
develop osteoporosis. 
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1.3 Clinical impact of osteoporotic fractures 
Locally, no report was found on the prevalence of postmenopausal osteoporosis.  
However, there are evidence that fracture rates has been increasing in Singapore.  One 
study reported the rate of hip fractures as having increased by 38 per cent, from 42 cases 
per 100,000 in 1990 to 58 in 1999. 18  A study by Koh et al in 2001, reported the hip 
fracture incidence rate in Singapore between 1991 and 1998 to have increased 1.2% 
annually in women above 50 years of age.  The study also reported Singapore to be one of 
the highest among Asian countries in hip fracture rates. 19  It can be inferred from these 
studies and the demographic changes that a significant contribution to the increased 
fracture rate is due to the increased number of women with osteoporosis. 
 
The consequences associated with osteoporotic fractures can be serious.  A study of 
patients who have sustained osteoporotic hip fractures in Singapore reported a mortality of 
26% in the first year.  Of the survivors, 9% were bedridden while 24% were wheelchair 
bound. 20   
 
A number of foreign studies have also reported similar or even higher mortality rates.  
One epidemiology study in the United States of America associated a 20 to 40% risk of 
death within 6 months in patients who sustain a hip fracture. 21  Similarly, an European 
case series reported a three-month mortality of 20.6% whereas an Irish case series 
reported a 27% mortality with three months of follow-up. 22, 23 
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1.4 Financial impact of postmenopausal osteoporotic fractures in Singapore 
The financial impact of osteoporotic fractures on overall healthcare costs in Singapore 
could be first explored by quantifying the costs of hip or vertebral fractures in women.  
The costs were estimated from the local rate of hip and vertebral fractures and the costs of 
treatment. 
 
The baseline fracture rates of Asians were first obtained from two epidemiology studies. 
19, 24
  One study by Koh et al, 2001 collated local fracture rate data from 1991 to 1998.  
The other study by Lau et al, 2001 looked at data from 1997 to 1998.  Both studies 
reported differential fracture rates based on age range of patients.  Local data based on 
hospital admissions was available for rate of hip but not vertebral fractures. 
 
From another local study, the mortality at one year after a hip fracture was about 25%. 25 
Assuming that these patients would be treated for the complications associated with hip 
fractures before death, the estimated costs of fractures based on local data of total cost 
before government grant (TCBGG) would be as follows : 
Hip Fractures per 100,000 per year 
Age 
Lau et al, 200124 Koh et al, 2001 19 
Estimated direct cost of hip fractures 
per 100,000 patients per year ($) 
50-54 22 12.4 55,475 - 98,423 
55-59 34.5 33.9 151,660 – 154,344 
60-64 48.6 54.2 217,424 - 242,477 
65-69 98.6 238.1 441,112 - 1,065,200 
70-74 210 384.1 939,488 - 1,718,367 
> 75 611 1352.5 3,578,474 - 7,921,254 
 
Table 1.1 : Direct costs of hip fractures based on total costs before government subsidy 
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The rate of vertebral fractures was more difficult to quantify as many incidences if not 
severe, may not be presented to the hospital.  Two Asian studies available reported 
prevalence instead of rate of occurrence of vertebral fractures. 26, 27 
 
A review by Kanis et al compared the incidence of hip fractures between a Singaporean 
and Swedish study, and extrapolated the rate of vertebral fractures to be of a factor of 0.62 
as compared to that reported in the Swedish study. 28  Results from another Australian 
study which reported on the rate of vertebral fracture was available. 29  It reported a very 
similar rate of vertebral fractures in women more than 55 years of age as compared to the 
extrapolated data from the Sweden study.   Hence both studies were utilised to determine 
the estimated range of direct costs of vertebral fractures. 
 
Similar to the hip fracture cost estimation, a complication rate of 25% was utilised to 
calculate the direct healthcare costs of vertebral fractures.   As the complication rate was 
not reported in either study, a 25% complication rate was estimated based on the July 
2000 to March 2001 volume of cases for DRGs of complicated and uncomplicated back 
problems in restructured hospitals, which were 840 and 2235 cases respectively. 
Vertebral Fractures per 100,000 per year 
Age 
Kanis, 2002 28 Sanders et al, 1999 29 
Estimated direct cost of vertebral fractures 
per 100,000 patients per year ($) 
50-54 100 50 $105,663 - 211,325 
55-59 98 90 $190,193 - 207,099 
60-64 188 200 $397,291 - 422,650 
65-69 272 310 $574,804 - 655,108 
70-74 482 510 $1,018,587 - 1,077,758 
> 75 688 – 721 760 – 770 $2,463,556 - 2,757,178 
 
Table 1.2 : Direct costs of vertebral fractures based on total costs before government subsidy 
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An estimation of the total financial burden could then be obtained by using information on 
population breakdown by age in Singapore as of June 2001 30 (Table 1.3) and assuming 
osteoporotic hip and vertebral fractures to be independent events.  From this, the total 
costs per year due to hip and vertebral fractures in Singapore were calculated in the 
following table (Table 1.4). 






> 75 50,600 
 
Table 1.3 : Breakdown of number of Singapore women by age range 
 
Age Hip Fractures Vertebral Fractures 
50-54 $ 61,965.02 - 109,937.93 $ 118,025.01 - 236,050.03 
55-59 $ 96,000.86 - 97,699.99 $ 120,391.85 - 131,093.35 
60-64 $ 132,628.79 - 147,911.12 $ 242,347.51 - 257,816.50 
65-69 $ 208,204.75 - 502,774.34 $ 271,307.49 - 309,210.74 
70-74 $ 352,307.81 - 644,387.77 $ 381,969.94 - 404,159.06 
> 75 $ 1,810,707.97 - 4,008,154.71 $ 1,246,559.34 - 1,395,131.82 
Total $ 2,661,815.20 - 5,510,865.86 $ 2,380,601.14 - 2,733,461.49 
 
Table 1.4 : Costs of Fractures in the population in different age range 
 
In total, the costs of hip and vertebral compression fractures alone would result in an 
approximate $5 to 8 million per year in healthcare costs.  Based on the year 2000 
healthcare expenditure of $ 4.7 billion or 3% of the gross domestic product (GDP), this 
works out to be 0.11 to 0.17% of the total healthcare expenditure in Singapore. 
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Due to the high financial burden, it is therefore of utmost importance that among the 
numerous pharmacological agents for prevention and treatment of postmenopausal 
osteoporosis, clinically effective as well as cost effective therapies be chosen. 
  9 
CHAPTER 2: MANAGEMENT OF OSTEOPOROSIS – ROLE OF 
BISPHOSPHONATES 
2  
2.1 Overview of agents for osteoporosis 
A wide range of pharmacological agents indicated for the management of postmenopausal 
osteoporosis are available in Singapore.  Examples of such agents include the 
• Bisphosphonates : Alendronate, Etidronate, Risedronate 
• Selective estrogen receptor modulators : Raloxifene 
• Vitamin D analogues : alfacalcidol 
• Natural and synthetic hormones : Teriparatide, Nasal Calcitonin, Tibolone, 
estrogens and progestogens, Flavinoids 
• Minerals : Calcium, Fluoride, Magnesium, Ossein-hydroxyapatite, Boron 
 
Studies have also correlated the effects of non-pharmacological modalities such as 
exercise programs and diets to the prevalence of osteoporosis.  Experimental therapies 
such as the use of HMG-CoA reductase inhibitors eg. simvastatin have also been explored 
for the management of osteoporosis. 31-33 
 
It may be interesting to note that for alendronate, only the 10mg and 70mg preparations 
are available in Singapore.  The 5mg preparation, which is approved in the United States 
for prevention of osteoporosis in postmenopausal women without osteoporosis, is not 
available and the company, MSD has no plans to bring it into Singapore in the near future. 
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2.2 Pharmacological agents for osteoporosis in KK Hospital  
In KK Women’s & Children’s Hospital, the following pharmacological therapies for 
management of primary Type I osteoporosis were available in Year 2001:  
• Bisphosphonates : Alendronate 
• Selective estrogen receptor modulator (SERM) : Raloxifene 
• Synthetic steroidal agent : Tibolone 
• Hormone replacement therapy (HRT) preparations eg. Prempak C, Activelle, 
Conjugated Estrogen, Estradiol valerate, Estradiol hemihydrate, Progesterone 
Medroxyprogesterone and Dydrogesterone 
• Vitamin D analogue : Alfacalcidol 
• Calcium supplements 
 
Among these agents, four were among the list of top 20 drugs in expenditure (quantity X 
patient price) in Year 2001.  They were : 
DRUG Expenditure 
Alendronate (Fosamax) $724,929.95 
Raloxifene (Evista) $280,940.00 
Conjugated Equine Estrogen (Premarin) $276,448.21 
Medroxyprogesterone (Provera) $149,222.66 
 
Table 2.1 : Expenditure of drugs for osteoporosis from KK Hospital 
 
Alendronate topped the list with three-quarter of a million dollars spent on the agent alone 
in year 2001.  With recent adverse reports of cyclical combined HRT being associated 
with an increased risk of breast cancer as well as the lack of beneficial benefits on 
prevention of coronary heart disease, 34 the usage volume and therefore, financial  impact 
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of HRT is expected to be reduced.  Conversely, newer therapies, which are generally more 
costly as compared to conventional HRT, are likely to become more widely used. 
 
In view of the high financial impact of alendronate, as well as the availability of 
alternative bisphosphonates, a retrospective drug usage review was done on the drug to 
look at the appropriateness of prescribing of alendronate in KK Hospital. 
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2.3 Pre-study review of alendronate usage in KK Hospital  
Details of patients who were prescribed alendronate and those who had a BMD 
measurement in year 2000 or 2001 were retrieved from the respective computerised 
systems and analysed. 
 
The usage of alendronate had increased significantly in year 2001.  The average number 
of defined daily dose (DDD) per working day increased from approximately 450 in 
January 2001 to more than 1000 DDD per working day in December 2001 (Figure 2.1). 
 
The total DDD from alendronate for year 2001 was 245,567 and total healthcare 
expenditure attributed to alendronate was more than $700,000.  A total number of 1158 
distinct patients were prescribed alendronate, each spending an average of $600 on the 




















Figure 2.1 : Average number of defined daily dose of alendronate used per month from Jan to Dec 2001 






































































Figure 2.2 : Moving average of defined daily dose of alendronate used per month from Jan 2000 to Dec 2001 
 
In the same year, 3632 patients (3645 sets of BMD scans) received BMD scans in KK 
Women’s & Children’s Hospital.  A breakdown of the results of the lumbar vertebral and 
femoral neck BMD scans are as shown in the table below. 
 
 
No. of sets 
of valid data 
< -2.5 SD 
(% of valid data) 
-1.0 to -2.5 SD 
(% of valid data) 
> -1.0 SD 
(% of valid data) 
Lumbar (L1-4) T-Score 3461 1040 (30.05%) 773 (22.33%) 1648 (47.62%) 
Lumbar (L1-4) Z-Score 3452 248 (7.18%) 766 (22.19%) 2438 (70.63%) 
Femoral Neck T-Score 3462 136 (3.93%) 576 (16.64%) 2750 (79.43%) 
Femoral Neck Z-Score 3450 4 (0.12%) 107 (3.10%) 3339 (96.78%) 
 
Table 2.2 : Number (percentage) of patients with T-scores and Z-scores classified as osteoporotic, osteopenic or normal 
 
Among patients who received a BMD scan, 543 of the 3632 patients (15%) received at 
least one prescription of alendronate after their BMD scan.  Data-matching revealed that 
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the 543 patients represented 47% of all patients who were prescribed alendronate in Year 
2001. 
 
Among the patients prescribed alendronate, a breakdown of their BMD results taken 
before their prescription of alendronate were as follows: 
 
 
No. of sets 
of valid data < -2.5 SD 
-1.0 to -2.5  
SD > -1.0 SD 
Lumbar (L1-4) T-Score 542 295 (54.43%) 126 (23.25%) 121 (22.32%) 
Lumbar (L1-4) Z-Score 541 99 (18.30%) 172 (31.79%) 270 (49.91%) 
Femoral Neck T-Score 542 46 (8.49%) 144 (26.57%) 352 (64.94%) 
Femoral Neck Z-Score 540 0 (0.00%) 24 (4.44%) 516 (95.56%) 
 
Table 2.3 : Number (percentage) of patients on alendronate with T-scores and Z-scores classified as osteoporotic, 
osteopenic or normal 
 
Of the 1040 patients with lumbar (L1-4) T-score below 2.5 standard deviations (Table 
2.2), which according to the WHO definition would indicate osteoporosis, only 295 
(28.4%) were prescribed alendronate.  This was despite the fact that bisphosphonates had 
been recommended as one of the choice of therapy for treatment of established 
osteoporosis.  One possible reason could be the lack of affordability of alendronate, the 
only bisphosphonate that was available in the hospital at that time. 
 
On the other hand, 247 (45.6%) of 542 patients, who were not osteoporotic by lumbar T-
score definitions, were prescribed alendronate for treatment of osteoporosis.  A significant 
proportion of patients from this group could represent those who were either able to afford 
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the drug or were under some form of healthcare benefit scheme which paid for a 
significant percentage or all of their medication bills. 
 
Extrapolating from the total healthcare expenditure attributed to alendronate, prescribing 
of alendronate 10mg daily to non-osteoporotic patients could potentially result in more 
than $300,000 per year in drug expenditure in KK Hospital alone. 
 
The usage evaluation on alendronate indicated a possibility of patients who required but 
could not afford bisphosphonates as well as a significant proportion of patients who may 
be inappropriately prescribed alendronate. 
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2.4 Clinical guidelines on osteoporosis 
Though guidelines for management of postmenopausal osteoporosis from KK Hospital as 
well as by the Ministry of Health (MOH) are available, these guidelines did not specify 
the bisphosphonate of choice to be used for treatment of osteoporosis based on the local 
context. 
 
The MOH Clinical practice guidelines listed 5 bisphosphonates under the treatment table 
for osteoporosis, namely alendronate, clodronate, etidronate, risedronate and 
zoledronate.35  The KK Hospital Menopause Management Guidelines listed alendronate 
for prevention of osteoporosis; alendronate, clodronate and risedronate for treatment of 
osteoporosis. 36 
 
However, the guidelines available are derived from data from Caucasian populations.  The 
lower fracture rates in Asian as compared to Caucasian populations with similar BMD 
could affect the decision to treat and hence, the applicability of these guidelines to Asian 
populations. 37-39  Hence, there may be a need to look at other factors that may affect 
clinical decision for treatment of osteoporosis in our local context, such as the correlation 
between age of patients and rate of fractures in the Asian population. 
 
With this analysis, if a unique set of guidelines may be established, it may also be 
applicable for Asians living among Caucasian populations. 
 
To establish guidelines, the relative efficacy of the bisphosphonates have first to be 
established.  Ideally, in order to determine the most efficacious bisphosphonate, a multi-
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arm head-on randomised controlled trial between the bisphosphonates reporting on 
fracture rates would be required.  However, until recently, most trials were placebo-
controlled and the very few head-on comparisons have been published. 40, 41 
 
Moreover due to the low rate of osteoporotic fracture in the general population, a large 
patient population trial over a long duration would probably be required to demonstrate 
efficacy of fracture against placebo, and an even larger or longer trial to demonstrate 
statistically significant difference among the various bisphosphonates. 
 
Due to the large amount of resources required to carry out a clinical trial measuring 
clinical endpoints such as fracture rates, it is not feasible to carry out such trials in the 
local environment.  As an alternative, it would therefore be appropriate to perform a meta-
analysis in order to study the efficacy and safety profile of bisphosphonates for prevention 
of fractures in women with postmenopausal osteoporosis. 
 
Performing a meta-analysis would also provide the necessary data to construct a 
pharmacoeconomic model which could be used to simulate head-to-head comparisons 
between the agents. 42, 43 
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2.5 Economic considerations of bisphosphonates 
As of June 2002, there are seven bisphosphonates registered in Singapore. 44  They are 
Alendronate (Fosamax), Clodronate (Bonefos), Etidronate (Difosfen), Pamidronate 
(Aredia), Risedronate (Actonel) and Tiludronate (Skelid) and zoledronate (Zometa).  
A brief overview of the bisphosphonates can be found in Appendix 1. 
 
Among these bisphosphonates, etidronate is least expensive in acquisition costs.  Though 
claimed by some clinicians to have lower efficacy for treatment or prevention of 
osteoporosis, studies have reported efficacy in preventing both vertebral and non-vertebral 
fractures. 45-47  It is however, currently not available in KK Hospital’s drug listing.  
Risedronate, a recently registered alternative to alendronate, has just been made available 
in the hospital.  It is lower in acquisition costs to alendronate, but again, there have been 
claims that it is of lower efficacy due to poorer compliance as compared to weekly 
adminstered alendronate. 48 
 
As of current, none of the bisphosphonate is subsidised by the government.  Due to the 
relatively higher acquisition costs of bisphosphonates, a pharmacoeconomic analysis 
comparing the various agents would provide additional information regarding cost-
effectiveness for the Hospital P&T Committees as well as MOH Drug Advisory 
Committee when making decisions either to include agents into the hospital formulary or 
to provide subsidy for such agents. 
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These data would assist the streamlining of bisphosphonates kept in each institution and 
allow for improved stock holdings and inventory control, which would indirectly lead to 
reduced healthcare costs. 
 
In summary, with the above clinical and economic considerations, the results from this 
thesis evaluating the bisphosphonates would provide significant insights on prevention of 
fractures in women with postmenopausal osteoporosis in Singapore. 
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CHAPTER 3: OBJECTIVES 
3  
3.1 Primary objective 
The primary objective of this thesis is to elucidate the most appropriate bisphosphonate 
for prevention of hip and vertebral fractures in postmenopausal women, taking local 
costing factors and fracture rates into consideration. 
 
3.2 Secondary objective 
Furthermore, the pharmacoeconomic models constructed for the current study might 
provide a base model for comparing the cost-effectiveness of newer osteoporotic agents 
against the bisphosphonates in the future. 
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CHAPTER 4: METHODOLOGY 
4  
4.1 Summary 
a. A hand-search were done for 3 relevant journals to obtain published randomised 
controlled trials on bisphosphonates for prevention of postmenopausal 
osteoporosis 
b. Based on the articles retrieved, the inclusion criteria, exclusion criteria and search 
methodology were formulated 
c. The search methodology was then applied to retrieve relevant literature on the 
topic 
d. Studies retrieved were evaluated using a set of pre-defined inclusion and exclusion 
criteria, as well as scored on quality based on a pre-defined questionnaire 
e. The full-text of the articles that may possibly be included were retrieved 
f. Relevant data was extracted by the author from each study and transcribed into 
Review Manager version 4.1 for pooling of data. 49 
g. Heterogeneity of the meta-analysis results were tested using various criteria. 50 
h. Correlation studies with osteoporotic fractures were carried out on surrogate 
efficacy variables utilised 
i. Pharmacoeconomic analyses were then performed using the decision analysis 
software DATA (version 3.5 by Treeage) 51  using a broad societal perspective 52 
to ensure applicability of results to the health authority and congruity with the 
perspective of public health. 
j. Sensitivity analyses were also performed on the models.  
k. No outside university funding assistance was utilised in carrying out the study 
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Figure 4.1 : Flowchart of the overview of the methodology 
Hand Search for 
Literature
5 random articles 
with fulltext chosen
1. Formulate Efficacy & Safety Variables
2. Establish Inclusion & Exclusion Criteria
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4.2 Literature search and retrieval 
A systematic approach was employed to identify relevant randomised control trials 
comparing individual bisphosphonates with placebo for prevention of postmenopausal 
osteoporosis. 
a. A manual search of the last 3 years (June 1998 to June 2001) of 3 osteoporosis 
related journals available in the University Medical library was carried out.  These 3 
journals have relatively high journal impact factor of above 3. 53  The 3 journals 
were : 
- Osteoporosis International (via Springer Verlag website) 
- Bone (via Elseiver ScienceDirect website) 
- Journal of Bone and Mineral Research (via American Society for Bone and 
Mineral Research website) 
b. Specific keywords were retrieved from articles in the 3 journals.  They were : 
- Drug related keywords : truncated forms of Alendronate, Clodronate, 
Etidronate, Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronate  
- Drug Related  Medical subject headings (MeSH) : “diphosphonates” 
- Non-drug MeSH : “Osteoporosis, Postmenopausal” and “bone density” and 
“Fractures” 
c. A search strategy adapted from Dickersin et al, 1994 for use in OVID Medline and 
PreMedline bibliographic databases was then drawn up to include the above 
keywords. 54 (See Appendix 2) 
d. OVID citations autoalert was subscribed to in order to ensure that new articles 
before the cut-off date of June 2002 were not missed out.  The subscription features 
an automatic selective dissemination of information (SDI), which enables automatic 
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searching of the outlined search strategy for any new citations whenever there is an 
update to the database and notification via email.  (see Appendix 3). 
e. A search was then performed on the National Library of Medicine (NLM) Medical 
Literature Analysis and Retrieval System Online (MEDLINE) as well as the 
Cochrane Controlled Trial Register (CCTR) provided by OVID Technologies. 
f. In order to optimise the retrieval of relevant studies, the following steps were taken. 
- Individual drug companies were approached for any available randomised 
control trials for evaluation. 
- Citations were obtained with those from the US National Library of Medicine 
Current Bibliographies in Medicine for Osteoporosis 55 and individual drug 
monographs under the Micromedex Drugdex. 56 
- Citations were also obtained from bibliographs of available review articles or 
meta-analyses that were available to the author 
g. Three other persons experienced in literature search were also approached to 
independently formulate a search strategy on the topic.  They were a : 
- Medical Librarian from KK Hospital 
- Drug information service pharmacist from National University Hospital, 
Singapore 
- Product specialist from OVID, vendor of MEDLINE utilised for performing 
the bibliograhic database searches 
h. All 3 were instructed to construct an optimally search strategy to retrieve 
randomised, placebo controlled trials on the topic “bisphosphonates for 
postmenopausal osteoporosis, reporting on spinal or vertebral bone mineral density 
and / or fracture rates”. (see Appendix 2) 
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i. Based on all potentially relevant studies obtained, the specificity (proportion of 
publications retrieved that were relevant randomised clinical trials, a measure of 
precision) and sensitivity (proportion of the total number of known randomised 
clinical trails identified by the search, a measure of accuracy) as defined by 
Dickersin et al 54 were calculated for the search strategy designed in order to 
determine if the search strategy was optimally sensitive without compromising for 
precision. 
j. A search strategy similar to that utilised to retrieve efficacy studies was applied to 
retrieve articles reporting on side effects of bisphosphonates. 
Specific Keywords retrieved were as follows: 
- Drug related : truncated forms of Alendronate, Clodronate, Etidronate, 
Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronate as well as 
the MeSH headings “diphosphonates” 
- Non-drug Medical Subject Headings : “Osteoporosis, Postmenopausal”, 
Gastrointestinal diseases, Gastrointestinal haemorrhage, Peptic ulcer 
haemorrhage, Stomach ulcer or Duodenal ulcer or Gastritis 
- Non-drug Keywords: Gastrointestinal, ulcer, adverse, side effect and wild card 
search of “tolera” to include keywords such as tolerability, tolerance, 
tolerating etcetera. 
k. All studies retrieved for efficacy data were also manually searched for relevant 
information reported on gastrointestinal side effects. 
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4.3 Criteria 
The inclusion and exclusion criteria were first defined, tested and refined with five 
randomly chosen articles to ensure that all aspects were covered and minimise any ad hoc 
changes later. 
 
4.3.1 Inclusion criteria 
Studies to be included for evaluation and analysis were required to fulfil the following 
criteria: 
a. Study design must be placebo controlled, parallel, prospective and appropriately 
randomised.  (Non-randomised studies were not included as it has been shown in 
many clinical topics to produce statistically significant discrepancies in magnitude 
of treatment effect to randomised studies.) 57 
b. All studies regardless of dosing regimen were included.  Subgroup analysis was 
done utilising the dosing regimen recommended by manufacturer (if available) for 
prevention of postmenopausal osteoporosis.  If the manufacturer did not provide 
any recommendation, the dosing range found to be effective and recommended in 
dosing range studies was utilised instead. 
c. Only studies measuring and reporting the following outcomes were included for 
analysis of efficacy of bisphosphonates :  
- Spinal BMD, a surrogate marker of vertebral fracture rate 
- Hip (Femoral Neck) BMD, a surrogate marker of hip fracture rate 
d. Only studies measuring and reporting the following outcomes were included for 
analysis of safety of bisphosphonates :  
- All gastrointestinal side effects 
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- Serious gastrointestinal toxicity 
Studies that only report all gastrointestinal side effects were included in the meta-
analyses for “all gastrointestinal side effects” but not included in the data pooling 
for “severe gastrointestinal side effects. 
e. Only measurements of BMD utilising Dual Energy X-Ray absorptiometry (DEXA) 
machines such as the Hologic QDR, Norland XR or Lunar DPX-L were included 
in the analysis since DEXA machines are reported to have the highest 
reproducibility with assessing of BMD. 58  Moreover, it has been suggested that 
other techniques such as quantitative computed tomography may provide poor 
correlation. 59, 60 
f. Studies on patients with or without prior fractures before being put on 
bisphosphonates were included in the meta-analysis as prior fractures is not 
expected to significantly change the BMD response to bisphosphonates. 
g. All studies, including North american and European studies are included in the 
meta-analysis.  The results were subsequently extrapolated to perform a 
pharmacoeconomic analyses based on local cost factors to determine the most 
appropriate bisphosphonate for fracture prevention 
 
4.3.2 Exclusion criteria 
a. Studies without sufficient information after unsuccessful attempt to contact the 
author(s) for additional information were excluded from the analysis 
b. Studies of drugs for indications other than Type I primary osteoporosis.  The only 
exception was for studies in women who have undergone total hysterectomy as 
they would have a physiologic condition similar to postmenopausal women 
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c. Studies from the same trial appearing in different journals after checking for : 
- similar authors / institution address 
- similar initial patient size 
- similar trial acronym 
d. Non-english articles are excluded 
 
  29 
4.4 Initial evaluation of literature  
a. The citation and abstracts of all studies retrieved were first imported into Endnote 
version 5.0.2,  a citation management software. 61 
b. All citation abstracts were scrutinized to remove obviously irrelevant articles.  All 
citations for review articles, letters, editorials and meta-analyses were also 
removed. 
c. The full-text of the remaining studies were then obtained, including those that 
could not be determined to be relevant or not from their title and/or abstracts 
d. The methods section of the full-text articles were then carefully studied to 
determine if they fulfilled the inclusion and exclusion criteria for the meta-analysis 
as listed above. 
e. Quality of the studies to be included in data pooling were also evaluated by a pre-
determined scoring system as shown below. 
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4.5 Assessing quality of studies 
To score the quality of trials included based on the initial evaluation, the following 
inclusion criteria were added: 
- Specific mention of randomisation of patient population to the interventions 
- Clear description of methodology of trial on how relevant variables were determined 
 
In addition, the studies were scored using the following questions adapted from a number 
of questionnaires structured to measure the likelihood of bias. 62-64  All studies were 
scored on a scoring scale of -2 to +5 points based on 5 questions as follows: 
 
a. Was randomisation stated in study? 
- mentioned in study        1 
- unclear whether randomisation was done (go to Q3)   0 
@ but coded as a RCT (Randomised Controlled Trial) in bibliographic database 
 
b. If yes, was the method of sequence generation for randomisation adequate? 
- adequate e.g. block randomisation / computer generated  1 
- unclear / not stated       0 
- inadequate e.g. alternating, arranged according to birthday * 1 
 
* Any way whereby the patient has an unequal chance of being allocated a 
particular intervention arm.  For unblinded studies, randomisation was also considered 
inadequate if there was any indication that patients switched treatment after start of trial 
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c. Was double blinding stated in study ? 
- Stated that both investigator / patient are blinded   1 
- Double blinding not carried out in study (go to Q5)   -1 
- Not stated if double blinding was implemented   0 
 
d. If yes, was it adequate ?  Example - utilising double dummy if required 
- Adequate to conceal       1 
- Inadequate to conceal       -1 
- method is not clearly mentioned     0 
 
e. Were drop-outs or excluded patients adequately accounted for ? 
- Patients excluded / dropped out were accounted for #  1 
- Patients excluded / dropped out do not tally in study results or if dropouts 
were specifically mentioned, but not accounted for at all  -1 
- Unknown if there were any excluded or dropped out patients 0 
#  includes studies whereby it is specifically stated that no patients had dropped out.  
If the numbers cannot be tallied due to the final number of patients not reported or the 
number of dropouts not reported, than, a score of zero is given. 
 
A sensitivity analysis was carried out with trials having a quality score of 2 and above to 
determine if studies with higher quality significantly affected the outcome variables.  
Score of 2 is chosen arbitrarily as it is above the midpoint of the scale (see below). 
2 3 4 5-2 -1 0 1
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4.6 Efficacy and safety variables 
From all the studies that were included for the meta-analysis, data on two continuous 
variables measuring efficacy were obtained.  They were the percentage change in bone 
mineral density of spine (lumbar vertebral) and hip (femoral neck) from baseline as 
compared to placebo. 
 
BMD measurements are objective and would preclude the need for chosen trials to be 
blinded.  It was chosen as a surrogate marker for fracture rate as there may be insufficient 
data reported on fracture rate for many of the pharmacological therapies and BMD has 
been shown in previous studies to be a reliable predictor of fracture rate. 2, 65-69  Moreover, 
many of the older studies also reported mainly bone mineral density and not fracture rates.   
 
Many studies either included some patients with fractures and some without or did not 
have baseline fragility fracture as an inclusion / exclusion criteria.  Hence, it is not 
possible to correlate if at endpoint, reported rate of fractures is attributable to patients with 
or without fractures at baseline.  Using BMD as a surrogate marker would circumvent this 
difficulty, since patients irregardless of fracture history, is not expected to have a different 
improvement in BMD to the same bisphosphonate. 
 
In order to ascertain a correlation between risk of fractures and BMD, studies that report 
both BMD and fracture rate were analysed.  The relative risk of hip, vertebral, any non-
vertebral and any fracture of individual study was then plotted against spinal and femoral 
BMD to obtain a linear model describing the correlation. 
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For purposes of uniformity of data extraction, if more than one location of spinal BMD 
were reported, the average posterior-anterior lumbar (L1-4) vertebral spinal BMD was 
utilised.  If more than one location of hip BMD was reported, the femoral neck BMD was 
utilised.  Femoral neck BMD was utilised as until recently, consensus has been to make 
clinical decisions based on femoral neck BMD, 70 and it was therefore, the most 
commonly reported type of hip BMD in studies for postmenopausal osteoporosis. 
 
As for safety variables, only the gastrointestinal side effect profile of bisphosphonates was 
evaluated. Studies have generally reported bisphosphonates to be well tolerated with 
adverse effect profiles comparable to placebo. 71  This is with the exception of 
gastrointestinal side effects such as esophagitis and epigastric pain, which have been 
reported in some aminobisphosphonates. 72-76 
 
Most randomised controlled trials report the incidence of general gastrointestinal side 
effects such as dyspepsia, gastric ulceration, bleeding, diarrhea, constipation, nausea and 
vomiting and any other related gastrointestinal side effects.  Some studies also reported 
severe gastrointestinal side effects defined as gastric or duodenal perforation, ulceration or 
bleeding.  This data was also extracted if reported in the study. 
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4.7 Pooling of efficacy data 
Efficacy data were pooled and analysed in the following sequence : 
a. The mean effect size of treatment arms was obtained from the full-text article. 
- If the mean and standard error of effect size was not reported but presented 
in graphs, the graphs were imported into Intellicad (a CAD Computer 
Aided Design software) for the effect size to be measured. 77 
b. The standard deviation (SD), standard error of mean (SEM) or confidence interval 
(CI) were obtained from each study. 78, 79    Since Revman v4.1 only allows entry 
of data as mean and deviation in pooling of data, SEM values are converted to SD. 
- If SEM was reported, the SD was estimated using the following formulae:  
 SD = SEM x (n)1/2 
- If CI was reported, the SEM was estimating using the following formulae:  
 SEM = (mean - lower confidence interval)/z  
where z is the z-statistics  (99% CI : z = 2.576, 98% CI : z = 2.326, 96% 
CI : z = 2.054, 95% CI : z = 1.960, 90% CI : z = 1.645) 
- For studies reporting the BMD and SE or SD of each study arm before and 




 = [(n1 – 1)s12 + (n2 – 1)s22] / (n1 + n2 – 2) 
- For results whereby more than one control group was available, the pooled 























- If neither SEM, SD nor CI was reported, the standard deviation of the 
outcome variable is estimated using the mean coefficient of variation of the 
other trials, weighted by sample size of each study 
c. If number of patients completing was not reported or accounted for, the number of 
patients randomized will be utilised instead 
d. Data was then entered into RevMan version 4.1 49 for calculation of pooled effect 
size and 95% confidence interval. 
e. For percentage change in lumbar or femoral BMD which is a continuous variable, 
the software calculates the weighted mean difference (WMD) and standard error of 
the WMD (seWDM) using the following formulae 80 : 
- WMD = m1 – m2   
 
- seWDM =  
 
Refer to table below for definitions : 
 Group size Mean Response Standard deviation 
Intervention n1 m1 sd1 
Control n2 m2 sd2 
 
Table 4.1 : Definition of group size, mean response and standard deviation in formulae 
 
 Data is pooled using the Inverse Variance Method (Fixed effects model). 
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- Heterogeneity statistic (Q) is obtained from the inverse variance of wt 
 Q =  Θ−Θ 2)ˆˆ( IVttw  
where tΘˆ is the WMD of effect size between treatment and control of each 
trial and IVΘˆ  is the pooled estimate by inverse variance method 
f. All data were first analysed according to a fixed effects model. 
g. For variables with significant heterogeneity, the studies were reviewed to 
determine any possible factor or factors that may lead to heterogeneity.  A 
subgroup analysis was done if such factors could be identified. 
h. If significant heterogeneity reported could not be accounted via subgroup analysis, 
a random effects model was then applied.  (Refer to Appendix 4 : Statistical 
Methods Programmed in MetaView Version 4, for formulae used in a random 
effects model) 
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4.8 Pooling of safety data 
Efficacy data were pooled and analysed in the following sequence: 
a. The following discrete variables were obtained from randomised controlled trials 
which reported both fracture rates as well as bone mineral density of subjects. 
- duration of patient intervention 
- number of patients in treatment / control arms 
- number of withdrawals in treatment / control arms by end of study 
- number of gastrointestinal adverse events in treatment / control arms 
- number of serious gastrointestinal adverse events in treatment / control arms 
b. Incidence density of gastrointestinal adverse events as well as serious 
gastrointestinal events was calculated separately for treatment / control arms with 
the equation : 
No. of patients with adverse event 
--------------------------------------------------------------------------------------- 
(No. of patients – No. of withdrawals / 2) x Treatment duration in years 
 
This equation assumes that withdrawals occur on average, halfway through the 
duration of intervention, as most studies do not report the exact time of patients 
who withdrew from intervention. 81 
c. The data is entered into the software “Compare2”, which is part of the PEPI 
suite.82  The software allows for pooling of studies to compare the occurrence of 
an event, with number of events as numerator and person-time as denominator 
d. The Mantel-Haenszel statistic (chi-squared and p-value) and the number needed to 
treat to produce one episode of harm are calculated by using the same software. 
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4.9 Prevention of data error 
The following approach was taken through the process of literature retrieval, data 
extraction and pooling to minimise errors in data interpretation and transcribing. 
a. All full-text articles that were not available in electronic copy were scanned into 
the computer as portable document format (pdf), which then allows the figures and 
diagrams to be viewed clearly by zooming in. 
b. Data for study characteristics, efficacy and safety variables were first extracted 
from that electronic version of the articles into a standard data sheet. 
c. A re-checked was carried out using the paper version, with the relevant data 
highlighted to allow for any further rechecks. 
d. Pre-formatted electronic datasheets were developed for study characteristics using 
Microsoft Access and efficacy / safety variables using Microsoft Excel. 
e. To minimise errors due to transcribing from data sheets to the meta-analysis 
software, Revman v4.0, the “double data entry” feature of RevMan was utilised to 
match data by keying in a second time on a different day.  RevMan would only 
allow data analysis if the grids matched. 
f. The final efficacy variables (lumbar vertebral and femoral neck BMD) that have 
been entered into Revman were printed out, and then checked back against the 
graphs in each of the full-text study if available, as the graphs allowed for an 
estimation of the difference in BMD.  Any significant difference between the value 
printed from the software and that estimated manually from the graph were then 
thoroughly investigated and rectified. 
g. Funnel plots were done to determine the likelihood of publication bias. 
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4.10 Pharmacoeconomic analysis 
The type of pharmacoeconomic analysis to be applied depends on the outcome of the 
evaluation of the meta-analysis.  If the results do not show a difference in efficacy 
between the different bisphosphonates, a cost minimisation analysis would be carried out.   
 
However, if it is shown that there is a difference in the efficacy in improving BMD, a Cost 
Effectiveness Analysis (CEA) would be used, based on local cost of drugs and local 
guidelines for osteoporosis. 
 
     (Cost strategy A - Cost strategy B) 
Incremental cost effectiveness Ratio =   --------------------------------------------- 
    (Effectstrategy A - Effect strategy B) 
 
If CEA is carried out, the incremental cost effectiveness ratio (ICER) would be 
determined for each of the bisphosphonate as compared to the lowest priced agent as the 
baseline comparator.  Threshold analysis was also carried out by varying the patient price 
of the most cost effective intervention. 
 
Local data on average bill size before government grant of various Diagnostic Related 
Groups (DRGs) were obtained for hip and vertebral fractures as well as for 
gastrointestinal conditions related to side effects of bisphosphonates such as esophagitis 
and gastroduodenal bleeding.  The information was obtained from data compiled by the 
Ministry of Health on TCBGG for the public sector for different DRGs. 
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CHAPTER 5.  RESULTS 
5  
5.1 Efficacy - Results from Meta-Analysis 
5.1.1 Literature retrieved for efficacy data 
Number of records retrieved from bibliographic databases was as follows: 
- MEDLINE (OVID)     : 200 citations 
- CCTR (OVID)      : 122 citations 
- Total Number of unique citations retrieved  : 215 citations 
 
The records were filtered as described in the methods section.  Among the 116 articles 
filtered out, 32 were not randomised controlled trials, 78 were irrelevant to the context of 
the study, 4 RCTs (randomised controlled trials) did not have placebo as a control and 2 
other studies of unclear design were excluded as there were no placebo arms.  Full-text 
articles were then obtained for the remaining 99 citations.  From the abstracts, a 
breakdown of placebo controlled trials is as follows: 
- Alendronate * : 48 articles (24 articles excluded) 68, 83-129 
- Clodronate : 9 articles (1 article excluded) 130-138 
- Etidronate : 24 articles (8 articles excluded) 46, 47, 127, 139-159 
- Ibandronate : 3 articles (1 article excluded) 160-162 
- Pamidronate : 5 articles (2 articles excluded) 163-167 
- Risedronate : 8 articles (2 articles excluded) 168-175 
- Tiludronate : 2 articles 176, 177 
- Zoledronate : 1 article (1 article excluded) 178 
- Unknown #  : 1 article (Blake et al, 2000) 179 
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* 2 articles were counted twice as both studies involved 2 bisphosphonates - one on alendronate and 
etidronate, the other on alendronate and ibandronate 
#  The exact bisphosphonate studied was not mentioned in the abstract of one article 
 
The table below lists the studies that were excluded as well as the reasons for exclusion. 
No. STUDY DRUG REASON FOR NON-INCLUSION 
1. Adami, 1993 87 Alendronate One year interim analysis of Adami, 1995 
2. Adami S, 1993 89 Alendronate Duplicate entry of Adami, 1993 
3. Bauer, 2000 90 Alendronate FIT population, reporting on gastrointestinal side effects 
4. Bauer, 1995 86 Alendronate FIT population, reporting on ultrasound BMD correlation to fracture rate 
5. Bettembuk, 1999 91 Alendronate FOSIT partial population – Hungary site only 
6. Black, 2000 93 Alendronate FIT population, 3 to 4 year extension data for women with 1 fracture or BMD < 2.5 SD 
7. Buffo L, 1996 95 Alendronate Non-English article 
8. Ensrud, 1997 101 Alendronate FIT partial population, reporting on patients with highest risk only 
9. Felsenberg, 1998 102 Alendronate FOSIT partial population, interim report on 20% of population 
10. Garnero, 1999 103 Alendronate BMD or percentage change in BMD from baseline not reported in results 
11. Hochberg, 1999 68 Alendronate FIT population, reporting only BMD correlation to fracture rate 
12. Hyldstrup, 2001 106 Alendronate Non-randomised open trial. 
13. McClung M, 1998 112 Alendronate Duplicate entry of McClung, 1998 
14. Ravn, 1999 115 Alendronate Early Postmenopausal Intervention Cohort Study Group - 2nd yr discontinuation results of Hosking, 1998 
15. Ravn, 1999 116 Alendronate Early Postmenopausal Intervention Cohort Study Group - Same population as Hosking 1998 
16. Ravn, 2000 117 Alendronate Unblinded extension of McClung 1998 
17. Ravn P, 1999 128 Alendronate/ Ibandronate Report on previous articles with new type of measurements of BMD 
18. Stock, 1997 120 Alendronate Follow-up of Chesnut, 1995 
19. Tiras, 2000 121 Alendronate No placebo group 
20. Tonino, 2000 122 Alendronate Osteoporosis Treatment Study Group - Extension report of Liberman 1995 
21. Tucci, 1996 85 Alendronate Osteoporosis Treatment Study Group - Partial report of Liberman 1995 
22. van der Poest Clement, 2000 123 Alendronate FOSIT partial population 
23. Wasnich, 1999 124 Alendronate Early Postmenopausal Interventional Cohort Study Group - Overlap population with Hosking 1998 
24. Watts, 2001 125 Alendronate Osteoporosis Treatment Study Group - Extension of Liberman 1995 
25. Drake 2002 180 * Alendronate No Lumbar spine or Hip BMD reported 
26. Palomba, 2002 181 * Alendronate No placebo arm 
27. Saarto, 1998 137 Clodronate Irrelevant results reported 
28. Iwamoto, 2001 47 Etidronate Irrelevant results reported 
29. Miller, 1991 148 Etidronate Irrelevant results reported 
30. Miller, 1997 149 Etidronate Extension study of combined Harris et al, 1993 and Watts et al, 1990 
31. Ross, 1993 152 Etidronate Same population as Watts 1990 
32. Terranova, 1999 157 Etidronate Non-english article 
33. Steiniche, 1991 154 Etidronate No placebo arm 
34. Storm, 1996 156 Etidronate Open continuation of Storm 1990 - all patients received treatment in 
open study 
35. Storm, 1993 155 Etidronate Same study as Storm 1990 
36. Thiebaud, 1994 167 Pamidronate No placebo arm  
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No. STUDY DRUG REASON FOR NON-INCLUSION 
37. Kollerup, 1997 163 Pamidronate Not reporting BMD or fracture rate 
38. Harris, 2001 172 Risedronate No placebo arm 
39. McClung, 2001 173 Risedronate Only hip fracture reported 
40. Reid, 2002 178 Zoledronate Standard deviation of BMD not reported and cannot be extrapolated as 
only one study is available 
 
Table 5.1 : List of studies retrieved but excluded from efficacy analysis and reasons for exclusion. 
 
* 2 articles were retrieved via eSDI after date of initial search as described under the search methodology section. 
 
Specificity of search strategy: 92 randomised placebo-controlled trials and 7 studies that 
could not be clearly determined to fulfill the inclusion / exclusion criteria from the title or 
abstract were retained.  Specificity or precision of search strategy = (92 + 7) / 215 = 0.46 
 
Sensitivity of search strategy:    RCTs from NLM Current Bibliographies in Medicine for 
Osteoporosis and from Micromedex that were not captured by the search were retrieved.   
There were 83 citations under the sections of bisphosphonates from the NLM Current 
Bibliographies in Medicine for Osteoporosis (January 1995 to December 1999).  Among 
them, abstracts were obtained for 13 citations.182-194  The remaining citations were either 
non-RCTs or did not study BMD.  From the evaluation of the abstracts, full-text articles 
were obtained for 6 of the citations.  The remaining 7 articles were either not randomised 
controlled trials or did not report the relevant variables.  Under Micromedex Drugdex, a 
total of 43 citations were retrieved.  Number of citations for each drug were as follows : 










Table 5.2  : Number of possibly relevant articles retrieved from Micromedex for each bisphosphonate 
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Out of the 43 citations, 7 were distinct from those retrieved via the search on Medline and 
CCTR.  Abstracts were retrieved for all 7 citations.  Full-text was obtained for one article 
having the potential for fulfilling the inclusion / exclusion criteria from the abstracts.  The 
table below lists the articles whereby full-text were obtained. 
STUDY (full-text retrieved) Source Remarks 
Fairney, 1998 184 NLM Current bibliographies Non-randomised, non-controlled, excluded 
Heaney, 1997 185 NLM Current bibliographies Excluded, retrospective, non-controlled 
Herd, 1997 186 NLM Current bibliographies Included 
Paparella P, 1995 188 NLM Current bibliographies Non-randomised, excluded 
Peretz, 1996 190 NLM Current bibliographies Non-randomised, non-controlled, excluded 
Vasikaran, 1995 193 NLM Current bibliographies Non-randomised, non-controlled, excluded 
Frediani B, 1998 195 Micromedex bibliographies Excluded, variables not reported 
 
Table 5.3 : List of relevant articles from National Library of Medicine current bibliographies and Micromedex Drugdex with 
full-text retrieved 
 
Four other relevant articles that were available to the author but not retrieved in the 
author’s search strategy were available 186, 196-198 and included in calculating the sensitivity 
of the search strategy as shown below. 
 
In addition to the articles retrieved above, 3 other articles were retrieved by automated 
electronic dissemination of search results via email from OVID after the date which the 
author’s search was performed (17th March 2002). 180, 181, 199 
 
A similar search was performed by the librarian from KK Hospital Medical Library, a 
specialist from the OVID Australian customer support as well as another drug information 
pharmacist from a general hospital (See appendix 2).  For each of the search strategy 
submitted, 2 additional limits were added to remove duplicate articles as well as articles 
that were classified as letters, meta-analysis, news or editorial in the “publication type” 
field. 
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The table below summaries the results of the OVID Medline search as compared to that 
done by the author.  All searches were updated as of 31st June 2002. 
 
Total number of distinct potentially relevant articles were 118.  Among them, 8 could not 
be determined from their abstracts if they were randomised controlled trials.  The 
sensitivity and specificity scores in brackets excluded these articles in the calculation. 
 
For calculation of sensitivity and specificity, the number of potentially relevant articles 
was used instead of the number of actual articles that were used in the meta-analysis, since 
using the actual number of articles may bias against a particular search strategy due to 
inclusion and exclusion criteria that were not considered in the search strategy. 
 
Table 5.4 : Sensitivity and specificity of different search strategies for MEDLINE 
 
From the above results, the search strategy for OVID Medline appeared to have a 
comparable sensitivity and specificity score as compared to those done by other drug 
information retrieval specialists. 




Total number of articles 
retrieved (excluding 
duplicates) 
203 159 170 141 
Number of possibly 
relevant articles 
92 RCTs + 8 unknown 
+ 3 new articles = 103 
81 same + 7 distinct 
= 88 
81 same + 15 
distinct = 96 
62 same + 12 
distinct = 74 
Specificity 0.50 (0.47) 0.55 (0.55) 0.56 (0.56) 0.52 (0.52) 
Sensitivity  0.86 (0.81) 0.75 (0.80) 0.81 (0.87) 0.63 (0.67) 
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5.1.2 Characteristics of efficacy studies 
Characteristics of included studies retrieved for evaluation and meta-analysis are shown in 
the tables below. 
 
Characteristics of included studies on Alendronate 
ID Study Parallel Controlled 
Random-












51 Adami, 1995       
56 Black, 1996       
58 Bone, 1997       
59 Braga, 1999       
61 Chesnut, 1995       
62 Cummings, 1998       
63 Devogelaer, 1996       
64 Downs, 2000       
65 Dursun, 2001       
69 Gonnelli, 1999       
71 Hosking, 1998       
73 Kung, 2000       
74 Lau, 2000       
75 Liberman, 1995       
76 Lindsay, 1999       
77 Malavolta, 1999       
78 McClung, 1998       
80 Murphy, 2001       
81 Passeri M, 1991       
82 Pols, 1999        
87 Rossini, 2000       
88 Rossini, 1994        
89 Sahota, 2000        
97 Yen, 2000        
98 Greenspan, 1998        
99 Shiraki, 1998       
101 Bone, 2000       
104 Johnell, 2002       
 
Table 5.5 : Characteristics of Included Studies on Alendronate 
 
*  A “” in this column represents that it is unclear from the methods section of the published journal article 
if the study is a randomised.  A“” in “Appropriate dosage” column represents inappropriate dosage, and 
similarly, a “” in the “baseline demo” column represents non-similar baseline demographics.
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Characteristics of Included Studies on Clodronate 














1 Filipponi, 1995       
2 Giannini, 1993       
3 Giannini, 1996       
4 Gnudi, 2001       
5 Heikkinen, 1997       
6 Rossini, 1999       
7 Saarto, 1997       
9 Tsai, 1999       
10 McCloskey, 2001       
  
Table 5.6 : Characteristics of Included Studies on Clodronate 
 
Characteristics of Included Studies on Etidronate 














27 Adami, 2000       
28 Blake, 1996       
29 Evans, 1993       
30 Gurlek, 1997       
31 Harris, 1993       
32 Hasling, 1994       
35 Lyritis, 1997       
36 Meunier, 1997       
39 Montessori, 1997       
40 Pouilles Jm, 1997       
42 Shiota E, 2001       
46 Storm, 1990       
48 Watts, 1990       
49 Wimalawansa, 1998       
50 Sahota, 2000       
51 Herd, 1997       
52 Wimalawansa, 1995       
53 Heath, 2000       
 
Table 5.7 : Characteristics of Included Studies on Etidronate 
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Characteristics of Included Studies on Ibandronate 













14 Ravn, 1996       
15 Riis, 2001       
16 Thiebaud, 1997       
  
Table 5.8 : Characteristics of Included Studies on Ibandronate 
 
Characteristics of Included Studies on Pamidronate 














10 Lees, 1996       
11 Reid, 1994       
12 Ryan, 2000       
 
Table 5.9 : Characteristics of Included Studies on Pamidronate 
 
Characteristics of Included Studies on Risedronate  














19 Clemmesen, 1997       
20 Delmas, 1997       
21 Fogelman, 2000       
23 Harris, 1999       
25 Mortensen, 1998       
26 Reginster, 2000       
  
Table 5.10 : Characteristics of Included Studies on Risedronate 
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Characteristics of Included Studies on Tiludronate 














17 Reginster, 1989       
18 Reginster, 2001       
  
Table 5.11 : Characteristics of Included Studies on Tiludronate 
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5.1.3 Quality of efficacy studies 
Quality Scores of Included Studies on Alendronate  
















51 Adami, 1995 1 1 1 1 -1 3 
56 Black, 1996 1 0 1 1 0 3 
58 Bone, 1997 1 0 1 0 -1 1 
59 Braga, 1999 1 1 -1 NA 0 1 
61 Chesnut, 1995 1 1 1 0 1 4 
62 Cummings, 1998 1 1 1 0 -1 2 
63 Devogelaer, 1996 1 1 1 0 -1 2 
64 Downs, 2000 1 0 1 1 1 4 
65 Dursun, 2001 1 0 -1 NA 0 0 
69 Gonnelli, 1999 1 0 -1 NA 1 1 
71 Hosking, 1998 1 0 1 0 1 3 
73 Kung, 2000 1 0 1 1 1 4 
74 Lau, 2000 1 1 1 0 1 4 
75 Liberman, 1995 1 0 1 0 1 3 
76 Lindsay, 1999 1 0 1 0 1 3 
77 Malavolta N, 1999 0 0 -1 NA 0 -1 
78 McClung, 1998 1 1 1 1 -1 3 
80 Murphy, 2001 1 0 1 1 1 4 
81 Passeri M, 1991 1 1 -1 NA 1 2 
82 Pols, 1999 1 0 1 1 -1 2 
87 Rossini, 2000 1 1 -1 NA 0 1 
88 Rossini, 1994 1 0 1 0 1 3 
89 Sahota, 2000 1 1 -1 NA 1 2 
97 Yen, 2000 1 1 1 0 1 4 
98 Greenspan, 1998 1 0 1 0 0 2 
99 Shiraki, 1998 1 1 -1 0 1 2 
100 Palomba, 2002 1 0 1 1 1 4 
101 Bone, 2000 1 1 1 0 1 4 
103 Johnell, 2002 1 1 1 1 -1 3 
 
Table 5.12 : Quality Score of Included Studies on Alendronate 
 
NA: Blinding method not applicable if study is not a blinded study (blinding score “-1”)
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1 Filipponi, 1995 1 0 -1 NA 1 1 
2 Giannini, 1993 1 0 -1 NA 1 1 
3 Giannini, 1996 1 1 -1 NA 1 2 
4 Gnudi, 2001 0 0 -1 NA 0 -1 
5 Heikkinen, 1997 1 1 0 NA 0 2 
6 Rossini, 1999 1 0 -1 NA 1 1 
7 Saarto, 1997 1 0 -1 NA 1 1 
9 Tsai, 1999 1 1 1 0 1 4 
10 McCloskey, 2001 1 1 1 1 0 4 
 
Table 5.13 : Quality Score of Included Studies on Clodronate 
 




















27 Adami, 2000 1 1 1 0 1 4 
28 Blake, 1996 1 0 1 0 0 2 
29 Evans, 1993 1 1 -1 NA 0 1 
30 Gurlek, 1997 1 1 -1 NA 0 1 
31 Harris, 1993 1 1 1 0 -1 2 
32 Hasling, 1994 1 0 -1 NA 1 1 
35 Lyritis, 1997 1 0 -1 NA 1 1 
36 Meunier, 1997 1 0 1 1 1 4 
39 Montessori, 1997 1 1 -1 NA 1 2 
40 Pouilles Jm, 1997 1 0 1 0 1 3 
42 Shiota E, 2001 1 0 -1 NA 0 0 
46 Storm, 1990 1 1 1 0 1 4 
48 Watts, 1990 1 1 1 0 1 4 
49 Wimalawansa, 1998 1 1 -1 NA -1 0 
50 Sahota, 2000 1 1 -1 NA 1 2 
51 Herd, 1997 1 0 1 0 1 3 
52 Wimalawansa, 1995 1 0 -1 NA 1 1 
53 Heath, 2000 1 0 -1 NA 1 1 
 
Table 5.14 : Quality Score of Included Studies on Etidronate 
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Blinding score Blinding Method 
appropriate 






14 Ravn, 1996 1 1 1 0 1 4 
15 Riis, 2001 1 0 1 1 -1 2 
16 Thiebaud, 1997 1 1 -1 0 1 2 
 
Table 5.15 : Quality Score of Included Studies on Ibandronate 
 
Quality Scores of Included Studies on Pamidronate 














10 Lees, 1996 1 0 1 1 1 4 
11 Reid, 1994 1 0 1 0 0 2 
12 Ryan, 2000 1 0 1 0 0 2 
 
Table 5.16 : Quality Score of Included Studies on Pamidronate 
 
Quality Scores of Included Studies on Risedronate 














19 Clemmesen, 1997 1 0 1 1 1 4 
20 Delmas, 1997 1 0 1 0 1 3 
21 Fogelman, 2000 1 0 1 0 -1 1 
23 Harris, 1999 1 1 1 1 1 5 
25 Mortensen, 1998 1 0 1 1 1 4 
26 Reginster, 2000 1 0 1 0 1 3 
 
Table 5.17 : Quality Score of Included Studies on Risedronate 
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Quality Scores of Included Studies on Tiludronate 





Blinding score Blinding Method 
appropriate 




17 Reginster, 1989 1 0 1 1 1 4 
18 Reginster, 2001 1 0 1 1 1 4 
 
Table 5.18 : Quality Score of Included Studies on Tiludronate 
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5.1.4 Efficacy tables 
The number of randomised controlled trials available for each bisphosphonate is as shown 
in the table below.  Funnel plots were carried out if there are more than 6 studies. 
(Appendix 5)  The funnel plots did not indicate any obvious publication bias in any of the 
data-pooling. 
Number of studies 
Lumbar Vertebral BMD Femoral Neck BMD Bisphosphonate 
1 Year 2 Years 3 Years 1 Year 2 Years 3 Years 
Alendronate 23 12 5 21 11 5 
Clodronate 9 5 0 6 4 0 
Etidronate 16 16 3 10 11 3 
Ibandronate 3 0 0 2 0 0 
Pamidronate 2 3* 0 2 3 0 
Risedronate 6 6 2 6 6 2 
Tiludronate 2 1 1 0 0 0 
Zoledronate 0 0 0 0 0 0 
 
Table 5.19 : Number of studies available for data pooling for each bisphosphonate (All studies) 
* One study on pamidronate had information at only 2 years 
 
 
The pooled efficacy data for percentage change in lumbar vertebral and femoral neck bone 
mineral density for each bisphosphonate are shown in the diagrams in the following pages.  
(Refer to Appendix 6 for raw data tables).  As there are only 3 studies reporting results of 
up to 4 years duration, data was considered for up to 3 years only. 
 
WMD labelled in the following figures refers to the weighted mean difference between 
treatment and placebo for the outcome variable as compared to placebo.   
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Except for pooled results of tiludronate, all other agents had statistically significant (p < 
0.05) improvement in overall effect as compared to placebo. 
 
 
Percentage change in Lumbar Vertebral BMD for alendronate at 1 year - All studies 
 
Review : Lumbar - Alendronate
Comparison : 01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 1995 65 4.06(4.43) 67 -0.83(4.83) 0.2 4.89[3.31,6.47]
Black 1996 1002 4.47(4.75) 1005 1.10(5.39) 2.9 3.37[2.93,3.81]
Bone 1997 85 4.50(3.50) 90 0.28(3.42) 0.5 4.22[3.19,5.25]
Bone 2000 87 4.39(3.45) 46 -0.07(2.37) 0.6 4.46[3.46,5.46]
Chesnut 1995 30 5.06(3.29) 31 -1.05(3.84) 0.2 6.11[4.32,7.90]
Cummings 1998 2214 4.18(1.41) 2218 0.30(1.41) 82.2 3.88[3.80,3.96]
Devogelaer 1996 92 5.09(3.93) 188 -0.33(4.11) 0.6 5.42[4.42,6.42]
Downs 2000 105 5.28(4.10) 51 0.27(4.14) 0.3 5.01[3.63,6.39]
Dursun 2001 51 7.19(7.60) 50 -0.36(7.60) 0.1 7.55[4.59,10.51]
Gonnelli 1999 48 3.69(9.01) 46 -0.90(6.10) 0.1 4.59[1.49,7.69]
Greenspan 1998 46 4.93(3.12) 44 1.44(3.71) 0.3 3.49[2.07,4.91]
Hosking 1998 445 2.70(2.11) 461 -1.04(4.51) 2.7 3.74[3.28,4.20]
Johnell 2002 82 4.30(3.62) 83 -0.40(2.73) 0.6 4.70[3.72,5.68]
Kung 2000 28 5.86(3.60) 28 1.68(2.06) 0.2 4.18[2.64,5.72]
Lau 2000 41 5.49(3.52) 37 3.09(4.01) 0.2 2.40[0.72,4.08]
Liberman 1995 174 5.21(4.48) 347 -0.54(4.47) 0.9 5.75[4.93,6.57]
Lindsay 1999 203 3.61(4.27) 191 1.01(4.15) 0.8 2.60[1.77,3.43]
Murphy 2001 109 4.56(3.55) 36 0.55(2.82) 0.4 4.01[2.87,5.15]
Passeri 1991 18 9.59(14.25) 19 -2.78(18.19) 0.0 12.37[1.87,22.87]
Pols 1999 832 5.00(3.20) 865 0.10(3.40) 5.7 4.90[4.59,5.21]
Rossini 2000 42 2.51(3.24) 41 -1.30(1.66) 0.5 3.81[2.71,4.91]
Sahota 2000 31 5.70(10.58) 33 2.00(7.47) 0.0 3.70[-0.81,8.21]
Yen 2000 24 6.53(4.75) 22 -0.75(5.25) 0.1 7.28[4.38,10.18]
Total(95%CI) 5854 5999 100.0 3.96[3.88,4.03]
Test for heterogeneity chi-square=112.38  df=22  p<0.00001
Test for overall effect  z=103.03  p<0.00001
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Percentage change in Lumbar Vertebral BMD for alendronate at 3 years - All studies 
 
Review : Lumbar - Alendronate
Comparison : 01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 1995 65 5.20(4.60) 67 -0.01(5.48) 0.3 5.21[3.49,6.93]
Black 1996 1022 6.34(4.48) 1005 1.40(5.71) 4.2 4.94[4.49,5.39]
Bone 1997 85 6.23(3.96) 90 0.56(4.17) 0.6 5.67[4.47,6.87]
Bone 2000 87 6.00(4.66) 46 -0.60(3.39) 0.4 6.60[5.21,7.99]
Chesnut 1995 30 7.21(2.68) 31 -1.35(3.40) 0.4 8.56[7.03,10.09]
Cummings 1998 2214 5.64(1.88) 2218 0.68(1.41) 87.6 4.96[4.86,5.06]
Devogelaer 1996 92 6.41(3.93) 188 -0.36(4.66) 0.8 6.77[5.73,7.81]
Gonnelli 1999 48 4.99(10.32) 48 -1.59(5.40) 0.1 6.58[3.28,9.88]
Greenspan 1998 46 6.94(3.80) 44 1.75(3.05) 0.4 5.19[3.77,6.61]
Hosking 1998 396 3.50(3.98) 409 -1.80(4.04) 2.7 5.30[4.75,5.85]
Liberman 1995 180 6.89(3.35) 374 -0.54(4.83) 1.8 7.43[6.74,8.12]
McClung 1998 84 3.96(3.30) 78 -3.28(3.18) 0.8 7.24[6.24,8.24]
Total(95%CI) 4349 4598 100.0 5.07[4.98,5.16]
Test for heterogeneity chi-square=105.24  df=11  p<0.00001
Test for overall effect  z=108.56  p<0.00001
Review : Lumbar - Alendronate
Comparison :01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Black 1996 1022 7.98(5.75) 1005 1.73(5.71) 8.1 6.25[5.75,6.75]
Cummings 1998 2214 7.05(2.35) 2218 1.02(2.83) 85.4 6.03[5.88,6.18]
Devogelaer 1996 92 6.80(5.75) 188 -0.60(5.48) 1.0 7.40[5.99,8.81]
Liberman 1995 174 8.22(3.96) 332 -0.69(4.19) 3.6 8.91[8.17,9.65]
McClung 1998 84 3.95(3.57) 78 -3.51(3.18) 1.9 7.46[6.42,8.50]
Total(95%CI) 3586 3821 100.0 6.19[6.05,6.33]
Test for heterogeneity chi-square=64.54  df=4  p<0.00001
Test for overall effect  z=85.75  p<0.00001
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Percentage change in Lumbar Vertebral BMD for clodronate at 2 years - All studies 
 
  
Review : Lumbar - Clodronate
Comparison : 01 Clodronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Filipponi 1995 31 0.71(4.62) 28 -7.28(7.14) 12.4 7.99[4.89,11.09]
Gnudi 2001 32 3.22(3.60) 32 -1.24(4.85) 27.3 4.46[2.37,6.55]
Heikkinen 1997 21 -3.10(3.60) 22 -2.50(4.60) 19.7 -0.60[-3.06,1.86]
Rossini 1999 16 4.66(4.00) 30 -2.19(5.04) 16.8 6.85[4.19,9.51]
Saarto 1997 40 -2.20(5.44) 53 -5.90(5.46) 23.9 3.70[1.46,5.94]
Total(95%CI) 140 165 100.0 4.12[3.03,5.21]
Test for heterogeneity chi-square=24.35  df=4  p=0.0001
Test for overall effect  z=7.40  p<0.00001
Review : Lumbar - Clodronate
Comparison : 01 Clodronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Filipponi 1995 31 0.70(3.28) 28 -4.92(4.29) 7.1 5.62[3.66,7.58]
Giannini 1993 16 3.88(2.60) 20 -2.34(2.19) 10.8 6.22[4.62,7.82]
Giannini 1996 17 3.32(2.93) 14 -2.68(2.77) 6.8 6.00[3.99,8.01]
Gnudi 2001 32 2.63(3.40) 32 -0.12(3.52) 9.5 2.75[1.05,4.45]
Heikkinen 1997 21 -1.20(3.20) 22 -1.90(4.20) 5.5 0.70[-1.53,2.93]
McCloskey 2001 333 3.20(5.47) 341 0.50(5.54) 39.7 2.70[1.87,3.53]
Rossini 1999 24 4.40(4.75) 30 -0.42(5.42) 3.7 4.82[2.10,7.54]
Saarto 1997 40 -0.70(3.23) 53 -3.70(4.08) 12.4 3.00[1.51,4.49]
Tsai 1999 29 -0.95(4.85) 25 -2.20(4.50) 4.4 1.25[-1.25,3.75]
Total(95%CI) 543 565 100.0 3.46[2.93,3.98]
Test for heterogeneity chi-square=36.41  df=8  p<0.00001
Test for overall effect  z=12.94  p<0.00001
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Percentage change in Lumbar Vertebral BMD for etidronate at 2 years - All studies 
 
Review : Lumbar - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 2000 36 1.19(3.12) 41 -0.94(4.48) 7.2 2.13[0.42,3.84]
Blake 1996 61 2.48(3.05) 70 -0.71(2.84) 20.5 3.19[2.18,4.20]
Evans 1993 15 4.40(6.60) 11 -6.00(5.80) 0.9 10.40[5.61,15.19]
Gurlek 1997 10 4.52(18.25) 10 0.83(7.21) 0.1 3.69[-8.47,15.85]
Harris 1993 92 3.45(5.56) 90 0.96(6.93) 6.3 2.49[0.66,4.32]
Hasling 1994 16 1.56(6.00) 9 -0.20(4.29) 1.3 1.76[-2.30,5.82]
Heath 2000 38 0.38(4.56) 39 -1.09(3.31) 6.6 1.47[-0.31,3.25]
Herd 1997 67 2.57(3.03) 74 -0.71(2.84) 22.3 3.28[2.31,4.25]
Lyritis 1997 47 8.39(0.00) 44 -0.34(0.00) 0.0x Not Estimable
Meunier 1997 25 1.57(3.70) 24 -0.43(3.53) 5.1 2.00[-0.02,4.02]
Montessori 1997 40 4.25(4.36) 34 -0.60(2.92) 7.5 4.85[3.18,6.52]
Pouilles 1997 45 0.48(3.62) 46 -1.64(3.73) 9.2 2.12[0.61,3.63]
Sahota 2000 36 4.90(9.00) 34 2.00(7.58) 1.4 2.90[-0.99,6.79]
Shiota 2001 20 5.55(3.72) 20 -2.17(3.74) 3.9 7.72[5.41,10.03]
Storm 1990 28 1.18(7.36) 24 -1.23(7.64) 1.3 2.41[-1.69,6.51]
Watts 1990 92 3.46(5.56) 89 1.08(6.89) 6.3 2.38[0.55,4.21]
Total(95%CI) 668 659 100.0 3.10[2.64,3.56]
Test for heterogeneity chi-square=37.43  df=14  p=0.0006
Test for overall effect  z=13.26  p<0.00001
Review : Lumbar - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 2000 36 0.14(5.64) 41 -1.49(4.74) 5.4 1.63[-0.72,3.98]
Blake 1996 61 2.28(3.67) 70 -1.72(3.43) 19.8 4.00[2.78,5.22]
Evans 1993 15 2.40(9.10) 11 -4.70(4.40) 1.1 7.10[1.81,12.39]
Harris 1993 92 4.37(7.19) 90 1.41(5.79) 8.3 2.96[1.07,4.85]
Hasling 1994 16 -1.69(8.52) 9 -2.55(5.37) 1.0 0.86[-4.59,6.31]
Heath 2000 22 -0.09(4.50) 33 -2.88(3.96) 5.5 2.79[0.47,5.11]
Herd 1997 64 2.14(3.76) 71 -1.72(3.45) 19.8 3.86[2.64,5.08]
Lyritis 1997 47 12.31(0.00) 44 -1.76(0.00) 0.0x Not Estimable
Meunier 1997 25 0.60(4.40) 24 -2.31(3.97) 5.4 2.91[0.57,5.25]
Montessori 1997 40 6.28(5.06) 34 -0.03(9.21) 2.5 6.31[2.84,9.78]
Pouilles 1997 45 0.05(5.97) 46 -2.45(4.54) 6.2 2.50[0.32,4.68]
Shiota 2001 20 10.62(3.73) 20 -5.89(5.03) 3.9 16.51[13.77,19.25]
Storm 1990 22 4.68(7.93) 21 -4.53(8.34) 1.2 9.21[4.34,14.08]
Watts 1990 92 4.19(7.29) 89 1.37(6.89) 6.9 2.82[0.75,4.89]
Wimalawansa 1995 12 4.22(3.64) 11 -2.25(3.15) 3.8 6.47[3.69,9.25]
Wimalawansa 1998 16 4.30(2.80) 16 -0.90(2.40) 9.1 5.20[3.39,7.01]
Total(95%CI) 625 630 100.0 4.28[3.73,4.82]
Test for heterogeneity chi-square=102.33  df=14  p<0.00001
Test for overall effect  z=15.40  p<0.00001
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Percentage change in Lumbar Vertebral BMD for etidronate at 3 years - All studies 
 
 
Review : Lumbar - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Harris 1993 73 4.70(6.84) 72 1.49(6.87) 53.0 3.21[0.98,5.44]
Lyritis 1997 47 15.26(0.00) 44 -2.49(0.00) 0.0x Not Estimable
Montessori 1997 36 5.67(4.98) 31 0.17(4.90) 47.0 5.50[3.13,7.87]
Total(95%CI) 156 147 100.0 4.29[2.66,5.91]
Test for heterogeneity chi-square=1.90  df=1  p=0.17
Test for overall effect  z=5.17  p<0.00001
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Percentage change in Lumbar Vertebral BMD for ibandronate at 1 year - All studies 
 
 
Review : Lumbar - Ibandronate
Comparison : 01 Ibandronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Ravn 1996 30 4.60(3.10) 30 0.70(2.70) 35.4 3.90[2.43,5.37]
Riis 2001 81 4.90(3.51) 81 1.58(4.68) 47.2 3.32[2.05,4.59]
Thiebaud 1997 19 5.19(4.14) 24 0.85(2.45) 17.3 4.34[2.24,6.44]
Total(95%CI) 130 135 100.0 3.70[2.83,4.58]
Test for heterogeneity chi-square=0.77  df=2  p=0.68
Test for overall effect  z=8.29  p<0.00001
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Review : Lumbar - Pamidronate
Comparison : 01 Pamidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Reid 1994 26 5.06(3.88) 22 0.49(6.24) 47.9 4.57[1.57,7.57]
Ryan 2000 40 5.06(5.44) 41 1.50(7.62) 52.1 3.56[0.68,6.44]
Total(95%CI) 66 63 100.0 4.04[1.97,6.12]
Test for heterogeneity chi-square=0.23  df=1  p=0.63
Test for overall effect  z=3.81  p=0.0001
Review : Lumbar - Pamidronate
Comparison : 01 Pamidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Lees 1996 22 2.80(2.10) 32 -1.60(3.10) 72.1 4.40[3.01,5.79]
Reid 1994 26 7.00(5.10) 22 -1.20(6.10) 13.4 8.20[4.98,11.42]
Ryan 2000 40 6.10(5.50) 41 1.13(8.45) 14.5 4.97[1.87,8.07]
Total(95%CI) 88 95 100.0 4.99[3.81,6.17]
Test for heterogeneity chi-square=4.52  df=2  p=0.1
Test for overall effect  z=8.31  p<0.00001
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Percentage change in Lumbar Vertebral BMD for risedronate at 1 year - All studies 
 
 




Percentage change in Lumbar Vertebral BMD for risedronate at 3 years - All studies 
Review : Lumbar - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Clemmesen 1997 44 1.74(3.78) 44 0.18(4.25) 6.6 1.56[-0.12,3.24]
Delmas 1997 27 0.62(3.59) 26 -1.39(2.86) 6.1 2.01[0.27,3.75]
Fogelman 2000 139 3.50(3.65) 143 0.20(3.71) 25.3 3.30[2.44,4.16]
Harris 1999 259 3.98(4.35) 265 0.97(3.74) 38.7 3.01[2.31,3.71]
Mortensen 1998 32 1.30(3.96) 32 -2.80(3.96) 5.0 4.10[2.16,6.04]
Reginster 2000 251 4.56(5.86) 221 0.64(5.35) 18.3 3.92[2.91,4.93]
Total(95%CI) 752 731 100.0 3.15[2.71,3.58]
Test for heterogeneity chi-square=8.50  df=5  p=0.13
Test for overall effect  z=14.26  p<0.00001
Review : Lumbar - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Clemmesen 1997 44 1.20(4.84) 44 0.60(5.90) 3.7 0.60[-1.65,2.85]
Delmas 1997 27 -0.15(4.31) 26 -2.69(3.77) 4.0 2.54[0.36,4.72]
Fogelman 2000 139 4.10(4.13) 143 0.00(4.19) 19.9 4.10[3.13,5.07]
Harris 1999 480 5.19(5.04) 495 0.81(4.45) 52.5 4.38[3.78,4.98]
Mortensen 1998 17 1.40(3.30) 20 -4.30(3.13) 4.3 5.70[3.62,7.78]
Reginster 2000 251 6.28(6.34) 221 0.91(5.80) 15.6 5.37[4.27,6.47]
Total(95%CI) 958 949 100.0 4.32[3.89,4.76]
Test for heterogeneity chi-square=18.47  df=5  p=0.0024
Test for overall effect  z=19.57  p<0.00001
Review : Lumbar - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Harris 1999 425 5.40(5.98) 398 1.10(5.79) 75.9 4.30[3.50,5.10]
Reginster 2000 251 7.14(8.40) 221 1.37(7.43) 24.1 5.77[4.34,7.20]
Total(95%CI) 676 619 100.0 4.65[3.95,5.35]
Test for heterogeneity chi-square=3.09  df=1  p=0.079
Test for overall effect  z=13.02  p<0.00001
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Percentage change in Lumbar Vertebral BMD for tiludronate at 3 years - All studies 
 
 
Review : Lumbar - Tiludronate
Comparison : 01 Tiludronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Reginster 1989 38 1.33(4.93) 38 -2.10(4.93) 72.1 3.43[1.21,5.65]
Reginster 2001 141 -15.95(11.28) 144 -9.60(18.60) 27.9 -6.35[-9.91,-2.79]
Total(95%CI) 179 182 100.0 0.70[-1.18,2.58]
Test for heterogeneity chi-square=20.87  df=1  p<0.00001
Test for overall effect  z=0.73  p=0.5
Review : Lumbar - Tiludronate
Comparison : 01 Tiludronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Reginster 2001 141 -8.27(15.67) 144 1.06(23.04) 100.0 -9.33[-13.90,-4.76]
Total(95%CI) 141 144 100.0 -9.33[-13.90,-4.76]
Test for heterogeneity chi-square=0.0  df=0
Test for overall effect  z=4.00  p=0.00006
Review : Lumbar - Tiludronate
Comparison : 01 Tiludronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Reginster 2001 141 -4.99(15.67) 144 5.10(18.84) 100.0 -10.09[-14.11,-6.07]
Total(95%CI) 141 144 100.0 -10.09[-14.11,-6.07]
Test for heterogeneity chi-square=0.0  df=0
Test for overall effect  z=4.92  p<0.00001
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Percentage change in Femoral Neck BMD for alendronate at 1 year - All studies 
 
 
Percentage change in Femoral Neck BMD for alendronate at 2 years - All studies 
Review : Femoral - Alendronate
Comparison : 01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 1995 61 2.25(5.70) 62 -1.38(6.14) 0.6 3.63[1.54,5.72]
Black 1996 1022 2.08(5.75) 1005 0.15(5.39) 11.7 1.93[1.44,2.42]
Bone 1997 82 1.01(4.07) 85 -0.52(4.89) 1.5 1.53[0.17,2.89]
Bone 2000 87 2.19(3.54) 46 -0.22(3.46) 1.8 2.41[1.16,3.66]
Chesnut 1995 30 3.88(4.33) 31 -0.38(3.56) 0.7 4.26[2.27,6.25]
Cummings 1998 2214 1.83(3.76) 2218 0.24(4.24) 49.3 1.59[1.35,1.83]
Devogelaer 1996 72 3.49(4.67) 156 0.29(4.75) 1.6 3.20[1.89,4.51]
Downs 2000 105 2.85(4.51) 51 -1.18(4.36) 1.3 4.03[2.55,5.51]
Dursun 2001 51 3.75(6.16) 50 2.33(4.32) 0.6 1.42[-0.65,3.49]
Greenspan 1998 46 2.71(3.26) 44 0.76(2.65) 1.8 1.95[0.72,3.18]
Johnell 2002 82 2.70(4.53) 83 0.20(3.64) 1.7 2.50[1.25,3.75]
Kung 2000 28 2.33(3.23) 28 -0.23(3.65) 0.8 2.56[0.75,4.37]
Lau 2000 41 3.98(3.91) 37 0.12(4.44) 0.8 3.86[1.99,5.73]
Liberman 1995 180 2.99(4.96) 374 0.27(6.00) 3.1 2.72[1.77,3.67]
Lindsay 1999 203 1.70(5.70) 191 0.80(5.53) 2.2 0.90[-0.21,2.01]
McClung 1998 88 2.05(3.75) 78 -0.98(3.00) 2.6 3.03[2.00,4.06]
Murphy 2001 109 1.45(4.49) 36 0.35(3.60) 1.3 1.10[-0.35,2.55]
Pols 1999 832 2.30(4.50) 865 -0.20(4.50) 15.0 2.50[2.07,2.93]
Rossini 2000 42 1.51(5.70) 41 -0.69(2.63) 0.8 2.20[0.30,4.10]
Sahota 2000 31 2.60(5.01) 33 0.40(3.45) 0.6 2.20[0.08,4.32]
Yen 2000 24 6.86(6.81) 22 1.20(5.91) 0.2 5.66[1.98,9.34]
Total(95%CI) 5430 5536 100.0 1.98[1.82,2.15]
Test for heterogeneity chi-square=55.84  df=20  p<0.00001
Test for overall effect  z=23.44  p<0.00001
Review : Femoral - Alendronate
Comparison : 01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 1995 65 1.19(7.09) 67 -2.58(7.28) 0.8 3.77[1.32,6.22]
Black 1996 1022 2.80(5.43) 1005 -0.23(5.71) 19.8 3.03[2.54,3.52]
Bone 1997 82 1.89(4.44) 85 -1.51(5.35) 2.1 3.40[1.91,4.89]
Bone 2000 87 2.90(4.66) 46 -0.60(4.07) 2.0 3.50[1.97,5.03]
Chesnut 1995 30 5.27(3.83) 31 -1.20(3.56) 1.4 6.47[4.61,8.33]
Cummings 1998 2214 2.75(5.18) 2218 -0.01(5.65) 45.9 2.76[2.44,3.08]
Devogelaer 1996 72 3.22(4.41) 156 -0.83(4.87) 2.9 4.05[2.78,5.32]
Greenspan 1998 46 2.49(4.21) 44 0.12(3.18) 2.0 2.37[0.83,3.91]
Hosking 1998 396 1.30(3.98) 409 -1.60(4.04) 15.2 2.90[2.35,3.45]
Liberman 1995 174 3.49(5.54) 347 -0.77(5.03) 4.9 4.26[3.28,5.24]
McClung 1998 84 1.89(3.57) 78 -3.15(4.33) 3.1 5.04[3.81,6.27]
Total(95%CI) 4272 4486 100.0 3.09[2.88,3.31]
Test for heterogeneity chi-square=36.29  df=10  p=0.0001
Test for overall effect  z=28.06  p<0.00001
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Percentage change in Femoral Neck BMD for alendronate at 3 years - All studies 
 
 
Review : Femoral - Alendronate
Comparison : 01 Alendronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Black 1996 1022 3.59(5.43) 1005 -0.45(5.71) 28.1 4.04[3.55,4.53]
Cummings 1998 2214 3.31(6.12) 2218 -0.55(5.18) 59.3 3.86[3.53,4.19]
Devogelaer 1996 72 4.80(5.09) 156 -0.70(5.00) 3.3 5.50[4.09,6.91]
Liberman 1995 174 4.69(6.33) 332 -1.22(5.65) 5.3 5.91[4.79,7.03]
McClung 1998 84 2.27(4.22) 78 -3.95(4.15) 4.0 6.22[4.93,7.51]
Total(95%CI) 3566 3789 100.0 4.17[3.91,4.42]
Test for heterogeneity chi-square=25.97  df=4  p<0.00001
Test for overall effect  z=31.76  p<0.00001
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Review : Femoral - Clodronate
Comparison : 01 Clodronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Giannini 1996 17 -0.14(3.05) 14 -1.84(2.81) 8.1 1.70[-0.37,3.77]
Gnudi 2001 32 1.21(4.58) 32 0.40(3.50) 8.6 0.81[-1.19,2.81]
Heikkinen 1997 21 0.70(2.90) 22 -1.30(2.80) 11.9 2.00[0.29,3.71]
McCloskey 2001 333 1.30(5.47) 341 0.40(5.54) 49.9 0.90[0.07,1.73]
Saarto 1997 40 -0.40(4.49) 53 -1.50(3.13) 13.0 1.10[-0.53,2.73]
Tsai 1999 29 -0.78(4.47) 25 -2.13(3.05) 8.5 1.35[-0.67,3.37]
Total(95%CI) 472 487 100.0 1.15[0.56,1.74]
Test for heterogeneity chi-square=1.73  df=5  p=0.89
Test for overall effect  z=3.84  p=0.0001
Review : Femoral - Clodronate
Comparison : 01 Clodronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Gnudi 2001 32 1.58(3.97) 32 -1.04(4.24) 30.3 2.62[0.61,4.63]
Heikkinen 1997 21 -1.90(3.30) 22 -3.20(3.50) 29.7 1.30[-0.73,3.33]
Rossini 1999 16 0.62(4.04) 30 -1.29(5.31) 16.3 1.91[-0.83,4.65]
Saarto 1997 40 0.90(5.44) 53 -2.00(5.68) 23.7 2.90[0.62,5.18]
Total(95%CI) 109 137 100.0 2.18[1.07,3.29]
Test for heterogeneity chi-square=1.33  df=3  p=0.72
Test for overall effect  z=3.85  p=0.0001
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Percentage change in Femoral Neck BMD for etidronate at 2 years - All studies 
 
 
Review : Femoral - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 2000 36 -0.91(3.60) 41 -1.70(4.23) 8.4 0.79[-0.96,2.54]
Blake 1996 61 -0.17(3.05) 70 -1.02(3.26) 22.0 0.85[-0.23,1.93]
Harris 1993 92 1.36(6.33) 90 0.66(7.87) 6.0 0.70[-1.38,2.78]
Heath 2000 38 0.36(3.88) 39 -1.63(3.87) 8.6 1.99[0.26,3.72]
Herd 1997 66 -0.14(3.17) 74 -0.93(3.35) 22.1 0.79[-0.29,1.87]
Lyritis 1997 47 1.13(0.00) 44 -1.17(0.00) 0.0x Not Estimable
Meunier 1997 25 1.56(2.75) 24 -0.52(3.09) 9.6 2.08[0.44,3.72]
Montessori 1997 40 2.73(3.92) 34 0.07(3.27) 9.6 2.66[1.02,4.30]
Pouilles 1997 45 0.29(3.89) 46 -0.27(4.14) 9.5 0.56[-1.09,2.21]
Sahota 2000 36 2.00(6.60) 34 0.40(3.50) 4.3 1.60[-0.86,4.06]
Total(95%CI) 486 496 100.0 1.22[0.71,1.72]
Test for heterogeneity chi-square=7.02  df=8  p=0.53
Test for overall effect  z=4.70  p<0.00001
Review : Femoral - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Adami 2000 36 -0.06(5.58) 41 -2.20(6.98) 4.3 2.14[-0.67,4.95]
Blake 1996 61 1.63(4.14) 70 -0.09(3.35) 20.2 1.72[0.42,3.02]
Harris 1993 92 1.13(7.39) 90 0.05(7.97) 6.9 1.08[-1.15,3.31]
Herd 1997 63 1.86(4.60) 70 -0.03(3.35) 18.0 1.89[0.51,3.27]
Lyritis 1997 47 1.63(0.00) 44 -1.99(0.00) 0.0x Not Estimable
Meunier 1997 25 0.03(2.60) 24 -1.76(2.74) 15.3 1.79[0.29,3.29]
Montessori 1997 40 3.64(5.31) 34 -1.37(3.50) 8.4 5.01[2.99,7.03]
Pouilles 1997 45 -0.35(5.84) 46 -1.32(5.43) 6.4 0.97[-1.35,3.29]
Watts 1990 92 3.66(9.88) 89 0.51(8.11) 5.0 3.15[0.52,5.78]
Wimalawansa 1995 12 1.54(2.22) 11 -3.21(3.85) 5.1 4.75[2.15,7.35]
Wimalawansa 1998 16 1.20(2.80) 16 -2.20(2.40) 10.5 3.40[1.59,5.21]
Total(95%CI) 529 535 100.0 2.36[1.78,2.95]
Test for heterogeneity chi-square=16.06  df=9  p=0.066
Test for overall effect  z=7.92  p<0.00001
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Percentage change in Femoral Neck BMD for etidronate at 3 years- All studies 
Review : Femoral - Etidronate
Comparison : 01 Etidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Harris 1993 73 0.98(7.78) 72 0.13(8.82) 50.0 0.85[-1.86,3.56]
Lyritis 1997 47 1.92(0.00) 90 -3.17(0.00) 0.0x Not Estimable
Montessori 1997 36 1.44(6.24) 31 -2.97(5.07) 50.0 4.41[1.70,7.12]
Total(95%CI) 156 193 100.0 2.63[0.71,4.54]
Test for heterogeneity chi-square=3.32  df=1  p=0.069
Test for overall effect  z=2.69  p=0.007
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Percentage change in Femoral Neck BMD for ibandronate at 1 year - All studies 
 
 
Review : Femoral - Ibandronate
Comparison : 01 Ibandronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Ravn 1996 30 2.50(3.10) 30 1.20(2.70) 68.6 1.30[-0.17,2.77]
Thiebaud 1997 19 1.35(3.92) 24 0.25(3.18) 31.4 1.10[-1.07,3.27]
Total(95%CI) 49 54 100.0 1.24[0.02,2.46]
Test for heterogeneity chi-square=0.02  df=1  p=0.88
Test for overall effect  z=1.99  p=0.05
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Review : Femoral - Pamidronate
Comparison : 01 Pamidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Reid 1994 26 1.60(4.84) 22 -1.61(8.02) 16.1 3.21[-0.62,7.04]
Ryan 2000 40 1.00(3.54) 41 -1.37(4.16) 83.9 2.37[0.69,4.05]
Total(95%CI) 66 63 100.0 2.51[0.97,4.04]
Test for heterogeneity chi-square=0.15  df=1  p=0.69
Test for overall effect  z=3.19  p=0.001
Review : Femoral - Pamidronate
Comparison : 01 Pamidronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Lees 1996 22 1.20(2.30) 32 -1.90(3.90) 48.0 3.10[1.44,4.76]
Reid 1994 26 1.00(4.59) 22 -1.06(4.92) 18.0 2.06[-0.65,4.77]
Ryan 2000 40 1.67(4.55) 41 -1.11(4.48) 34.1 2.78[0.81,4.75]
Total(95%CI) 88 95 100.0 2.80[1.66,3.95]
Test for heterogeneity chi-square=0.41  df=2  p=0.81
Test for overall effect  z=4.79  p<0.00001
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Percentage change in Femoral Neck BMD for risedronate at 1 year - All studies 
 
 
Percentage change in Femoral Neck BMD for risedronate at 2 years - All studies 
 
 
Percentage change in Femoral Neck BMD for risedronate at 3 years - All studies 
Review : Femoral - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Clemmesen 1997 44 1.98(5.84) 44 -1.15(5.44) 3.7 3.13[0.77,5.49]
Delmas 1997 27 -0.58(3.53) 26 -1.94(2.70) 7.3 1.36[-0.33,3.05]
Fogelman 2000 139 1.20(3.89) 143 -0.20(3.35) 29.0 1.40[0.55,2.25]
Harris 1999 265 2.04(4.72) 266 0.33(4.24) 35.8 1.71[0.95,2.47]
Mortensen 1998 17 0.57(2.64) 20 -0.89(2.28) 8.1 1.46[-0.14,3.06]
Reginster 2000 251 1.59(6.81) 221 0.74(5.80) 16.1 0.85[-0.29,1.99]
Total(95%CI) 743 720 100.0 1.49[1.03,1.95]
Test for heterogeneity chi-square=3.46  df=5  p=0.63
Test for overall effect  z=6.39  p<0.00001
Review : Femoral - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Clemmesen 1997 44 0.82(6.43) 44 -1.51(7.43) 2.3 2.33[-0.57,5.23]
Delmas 1997 27 -1.11(4.36) 26 -2.51(4.08) 3.8 1.40[-0.87,3.67]
Fogelman 2000 139 1.30(3.89) 143 -1.00(3.83) 24.3 2.30[1.40,3.20]
Harris 1999 504 1.91(5.61) 509 0.01(4.96) 46.4 1.90[1.25,2.55]
Mortensen 1998 17 0.70(4.12) 21 -2.39(3.62) 3.2 3.09[0.59,5.59]
Reginster 2000 251 1.21(5.70) 221 -0.61(5.35) 19.9 1.82[0.82,2.82]
Total(95%CI) 982 964 100.0 2.01[1.57,2.45]
Test for heterogeneity chi-square=1.69  df=5  p=0.89
Test for overall effect  z=8.86  p<0.00001
Review : Femoral - Risedronate
Comparison : 01 Risedronate vs Placebo












-10 -5 0 5 10
Favours Control Favours Treatment
Harris 1999 457 1.61(5.99) 419 -1.13(4.91) 79.1 2.74[2.02,3.46]
Reginster 2000 251 2.11(6.50) 221 -0.94(8.77) 20.9 3.05[1.64,4.46]
Total(95%CI) 708 640 100.0 2.80[2.16,3.45]
Test for heterogeneity chi-square=0.15  df=1  p=0.7
Test for overall effect  z=8.55  p<0.00001
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5.1.5 Pooled efficacy results from meta-analyses 
Data from studies with appropriate dosing regimen were pooled.  Only studies with the 
appropriate dosing regimen were included for these analyses as well as for subsequent 
subgroup analyses and pharmacoeconomic analyses as from experience with most drugs, 
initial dose ranging studies produced sub-optimal efficacy and therefore, may affect the 
overall results of the meta-analyses. 
 
Manufacturer’s recommended dosing regimen for alendronate (10mg daily), etidronate 
(400mg daily for 14 days in a 90-day cycle) and risedronate (5mg daily) was utilised.  
Cost of clodronate was taken as 800mg once daily based on the lowest dose reported to be 
effective in management of postmenopausal osteoporosis.  The number of studies 
available for analysis is as shown. 
Number of studies 
Lumbar Vertebral BMD Femoral Neck BMD Bisphosphonate 
1 Year 2 Years 3 Years 1 Year 2 Years 3 Years 
Alendronate 15 7 3 15 6 3 
Clodronate 2 1 0 2 1 0 
Etidronate 11 11 2 9 8 2 
Ibandronate 2 0 0 1 0 0 
Pamidronate 1 2 0 1 2 0 
Risedronate 4 4 2 4 4 2 
Tiludronate 0 0 0 0 0 0 
Zoledronate 0 0 0 0 0 0 
 
Table 5.20 : Number of studies available for data pooling for each bisphosphonate (all studies) 
 
The results of the meta-analyses are shown in the following tables.  The last 2 columns of 
the table are the chi-squared value and p-value for the test for heterogeneity.  For drugs 
whereby only one study was available for pooling, both the chi-squared value and p-value 
are listed as not applicable (NA). 
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Percentage Change in Lumbar Vertebral Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 15 3729 4.91 [4.67,5.15] 1799 1930 25.54 0.03 
Clodronate 2 767 2.77 [2.05,3.50] 373 394 0.12 0.73 
Etidronate 11 1099 2.94 [2.46,3.41] 547 552 21.09 0.02 
Ibandronate 2 222 3.57 [2.61,4.53] 111 111 0.34 0.56 
Pamidronate 1 81 3.56 [0.68,6.44] 40 41 NA NA 
Risedronate 4 1342 3.35 [2.88,3.81] 681 661 2.73 0.44 
Table 5.21 : Percentage Change in Lumbar Vertebral BMD at 1 Year (studies with appropriate dosing regimen) 
 
Percentage Change in Lumbar Vertebral Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 7 1418 7.14 [6.71,7.57] 586 832 10 0.12 
Clodronate 1 93 3.7 [1.46,5.94] 40 53 NA NA 
Etidronate 11 1024 3.58 [2.99,4.17] 482 487 13.71 0.13 
Pamidronate 2 135 4.5 [3.23,5.76] 73 62 0.11 0.74 
Risedronate 4 1766 4.55 [4.10,5.00] 887 879 4.46 0.22 
 
Table 5.22 : Percentage Change in Lumbar Vertebral BMD at 2 Years (studies with appropriate dosing regimen) 
 
Percentage Change in Lumbar Vertebral Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 3 948 8.26 [7.71,8.82] 350 598 6.65 0.036 
Etidronate 2 212 4.29 [2.66,5.91] 109 103 1.9 0.17 
Risedronate 2 1295 4.65 [3.95,5.35] 676 619 3.09 0.079 
 
Table 5.23 : Percentage Change in Lumbar Vertebral BMD at 3 Years (studies with appropriate dosing regimen) 
 
Percentage Change in Femoral Neck Bone Mineral Density at 1 Year 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 15 3773 2.68 [2.39,2.97] 1821 1952 18.69 0.18 
Clodronate 2 767 0.94 [0.20,1.68] 373 394 0.05 0.83 
Etidronate 9 891 1.22 [0.71,1.72] 439 452 7.02 0.53 
Ibandronate 1 60 1.3 [-0.17,2.77] 30 30 NA NA 
Pamidronate 1 81 2.37 [0.69,4.05] 40 41 NA NA 
Risedronate 4 1322 1.43 [0.95,1.91] 672 650 1.52 0.68 
 
Table 5.24 : Percentage Change in Femoral Neck BMD at 1 Year (studies with appropriate dosing regimen) 
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Percentage Change in Femoral Neck Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 6 1237 4.45 [3.90,5.01] 512 725 7.73 0.17 
Clodronate 1 93 2.9 [0.62,5.18] 40 53 NA NA 
Etidronate 8 918 2.09 [1.45,2.73] 454 464 10.86 0.14 
Pamidronate 2 135 2.97 [1.70,4.23] 62 73 0.06 0.81 
Risedronate 4 1805 2.03 [1.57,2.49] 911 894 1.36 0.71 
 
Table 5.25 : Percentage Change in Femoral Neck BMD at 2 Years (studies with appropriate dosing regimen) 
 
Percentage Change in Femoral Neck Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 3 896 5.9 [5.17,6.63] 330 566 15.94 0.76 
Etidronate 2 212 2.63 [0.71,4.54] 109 103 3.32 0.069 
Risedronate 2 1348 2.8 [2.16,3.45] 708 640 0.15 0.7 
 
Table 5.26 : Percentage Change in Femoral Neck BMD at 3 Years (studies with appropriate dosing regimen) 
 
Pooled overall treatment for all drugs produced statistically significant effects as 
compared to controls except for femoral neck BMD with ibandronate treatment.  
Alendronate appears to have the highest mean treatment effect among the agents.   
 
All results reported no statistically significant heterogeneity in the pooled studies, except 
for spinal BMD of alendronate at 1 and 3 years, and for etidronate spinal BMD at 1 year.  
Since most of the heterogeniety is removed by pooling studies with appropriate dosing 
instead of all randomised controlled trial using a fixed effects model, a random effects 
model is not utilised. 
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5.1.6 Analyses of heterogeniety of results of meta-analyses 
 
The impact of three criteria was explored for studies with appropriate dosing regimens to 
determine their impact, if any, on the results of the meta-analyses.  There were as follows: 
 
(A) Quality score more than or equal to 2.  The cut-off quality score of 2 was used as 
it was the mid-point in the scoring scale (see Chapter 4.5. Methods - Quality of 
Studies) 
 
(B) Double-blinded studies.  Subgroup analysis on only double-blinded studies 
determines if any unblinded study would skew the results of the analysis. 
 
(C) Studies with mean baseline lumbar bone mineral density less than 0.80g/cm2 or 
femoral neck bone mineral density less than 0.70g/cm2.  The chosen values were 
based on the local average BMD +/- SD for patients between 60 to 65 years old 
used to calculate Z-scores as provided by the local vendor of Hologic densitometry 
machines (eRay Systems Pte Ltd).  The BMD values for L1-4 and femoral neck 
are 0.805 +/- 0.122 and 0.682 +/- 0.108 g/cm2 respectively.  Studies with baseline 
BMD not reported were excluded from this analysis. 
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The number of studies available for each heterogeneity analysis are as follows : 
(A) With Quality score more than or equal to 2 : 
Number of studies 
Lumbar Vertebral BMD Femoral Neck BMD Bisphosphonate 
1 Year 2 Years 3 Years 1 Year 2 Years 3 Years 
Alendronate 13 6 3 14 6 3 
Clodronate 1 0 0 1 0 0 
Etidronate 9 8 2 8 8 2 
Ibandronate 2 0 0 1 0 0 
Pamidronate 1 2 0 1 0 0 
Risedronate 3 3 2 3 3 2 
Tiludronate 0 0 0 0 0 0 
Zoledronate 0 0 0 0 0 0 
 
Table 5.27 : Number of studies available for data pooling for each bisphosphonate (quality score ≥ 2) 
 
(B) Double blinded studies 
Number of studies 
Lumbar Vertebral BMD Femoral Neck BMD Bisphosphonate 
1 Year 2 Years 3 Years 1 Year 2 Years 3 Years 
Alendronate 12 6 3 13 6 3 
Clodronate 1 0 0 1 0 0 
Etidronate 7 7 1 6 7 1 
Ibandronate 2 0 0 1 0 0 
Pamidronate 1 2 0 1 2 0 
Risedronate 4 4 2 4 4 2 
Tiludronate 0 0 0 0 0 0 
Zoledronate 0 0 0 0 0 0 
 
Table 5.28 : Number of studies available for data pooling for each bisphosphonate (double blinded studies) 
 
(C) Baseline lumbar vertebral BMD ≤ 0.80g/cm2 or femoral neck BMD ≤ 0.70g/cm2 
Number of studies 
Lumbar Vertebral BMD Femoral Neck BMD Bisphosphonate 
1 Year 2 Years 3 Years 1 Year 2 Years 3 Years 
Alendronate 11 5 2 8 2 1 
Clodronate 1 0 0 1 0 0 
Etidronate 1 1 1 2 2 2 
Ibandronate 1 0 0 1 0 0 
Pamidronate 1 1 0 1 1 0 
Risedronate 2 2 1 3 3 2 
Tiludronate 0 0 0 0 0 0 
Zoledronate 0 0 0 0 0 0 
 
Table 5.29 : Number of studies available for data pooling for each bisphosphonate (Baseline femoral neck BMD ≤ 0.7 
g/cm2 or lumbar vertebral BMD ≤ 0.8 g/cm2) 
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Results of the heterogeneity analyses are presented in the following tables. 
 
(A) Studies with Quality Score greater or equal to 2 AND appropriate dosing regimen 
(A) Percentage Change in Lumbar Vertebral Bone Mineral Density at 1 Year 




(Fixed) [95% CI] Control Tx Chi-square P 
Alendronate 13 3534 4.9 [4.66,5.13] 1700 1834 22.44 0.033 
Clodronate 1 674 2.7 [1.87,3.53] 333 341 NA NA 
Etidronate 9 996 2.97 [2.47,3.46] 494 502 9.13 0.33 
Ibandronate 2 222 3.57 [2.61,4.53] 111 111 0.34 0.56 
Pamidronate 1 81 3.56 [0.68,6.44] 41 40 NA NA 
Risedronate 3 1060 3.37 [2.82,3.92] 542 518 2.71 0.26 
 
Table 5.30 : Percentage Change in Lumbar Vertebral BMD at 1 Year (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
 
(A) Percentage Change in Lumbar Vertebral Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx Chi-square P 
Alendronate 6 1322 7.15 [6.71,7.58] 538 784 9.89 0.079 
Etidronate 8 920 3.44 [2.81,4.07] 455 465 7.68 0.36 
Pamidronate 2 135 4.5 [3.23,5.76] 73 62 0.11 0.74 
Risedronate 3 1484 4.67 [4.16,5.18] 748 736 3.41 0.18 
 
Table 5.31 : Percentage Change in Lumbar Vertebral BMD at 2 Years (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
 
(A) Percentage Change in Lumbar Vertebral Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx Chi-square P 
Alendronate 3 948 8.26 [7.71,8.82] 350 598 6.65 0.036 
Etidronate 2 212 4.29 [2.66,5.91] 109 103 1.9 0.17 
Risedronate 2 1295 4.65 [3.95,5.35] 676 619 3.09 0.079 
 
Table 5.32 : Percentage Change in Lumbar Vertebral BMD at 3 Years (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
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(A) Percentage Change in Femoral Neck Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 14 3672 2.71 [2.41,3.00] 1770 1902 17.39 0.18 
Clodronate 1 674 0.9 [0.07,1.73] 333 341 NA NA 
Etidronate 8 814 1.14 [0.61,1.68] 401 413 6.18 0.52 
Ibandronate 1 60 1.3 [-0.17,2.77] 30 30 NA NA 
Pamidronate 1 81 2.37 [0.69,4.05] 40 41 NA NA 
Risedronate 3 1040 1.45 [0.86,2.03] 533 507 1.51 0.47 
 
Table 5.33 : Percentage Change in Femoral Neck BMD at 1 Year (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
 
(A) Percentage Change in Femoral Neck Bone Mineral Density at 2 Years  




(Fixed) [95% CI] Control Tx Chi-square P 
Alendronate 6 1237 4.45 [3.90,5.01] 512 725 7.73 0.17 
Etidronate 8 918 2.09 [1.45,2.73] 454 464 10.86 0.14 
Risedronate 3 1523 1.93 [1.40,2.46] 772 751 0.88 0.64 
 
Table 5.34 : Percentage Change in Femoral Neck BMD at 2 Years (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
 
(A) Percentage Change in Femoral Neck Bone Mineral Density at 3 Years  




(Fixed) [95% CI] Control Tx Chi-square P 
Alendronate 3 896 5.9 [5.17,6.63] 330 566 0.54 0.76 
Etidronate 2 212 2.63 [0.71,4.54] 109 103 3.32 0.069 
Risedronate 2 1348 2.8 [2.16,3.45] 708 640 0.15 0.7 
 
Table 5.35 : Percentage Change in Femoral Neck BMD at 3 Years (studies with appropriate dosing regimen and Quality 
Score ≥ 2) 
 
It appears that except for lumbar BMD measurements for alendronate, adjusting for 
studies with quality score greater than 2 resulted in chi-squared heterogeneity scores 
greater than 0.05 (non-significant heterogeneity). 
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(B) Double blinded studies with appropriate dosing regimen 
(B) Percentage Change in Lumbar Vertebral Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 12 3470 4.9 [4.66,5.14] 1669 1801 22.17 0.023 
Clodronate 1 674 2.7 [1.87,3.53] 333 341 NA NA 
Etidronate 7 852 2.79 [2.26,3.31] 418 434 3.78 0.71 
Ibandronate 2 222 3.57 [2.61,4.53] 111 111 0.34 0.56 
Pamidronate 1 81 3.56 [0.68,6.44] 41 40 NA NA 
Risedronate 4 1342 3.35 [2.88,3.81] 681 661 2.73 0.44 
 
Table 5.36 : Percentage Change in Lumbar Vertebral BMD at 1 Year (studies with appropriate dosing regimen and double 
blinded) 
 
(B) Percentage Change in Lumbar Vertebral Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 6 1322 7.15 [6.71,7.58] 538 784 9.89 0.079 
Etidronate 7 846 3.34 [2.70,3.98] 415 431 4.95 0.55 
Pamidronate 2 135 4.5 [3.23,5.76] 73 62 0.11 0.74 
Risedronate 4 1766 4.55 [4.10,5.00] 887 879 4.46 0.22 
 
Table 5.37 : Percentage Change in Lumbar Vertebral BMD at 2 Years (studies with appropriate dosing regimen and double 
blinded) 
 
(B) Percentage Change in Lumbar Vertebral Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 3 948 8.26 [7.71,8.82] 350 598 6.65 0.036 
Etidronate 1 145 3.21 [0.98,5.44] 73 72 NA NA 
Risedronate 2 1295 4.65 [3.95,5.35] 676 619 3.09 0.079 
 
Table 5.38 : Percentage Change in Lumbar Vertebral BMD at 3 Years (studies with appropriate dosing regimen and double 
blinded) 
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(B) Percentage Change in Femoral Neck Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 13 3608 2.72 [2.42,3.01] 1739 1869 17.18 0.14 
Clodronate 1 674 0.9 [0.07,1.73] 333 341 NA NA 
Etidronate 6 670 0.93 [0.35,1.51] 325 345 2.24 0.82 
Ibandronate 1 60 1.3 [-0.17,2.77] 30 30 NA NA 
Pamidronate 1 81 2.37 [0.69,4.05] 40 41 NA NA 
Risedronate 4 1322 1.43 [0.95,1.91] 672 650 1.52 0.68 
 
Table 5.39 : Percentage Change in Femoral Neck BMD at 1 Year (studies with appropriate dosing regimen and double 
blinded) 
 
(B) Percentage Change in Femoral Neck Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 6 1237 4.45 [3.90,5.01] 512 725 7.73 0.17 
Etidronate 7 844 1.77 [1.10,2.44] 414 430 1.98 0.92 
Pamidronate 2 135 2.97 [1.70,4.23] 62 73 0.06 0.81 
Risedronate 4 1805 2.03 [1.57,2.49] 911 894 1.36 0.71 
 
Table 5.40 : Percentage Change in Femoral Neck BMD at 2 Years (studies with appropriate dosing regimen and double 
blinded) 
 
(B) Percentage Change in Femoral Neck Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 3 896 5.9 [5.17,6.63] 330 566 15.94 0.00001 
Etidronate 1 145 0.85 [-1.86,3.56] 73 72 NA NA 
Risedronate 2 1348 2.8 [2.16,3.45] 708 640 0.15 0.7 
 
Table 5.41 : Percentage Change in Femoral Neck BMD at 3 Years (studies with appropriate dosing regimen and double 
blinded) 
 
The analysis with double blinded studies only does not appear to have any significant 
impact on the outcome variables.  This may be expected as both variables were objective 
measurements and therefore, less likely to be subjected to observational bias. 
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(C) Studies with Baseline Lumbar Vertebral BMD ≤ 0.80mg/cm2 or Femoral BMD ≤ 
0.70mg/cm2 AND appropriate dosing regimen 
(C) Percentage Change in Lumbar Vertebral Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 11 3276 4.89 [4.65,5.14] 1729 1547 22.18 0.014 
Clodronate 1 674 2.7 [1.87,3.53] 333 341 NA NA 
Etidronate 1 74 4.85 [3.18,6.52] 34 40 NA NA 
Ibandronate 1 162 3.32 [2.05,4.59] 81 81 NA NA 
Pamidronate 1 81 3.56 [0.68,6.44] 41 40 NA NA 
Risedronate 2 754 3.56 [2.91,4.21] 364 390 0.84 0.36 
 
Table 5.42 : Percentage Change in Lumbar Vertebral BMD at 1 Year (studies with appropriate dosing regimen and 
Baseline Lumbar BMD ≤ 0.8g/cm2) 
 
(C) Percentage Change in Lumbar Vertebral Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 5 1124 7.27 [6.78,7.77] 687 437 4.87 0.3 
Etidronate 1 74 6.31 [2.84,9.78] 34 40 NA NA 
Pamidronate 1 81 4.97 [1.87,8.07] 41 40 NA NA 
Risedronate 2 754 4.66 [3.93,5.39] 364 390 2.89 0.089 
 
Table 5.43 : Percentage Change in Lumbar Vertebral BMD at 2 Years (studies with appropriate dosing regimen and 
Baseline Lumbar BMD ≤ 0.8g/cm2) 
 
(C) Percentage Change in Lumbar Vertebral Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 2 786 8.58 [7.93,9.24] 520 266 3.44 0.063 
Etidronate 1 67 5.5 [3.13,7.87] 31 36 NA NA 
Risedronate 1 472 5.77 [4.34,7.20] 221 251 NA NA 
 
Table 5.44 : Percentage Change in Lumbar Vertebral BMD at 3 Years (studies with appropriate dosing regimen and 
Baseline Lumbar BMD ≤ 0.8g/cm2) 
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(C) Percentage Change in Femoral Neck Bone Mineral Density at 1 Year  




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 8 2864 2.56 [2.21,2.90] 1507 1357 9.7 0.21 
Clodronate 1 674 0.9 [0.07,1.73] 333 341 NA NA 
Etidronate 2 256 1.91 [0.62,3.20] 124 132 2.11 0.15 
Ibandronate 1 60 1.3 [-0.17,2.77] 30 30 NA NA 
Pamidronate 1 81 2.37 [0.69,4.05] 40 41 NA NA 
Risedronate 3 1285 1.43 [0.92,1.94] 630 655 1.52 0.47 
 
Table 5.45 : Percentage Change in Femoral Neck BMD at 1 Year (studies with appropriate dosing regimen and Baseline 
Femoral Neck BMD ≤ 0.70g/cm2) 
 
(C) Percentage Change in Femoral Neck Bone Mineral Density at 2 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 2 653 4.19 [3.28,5.10] 414 239 0.13 0.72 
Etidronate 2 256 3.24 [1.74,4.74] 124 132 6.53 0.011 
Pamidronate 1 81 2.78 [0.81,4.75] 41 40 NA NA 
Risedronate 3 1767 1.99 [1.52,2.46] 873 894 0.64 0.73 
 
Table 5.46 : Percentage Change in Femoral Neck BMD at 2 Years (studies with appropriate dosing regimen and Baseline 
Femoral Neck BMD ≤ 0.70g/cm2) 
 
(C) Percentage Change in Femoral Neck Bone Mineral Density at 3 Years 




(Fixed) [95% CI] Control Tx 
Chi-
square P 
Alendronate 1 506 5.91 [4.79,7.03] 332 174 NA NA 
Etidronate 2 212 2.63 [0.71,4.54] 103 109 3.32 0.069 
Risedronate 2 1348 2.8 [2.16,3.45] 640 708 0.15 0.7 
 
Table 5.47 : Percentage Change in Femoral Neck BMD at 3 Years (studies with appropriate dosing regimen and Baseline 
Femoral Neck BMD ≤ 0.70g/cm2) 
 
It may be of interest to note that besides alendronate and risedronate, other 
bisphosphonates did not have more than 2 or 3 randomised controlled trials on patients 
with BMD lower than the cut-off limit specified in this analysis.   
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For all the heterogeneity analyses, data at 3 years were only available for alendronate, 
etidronate and risedronate.  Hence, as of current, there may be insufficient data from 
randomised controlled trials to support the use of other bisphosphonates besides 
alendronate, etidronate and risedronate for management of postmenopausal osteoporosis. 
 
The heterogeneity analyses did not appear to affect the rankings of the mean overall effect 
for each agent.  Pooled efficacy data on alendronate continued to be the highest amongst 
the agents for both lumbar vertebral and femoral neck BMD. 
 
Outcome variables from the meta-analyses of studies with appropriate regimen would 
later be applied into a model in order to explore the cost effectiveness of bisphosphonates 
for management of postmenopausal osteoporosis. 
 
In order to translate the improvement BMD as fracture prevention benefits for use in the 
model, a correlation study between BMD improvement and relative risk of fractures 
would first have to be carried out as detailed in the next section. 
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5.2 Correlation between relative risk of fracture and BMD 
The correlation between relative risk of hip, vertebral, any non-vertebral or any fracture to 
spinal or femoral BMD was studied.  For each study reporting both fracture rates and bone 
mineral density, the incidence density of fracture (defined as the rate of fracture per 
patient year) for each arm of the study was determined.  A total of 28 relevant studies 
were obtained.  Incidence density of various fractures were as shown below. 
Incidence density of 
Vertebral fracture 
Incidence density of 
Any Non-vertebral 
fracture 
Incidence density of 
Hip fracture 
Incidence density of 
any Fracture Study 
Tx Placebo Tx Placebo Tx Placebo Tx Placebo 
Black 1996 0.008 0.017 0.041 0.051 0.004 0.008 0.049 0.068 
Bone 1997 0.024 0.033 0.053 0.089 - - 0.076 0.122 
Cummings 1998 0.006 0.011 0.032 0.035 0.002 0.003 0.037 0.046 
Dursun 2001 0.316 0.400 - - - - - - 
Greenspan 1998 - - 0.020 0.007 0.000 0.007 - - 
Hosking 1998 - - 0.025 0.015 - - - - 
Liberman 1995 0.011 0.021 0.025 0.032 0.001 0.003 - - 
Murphy 2001 0.000 0.000 0.138 0.000 0.000 0.000 0.138 0.000 
Pols 1999 - - 0.020 0.039 0.002 0.003 - - 
Bone 2000 - - 0.027 0.040 - - - - 
Clemmesen 1997 0.148 0.227 0.045 0.045 - - 0.193 0.273 
Fogelman 2000 0.036 0.068 0.031 0.052 - - 0.067 0.120 
Harris 1999 0.029 0.046 0.014 0.021 0.005 0.006 - - 
McClung 2001 - - 0.011 0.016 0.011 0.016 - - 
Mortensen 1998 0.029 0.000 0.000 0.075 - - 0.029 0.075 
Reginster 2000 0.051 0.086 0.030 0.042 0.007 0.009 - - 
Harris 1993 0.048 0.058 0.061 0.049 0.002 0.004 0.109 0.107 
Herd 1997 0.000 0.000 - - - - - - 
Lyritis 1997 0.026 0.064 0.019 0.036 0.006 0.014 0.045 0.100 
Montessori 1997 0.000 0.029 - - - - - - 
Pouilles 1997 0.009 0.000 0.028 0.055 - - 0.037 0.055 
Shiota 2001 0.025 0.275 - - - - - - 
Storm 1990 0.180 0.340 - - 0.010 0.021 - - 
Watts 1990 0.026 0.055 - - 0.005 0.000 - - 
Wimalawansa 1998 0.054 0.089 0.018 0.018 - - 0.071 0.107 
Reid 1994 0.135 0.227 - - - - - - 
Ryan 2000 0.232 0.275 - - - - - - 
Mccloskey 2001 0.049 0.090 - - - - - - 
 
Table 5.48 : Incidence density of Vertebral, Hip, Any Non-vertebral and Any Fractures in studies 
Results were plotted for relative risk of fracture versus bone mineral density as shown 
below and fitted to an exponential trend line (y = cex). 






















Figure 5.1 : Relative risk of Fracture versus percentage change of BMD from baseline as compared to placebo
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Exponential instead of linear regression was done as reports of similar studies fitted 
similar data to non-linear models. 200, 201  The correlation coefficient and constants of the 
exponential models are shown in the table below. 
 
No. Correlation Studies Correlation coefficient (R2) Constant 
Remarks on 
correlation 
1 Relative risk of vertebral fracture vs Mean difference of % 
change lumbar vertebral BMD from baseline 0.4196 0.9141 Moderate 
2 Relative risk of vertebral fracture vs Mean difference of % change femoral neck BMD from baseline 0.3803 0.8251 Moderate 
3 Relative risk of hip fracture vs Mean difference of % change lumbar vertebral BMD from baseline 0.1278 0.6876 Weak 
4 Relative risk of hip fracture vs Mean difference of % 
change femoral neck BMD from baseline 0.1046 0.7439 Weak 
5 Relative risk of non-vertebral fracture vs Mean difference of % change lumbar vertebral BMD from baseline 0.0278 0.9403 None 
6 Relative risk of non-vertebral fracture vs Mean difference of % change femoral neck BMD from baseline 0.0011 0.8527 None 
7 Relative risk of  any vertebral fracture vs Mean difference 
of % change lumbar vertebral BMD from baseline 0.2235 0.7546 Weak 
8 Relative risk of any vertebral fracture vs Mean difference of % change femoral neck BMD from baseline 0.0673 0.7249 Weak 
 
Table 5.49 : Correlation coefficient of relative risk of fracture versus mean difference in percentage change in bone mineral 
density using an exponential model 
 
All graphs exhibited an inverse relationship whereby an increase in bone mineral density 
resulted in a decrease in relative risk of fracture.  Both spinal and femoral neck BMD had 
the poorest correlation with relative risk of non-vertebral fractures. 
 
Sensitivity analysis was carried out for relative risk of vertebral fracture / hip fracture 
versus mean percentage change in lumbar / femoral neck BMD, by varying the percentage 
change in BMD by 1.96 standard deviations from the mean (ie. using the upper and lower 
95% confidence intervals).  Trend line was fitted using similar exponential model as 
shown below. 



















































Figure 5.2 : Relative risk of Fracture versus percentage change of bone mineral density from baseline as compared to 
placebo 
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Similarly, the correlation coefficient and constant are summarised in the table below. 
No. Correlation Studies Correlation 
coefficient (R2) Constant 
Remarks on 
correlation 
9 Relative risk of vertebral fracture vs + 1.96 SD of Mean difference of % change lumbar vertebral BMD from baseline 0.4609 1.1439 Moderate 
10 Relative risk of vertebral fracture vs + 1.96 SD of Mean difference of % change femoral neck BMD from baseline 0.1165 0.8249 Weak 
11 Relative risk of vertebral fracture vs - 1.96 SD of Mean difference of % change lumbar vertebral BMD from baseline 0.4952 0.8979 Moderate 
12 Relative risk of vertebral fracture vs - 1.96 SD Mean difference of % change femoral neck BMD from baseline 0.2713 0.7007 Moderate 
13 Relative risk of hip fracture vs + 1.96 SD of Mean difference of % change lumbar vertebral BMD from baseline 0.3934 2.4896 Moderate 
14 Relative risk of hip fracture vs + 1.96 SD of Mean difference of % change femoral neck BMD from baseline 0.6647 1.7358 Moderate 
15 Relative risk of hip fracture vs - 1.96 SD of Mean difference of % change lumbar vertebral BMD from baseline 0.4359 0.9144 Moderate 
16 Relative risk of hip fracture vs - 1.96 SD Mean difference of % 
change femoral neck BMD from baseline 0.1619 0.6356 Weak 
 
Table 5.50 : Sensitivity analysis of relative risk of fracture versus mean difference in percentage change in bone mineral 
density using an exponential model 
 
Results of sensitivity analysis by varying the lumbar and femoral neck BMD by 1.96 
standard deviation did not result in significant changes in correlation coefficient.  Again, 
all the graphs (not shown) exhibited an inverse relationship with increasing difference in 
change in bone mineral density resulting in lower relative risk of fractures. 
 
In order to determine if other factors such as duration of treatment and type of 
bisphosphonate affected how BMD is correlated with relative risk of fracture and estimate 
their impact, a linear model utilising lumbar vertebral BMD (BMDvert) and relative risk of 
vertebral fracture (RRVert) was created.   
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A simple linear regression model was first created from the data entered in the base 
Statistical Package for the Social Sciences v 9.0 (SPSS) as follows: 
 RRvert = -0.0198 (BMDvert) + 0.702  
Spinal BMD showed statistically significant correlation to RRvert with p = 0.029 
 
From the model, an arbitrary increase in lumbar vertebral BMD of 8% would result in a 
relative risk of vertebral fracture in the intervention group of   
-0.0198 x 8 + 0.702 = 0.5436 
Percentage reduction in fracture as compared to placebo would be 45.64 %.  This is 
similar to the results from a study by Richard Wasnich et al, 2000 200 which pooled data 
on Alendronate, Etidronate, Tiludronate, reporting a 41% reduction in risk of fracture with 
an 8% improvement in spinal BMD. 
 
With the duration of treatment taken into consideration in the linear regression model, an 
equation as shown was obtained: 
 RRvert = -0.0211 (BMD) + 0.01724 (Years) + 0.667 
Spinal BMD showed statistically significant correlation to RRvert with p = 0.037 
However, duration of treatment did not show a significant correlation to RRvert, with p = 
0.713. 
 
Hence, change in BMD from baseline but not duration of treatment may be an important 
factor in predicting outcome of fracture within the constraints of most studies included 
which are between one to four years in duration.   
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From both models, it also appears that about 30% of reduction in relative risk of vertebral 
fracture could not be explained by improvement in BMD, lending supporting to the 
hypothesis that bisphosphonates may reduce fracture rate by more than one mechanism 
besides inducing an increase in BMD. 
 
Of interest was also whether each of the bisphosphonates may have a different degree of 
influence on fracture rates with the same percentage change in BMD.  Among the 
bisphosphonates studied, three of them had sufficient number of trials for subgroup 
analysis.  They were alendronate, etidronate and risedronate. 
 
A similar linear model taking into consideration the type of drug was created as follows: 
 RRvert = -0.0219 (BMD) + 0.697 + 0.0576 (A) - 0.0528 (R) 
where A = 1 indicates alendronate and R = 1 indicates risedronate.  Both A, R = 0 
indicates etidronate. 
 
Both A and R did not have statistically significant p-values, (p = 0.607 and 0.690 
respectively).  From the results, for the same reduction in BMD, risedronate appear to 
have an approximately 5 and 10% higher reduction in relative risk of vertebral fractures as 
compared to etidronate and alendronate respectively. 
 
A similar set of models were created to explore the relationship between femoral neck 
bone mineral density (BMDfem) and the relative risk of hip fracture (RRhip). 
 
A simple linear regression model derived the following equation: 
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 RRhip = -0.02807 (BMDfem) + 0.718 
BMDfem however, did not show statistically significant correlation to RRhip, with p = 0.476 
 
Similar to the spinal model, duration of treatment did not show a significant correlation to 
RRhip, with p = 0.757 
RRhip = -0.03802 (BMDfem) + 0.03805 (Years) + 0.644 
 
With subgroup analysis of the 3 different drugs alendronate, risedronate and etidronate as 
above,  
 RRhip = -0.00861 (BMDfem) + 0.808 - 0.211 (A) - 0.315 (E) 
where A = 1 indicates alendronate and E = 1 indicates etidronate. Both A, E = 0 indicates 
risedronate.   
 
Both A and E did not have statistically significant p-values (p = 0.231 and 0.144 
respectively).  From the results, for the same reduction in BMD, risedronate appear to 
have an approximately 23.1 and 14.4% lesser reduction in relative risk of hip fractures as 
compared to alendronate and etidronate respectively. 
 
From the correlation studies, two simple linear models as shown below would be utilised 
in the pharmacoeconomic simulations to translate change in BMD to risk of fractures as 
other factors such as the duration of treatment was not shown to have statistical 
significance in influencing the relative risk of fractures. 
RRvert = -0.0198 (BMDvert) + 0.702 
RRhip = -0.02807 (BMDfem) + 0.718 
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5.3 Gastrointestinal Side Effects 
5.3.1 Literature retrieved on gastrointestinal side effects 
Number of randomised controlled trials retrieved from MEDLINE and CCTR that 
reported on gastrointestinal side effects were as follows: 
- MEDLINE (OVID)      : 72 citations 
- CCTR (OVID)       : 51 citations * 
- Total number of citations retrieved (removing duplicates) : 74 citations 
* Although an “unduplication” command was performed in OVID, 1 duplicate citation 
was retrieved and discovered in Endnote when a duplicated citation search was carried 
out. 
 
The records were similarly imported into Endnote and the abstracts manually filtered 
through to remove citations not within the specified criteria, such as review articles, 
letters, editorials and meta-analysis.   
 
Among the 74 articles, 6 were non-English articles, 202-207 and two 208, 209 were not studies 
on bisphosphonates.  A breakdown of the remaining articles is as follows: 
- Alendronate :  33 articles (22 articles excluded) 71, 84, 85, 88, 90, 92, 96-100, 102, 105, 107-
109, 111, 113, 114, 119, 122, 127, 129, 197, 205, 210-218
 
- Clodronate :  3 articles (3 articles excluded) 133, 134, 219 
- Etidronate :  17 articles (12 articles excluded) 46, 127, 134, 139, 140, 143, 145-147, 149, 150, 
158, 203, 218, 220-223
 
- Ibandronate :  3 articles (1 article excluded) 160-162 
- Pamidronate :  2 articles 164, 166, 204, 206 
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- Risedronate :  10 articles (5 articles excluded) 71, 168-172, 174, 175, 224, 225 
- Tiludronate :  1 article 177 
- Zoledronate :  1 article 178 
 
Four of the articles were studies of more than one bisphosphonate.  The table below lists 
the excluded articles and reasons for their exclusion: 
No. STUDY Drug REASON FOR NON-INCLUSION 
1. Black, 1996 92 Alendronate Data reported in Bauer, 2000 
2. Bone, 1997 84 Alendronate No GI adverse effects data reported 
3. Chesnut, 1995 96 Alendronate Incomplete GI adverse effects data reported 
4. Cortet, 2001 218 Alendronate Incomplete GI adverse effects data reported 
5. Cummings, 1998 97 Alendronate Data reported in Bauer, 2000 
6. Dursun, 2001 100 Alendronate No GI adverse effects data reported 
7. Ensrud, 2000 211 Alendronate Data reported in Bauer, 2000 
8. Felsenberg, 1998 102 Alendronate Data reported in Pols, 1999 
9. Lanza, 2000 71 Alendronate No placebo control 
10. Lau, 2000 108 Alendronate Incomplete GI adverse effects data reported 
11. Liberman, 1995 109 Alendronate No GI adverse effects data reported 
12. Lindsay, 1999 129 Alendronate No GI adverse effects data reported 
13. Lowe, 2000 212 Alendronate Short term Endoscopic study 
14. Miller, 2000 213 Alendronate Inappropriate study population – rechallenged patients 
15. Murphy, 2001 113 Alendronate Incomplete GI adverse effects data reported 
16. Passeri, 1991 214 Alendronate No GI adverse effects data reported 
17. Rossini, 2000 119 Alendronate No GI adverse effects data reported 
18. Sahota, 2000 127 Alendronate Incomplete GI adverse effects data reported 
19. Schnitzer, 2000 215 Alendronate No placebo control 
20. Tonino, 2000 122 Alendronate Inappropriate study population – continuation of Liberman 1995 
21. Tucci, 1996 85 Alendronate Subgroup data of Liberman 1995 
22. Watts, 1999 216 Alendronate Incomplete GI adverse effects data reported 
23. Yilmaz, 2001 217 Alendronate Inappropriate study population – patients on glucocorticoids for 
rheumatoid arthritis 
24. Gnudi, 2001 133 Clodronate Incomplete GI adverse effects data reported 
25. Saarto T, 1997 219 Clodronate Inappropriate study population – patients on chemotherapeutic drugs 
26. Heikkinen, 1997 134 Clodronate No GI adverse effects data reported 
27. Burger, 2000 220 Etidronate Inappropriate study design – non RCT 
28. Guanabens, 2000 221 Etidronate No placebo control 
29. Gurlek, 1997 143 Etidronate No GI adverse effects data reported 
30. Harris, 1993 139 Etidronate No GI adverse effects data reported 
31. Lyritis, 1997 146 Etidronate No GI adverse effects data reported 
32. Montessori, 1997 150 Etidronate Incomplete GI adverse effects data reported 
33. Mulder, 1994 222 Etidronate Inappropriate study population – patients treated for corticosteroid induced osteoporosis 
34. Storm, 1990 46 Etidronate No GI adverse effects data reported 
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No. STUDY Drug REASON FOR NON-INCLUSION 
35. Watts, 1990 158 Etidronate No GI adverse effects data reported 
36. Cortet, 2001 218 Etidronate No GI adverse effects data reported 
37. Sahota, 2000 127 Etidronate Incomplete GI adverse effects data reported 
38. Heikkinen, 1997 134 Etidronate Inappropriate dosing regimen – intravenous etidronate studied 
39. Thiebaud, 1997 162 Ibandronate Inappropriate dosing regimen – intravenous ibandronate studied 
40. Clemmesen, 1997 168 Risedronate Incomplete GI adverse effects data reported 
41. Lanza, 2000 (A) 71 Risedronate Inappropriate study design – 14 days endoscopic study 
42. Lanza, 2000 (B) 224 Risedronate Inappropriate study design – 14 days endoscopic study 
43. Mortensen, 1998 174 Risedronate Incomplete GI adverse effects data reported 
44. Zegels, 2001 225 Risedronate Incomplete GI adverse effects data reported 
 
Table 5.51 : List of studies retrieved but excluded from safety analysis and reasons for exclusion 
 
 
The tables in the following pages list the extracted gastrointestinal side effects data from 
randomised controlled trials retrieved. 
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5.3.2 Tables of gastrointestinal side effects 
Alendronate side effects table 
Study Duration (Months) 
Total Patients 




Total GI Aes * 
(Tx / Control) 
Serious GI  * 
(Tx / Control) 
Adami, 1995 24 mths 68 / 71 2 / 4 10 / 10 0 / 0 
Bauer, 2000 36 mths 3236 / 3223 0 / 0 1535 / 1490 53 / 61 
Devogelaer, 1996 36 mths 102 / 205 3 / 11 15 / 35 - / - 
Downs, 1999 24 mths 93 / 91 13 / 9 18 / 19 1 / 1 
Downs, 2000 12 mths 118 / 58 13 / 7 21 / 12 - / - 
Hosking, 1998 24 mths 498 / 502 43 / 46 148 / 148 - / - 
Kung, 2000 12 mths 35 / 35 7 / 7 8 / 7 2 / 0 
McClung, 1998 36 mths 88 / 90 0 / 0 26 / 26 - / - 
Pols, 1999 12 mths 950 / 958 118 / 93 202 / 185 4 / 4 
Shiraki, 1998 8 mths 37 / 37 4 / 4 5 / 1 0 / 0 
Bone, 2000 24 mths 92 / 50 6 / 5 25 / 11 0 / 0 
Johnell, 2002 12 mths 83 / 82 14 / 14 * 15 / 7 - / - 
 
Table 5.52 : Incidence of Gastrointestinal Side effects in patients with Alendronate (* estimated from total withdrawals) 
 
* Serious GI :  perforation, ulceration and bleeding  
 
* Total GI :  all upper and lower GI adverse events reported in studies, including but not limited to dyspepsia, nausea etc 
 
Clodronate side effects table 
Study Duration (Months) 
Total Patients 




Total GI AEs 
(Tx / Control) 
Serious GI  
(Tx / Control) 
Tsai, 1999 12 mths 29 / 25 2 / 0 6 / 7  - / - 
McCloskey, 2001 12 mths 286 / 300 - / - 90 / 71 - / - 
 
Table 5.53 : Incidence of Gastrointestinal Side effects in patients with Clodronate 
 
Etidronate side effects table 
Study Duration (Months) 
Total Patients 
in (Tx / Control) 
Total 
Withdrawals 
(Tx / Control) 




(Tx / Control) 
Adami, 2000  24 mths 53 / 54 17 / 13 9 / 8 - / - 
Meunier, 1997  12 mths 27 / 27 0 / 0 13 / 17 - / - 
Miller, 1997  24 mths 93 / 100 - / - 38 / 38 - / - 
Pouilles, 1997  24 mths 54 / 55 9 / 9 25 / 44 - / - 
Evans, 1993 24 mths 11 / 15 3 / 3 * 15 / 5 - / - 
Heath, 2000 24 mths 38 / 39 16 / 6 11 / 1 - / - 
Herd, 1997 24 mths 75 / 77 11 / 6 9 / 21 - / - 
 
Table 5.54 : Incidence of Gastrointestinal Side effects in patients with Etidronate (* estimated from total withdrawals) 
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Ibandronate side effects table 
Study Duration (Months) 
Total Patients 
(Tx / Control) 
Total 
Withdrawals 
(Tx / Control) 
Total GI AEs  
(Tx / Control) 
Gastroduodenal 
bleed 
(Tx / Control) 
Ravn, 1996 12 mths 30 / 30 6 / 5 25 / 15 - / - 
Riis, 2001 12 mths 81 / 81 12 / 9 40 / 35 - / - 
 
Table 5.55 : Incidence of Gastrointestinal Side effects in patients with Ibandronate 
 
Pamidronate side effects table 
Study Duration (Months) 
Total Patients 
(Tx / Control) 
Total Withdrawals 
(Tx / Control) 
Total GI AEs 
(Tx / Control) 
Gastroduodenal 
bleed 
(Tx / Control) 
Lees, 1996 24 mths 38 / 42 17 / 10 11 / 0 - / - 
Ryan, 2000 24 mths 40 / 41 - / - 35 / 15 - / - 
Ried, 1994 24 mths 26 / 22 5 / 4 15 / 12 2 / 2 
 
Table 5.56 : Incidence of Gastrointestinal Side effects in patients with Pamidronate 
 
Risedronate side effects table 
Study Duration (Months) 
Total Patients 
(Tx / Control) 
Total Withdrawals 
(Tx / Control) 
Total GI AEs 
(Tx / Control) 
Gastroduodenal bleed 
(Tx / Control) 
Fogelman, 2000 24 mths 177 / 180 38 / 37 40 / 47 4 / 6 
Harris, 1999 36 mths 821 / 820 324 / 365 245 / 219 - / - 
Harris, 2001 12 mths 263 / 261 27 / 49 43 / 43 1 / 3 
Reginster, 2000 36 mths 407 / 407 63 / 81 104 / 109 6 / 10 
 
Table 5.57 : Incidence of Gastrointestinal Side effects in patients with Risedronate 
 
Tiludronate side effects table 
Study Duration (Months) 
Total Patients 
(Tx / Control) 
Total 
Withdrawals 
(Tx / Control) 
Total GI AEs 
(Tx / Control) 
Gastroduodenal bleed 
(Tx / Control) 
Reginster, 2001 36 mths 162 / 161 23 / 18 59 / 64 - / - 
 
Table 5.58 : Incidence of Gastrointestinal Side effects in patients with Tiludronate 
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5.3.3 Pooled results of gastrointestinal side effects data 
The pooled data on all types gastrointestinal adverse events are shown in the table below: 
 Mantel-Haenszel χ2 Mantel-Haenszel p NNTH Absolute risk increase (1/NNTH) 
Alendronate 1.24 0.265 183 0.55 % 
Clodronate 2.56 0.109 15.1 6.62 % 
Etidronate 0.08 0.778 143.2 0.70 % 
Ibandronate 2.26 0.133 6.4 15.6 % 
Pamidronate 12.94 < 0.0001 5.6 17.88 % 
Risedronate 0.01 0.935 1524.2 0.07 % 
Tiludronate NA NA 102 0.98 % 
 
Table 5.59 : Pooled incidence of all gastrointestinal adverse events 
 
* NNTH is the number needed to treat with drug to produce one additional episode of harm as compared to placebo. 
* NA : data pooling is not applicable as only one study is available 
 
From the Mantel-Haensezel P value, treatment of pamidronate was the only drug that had 
a statistically significant relationship with a higher incidence of total GI adverse events as 
compared to controls. 
 
Only studies with alendronate and risedronate had sufficient data for pooling of serious 
gastrointestinal adverse events as defined by perforation, ulceration and bleeding.  One 
study on pamidronate was also available.  Both drugs did not indicate statistically 
significant differences as compared to placebo. 
 Mantel-Haenszel χ2 Mantel-Haenszel p NNTH Absolute risk increase (1/NNTH) 
Alendronate 0.30 0.585 1759 0.06 % 
Pamidronate NA NA 134 0.75 % 
Risedronate 2.24 0.135 204.5 0.49 % 
 
Table 5.60 : Pooled incidence of serious gastrointestinal side effects 
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This analysis supports the reports from previous randomised controlled trials that if 
administered correctly, bisphosphonates except for pamidronate is not associated with 
significant gastrointestinal side effects. 
 
With the pooling of data on both efficacy and safety from published literature, the next 
section looks at application of these data into evaluating the relative cost-effectiveness of 
the various bisphosphonates. 
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5.4 Pharmacoeconomic analyses 
5.4.1 Preliminary calculations on costs 
Before performing of pharmacoeconomic analyses, various costing have to be determined. 
 
Costs of drugs were obtained from KK Women’s and Children’s Hospital if available.  
Maximum as well as minimum pricing of the various bisphosphonates were obtained 
based on patient prices from government, restructured hospitals (KK Hospital and Tan 
Tock Seng Hospital) as well as private retail pharmacies (Guardian and NTUC 
pharmacies).  The maximum and minimum pricing (see table below) were obtained for 
purposes of performing a one-way sensitivity analysis. 
Price per unit 
DRUG 
KK Hospital Minimum Maximum 
Price range per year of therapy 
for one patient based on 
















$ 10.3 1788.50 – 3759.50 
Etidronate 200mg * NA $ 0.67 $ 1.61 75.04 – 180.32 
Risedronate 5mg $ 2.50 $ 2.50 $ 3.32 912.50 – 1211.80 
 
Table 5.61 : Patient price of bisphosphonates at various institutions and retail pharmacies 
 
* Etidronate, Clodronate 400mg and Alendronate 10mg are not currently available in KK Hospital drug listing 
 
Cost of therapy with bisphosphonates was then calculated with the following assumptions: 
• Cost of bisphosphonate was calculated based on manufacturer’s recommended 
dosing regimen for alendronate (10mg daily), etidronate (400mg daily for 14 days in 
a 90-day cycle) and risedronate (5mg daily).  Cost of clodronate was taken as 800mg 
once daily, which was the lowest dose, reported to be effective for management of 
postmenopausal osteoporosis. 56 
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• Cost of no treatment was assumed to be nil 
• Other costs, such as that for consultation and BMD scan were also not taken into 
consideration as they were assumed to be similar for each arm irregardless of the 
bisphosphonate and for placebo. 
 
Derivation of costs of drug therapy for the one year cost-effectiveness model: 
 
Cost of drug = price per unit x number of units required for one year of therapy 
 
 COST OF DRUG 
DRUG Minimum Maximum Average 
Alendronate $1,007.40 $1,173.12 $1,090.26 
Clodronate $1,788.50 $3,759.50 $2,774.00 
Etidronate $75.04 $180.32 $127.68 
Risedronate $912.50 $1,211.80 $1,062.15 
 
Table 5.62 : Costs of bisphosphonate for one year 
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5.4.2 Cost effectiveness of bisphosphonates 
A cost effectiveness analysis was performed to compare between the various 
bisphosphonates studied.  As efficacy data was available for 1, 2 and 3 years, 3 separate 
models were created.  Separate models were also created for lumbar vertebral and hip 
BMD changes. 
 
The weighted mean difference in percentage change of BMD from baseline between 
treatment drug and placebo was entered as normal distributions in order to allow for 
Monte-Carlo simulation to be done.  Incremental cost effectiveness ratio (ICER) tables 
were constructed based on the lowest priced agent, etidronate, as the baseline comparator. 
 
The choice of etidronate as the baseline comparator in this model is based on the 
assumption that if efficacy might be equal among the bisphosphonates, the cheapest one 
would become the standard of care. 
 






Figure 5.3 : Decision tree for cost effectiveness pharmacoeconomic model 
Alendronate Outcome of Alendronate treatment
Clodronate Outcome of Clodronate treatment
Etidronate
Outcome of Etidronate treatment
Risedronate
Outcome of Risedronate treatment
Choice of 
Bisphosphonates
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Ibandronate, pamidronate and tiludronate were excluded from the analysis as there are no 
oral preparations available locally.  Values for cost and effectiveness were entered into the 
models and ICER tables were generated as shown below.  The ICER is the cost incurred 
for an increase 1 percent in BMD as compared to etidronate for the defined duration of 
treatment.  It is obtained by dividing the incremental costs by incremental effectiveness. 
 
ICER Table for Percentage Change in Lumbar BMD (as efficacy units) at One Year 





Average cost per 
expected efficacy unit ICER 
Etidronate 127.68 - 2.94% - 43.43 - 
Risedronate 1,062.15 934.47 3.35% 0.41% 317.06 2,279.20 
Alendronate 1,090.26 962.58 4.91% 1.97% 222.05 488.62 
Clodronate 2,774.00 2,646.32 2.77% -0.17% 1001.44 Dominated 
 
Table 5.63 : Incremental Cost effectiveness ratio of bisphosphonates for Lumbar BMD at 1 year 
 
ICER Table for Percentage Change in Lumbar BMD (as efficacy units) at Two Years 





Average cost per 
expected efficacy unit ICER 
Etidronate 255.36 - 3.58% - 71.33 - 
Risedronate 2,124.30 1,868.94 4.55% 0.97% 466.88 1,926.74 
Alendronate 2,180.52 1,925.16 7.14% 3.56% 305.39 540.78 
Clodronate 5,548.00 5,292.64 3.70% 0.12% 1499.46 44,105.33 
 
Table 5.64 : Incremental Cost effectiveness ratio of bisphosphonates for Lumbar BMD at 2 years 
 
ICER Table for Percentage Change in Lumbar BMD (as efficacy units) at Three Years 





Average cost per 
expected efficacy unit ICER 
Etidronate 383.04 - 4.29% - 89.23 - 
Risedronate 3,186.45 2,803.41 4.65% 0.36% 685.26 7,787.25 
Alendronate 3,270.78 2,887.74 8.26% 3.97% 395.98 727.39 
Clodronate Insufficient data for analysis 
 
Table 5.65 : Incremental Cost effectiveness ratio of bisphosphonates for Lumbar BMD at 3 years 
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From the average cost-effectiveness analysis, etidronate appears to be most cost-effective 
at 1, 2 and 3 years, followed by alendronate, risedronate and then finally clodronate.  In 
the incremental cost effectiveness analysis (compared against etidronate), clodronate is 
dominated at 1 year, has very high ICER at 2 years and does not have sufficient data for 3 
years. 
 
A one-way sensitivity analysis was carried out by varying the costs of bisphosphonates.  
Results of the sensitivity analysis showed that etidronate was still more cost effective with 
the pricing variation as compared to alendronate, clodronate and risedronate.  Risedronate 
is dominated at 2 and 3 years when one-way sensitivity analysis was carried out by 
varying its price. 
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Similarly, ICER tables were constructed based on Femoral Neck BMD with etidronate as 
the baseline comparator. 
 
ICER Table for Femoral Neck BMD at One Year 





Average cost per 
expected efficacy unit ICER 
Etidronate 127.68 - 1.22% - 104.66 - 
Risedronate 1,062.15  934.47 1.43% 0.21% 742.76 4,449.86 
Alendronate 1,090.26  962.58 2.68% 1.46% 406.81 659.30 
Clodronate 2,774.00  2,646.32 0.94% -0.28% 2,951.06 (Dominated) 
 
Table 5.66 : Incremental Cost effectiveness ratio of bisphosphonates for Femoral Neck BMD at 1 year 
 
ICER Table for Femoral Neck BMD at Two Years 





Average cost per 
expected efficacy unit ICER 
Etidronate 255.36 - 2.09% - 122.18 - 
Risedronate 2,124.30  1,868.94 2.03% -0.06% 1,046.45 (Dominated) 
Alendronate 2,180.52  1,925.16 4.45% 2.36% 490.00 815.75 
Clodronate 5,548.00  5,292.64 2.90% 0.81% 1,913.10 6,534.12 
 
Table 5.67 : Incremental Cost effectiveness ratio of bisphosphonates for Femoral Neck BMD at 2 years 
 
ICER Table for Femoral Neck BMD at Three Years 





Average cost per 
expected efficacy unit ICER 
Etidronate 383.04 - 2.63% - 145.64 - 
Risedronate 3,186.45  2,803.41 2.80% 0.17% 1,138.02 $16,490.65 
Alendronate 3,270.78  2,887.74 5.90% 3.27% 554.37 $883.10 
Clodronate Not applicable - efficacy data not available at 3 years 
  
Table 5.68 : Incremental Cost effectiveness ratio of bisphosphonates for Femoral Neck BMD at 3 years 
 
Very similar results were obtained from the cost effectiveness analysis using femoral neck 
bone mineral density.  Etidronate appears to be the most cost effective therapy with 
alendronate being the second. 





















































Monte Carlo Simulation -
























5.4.3 Monte Carlo simulation of cost-effectiveness model  
Monte-carlo simulation was performed on the CEA with optimal strategy being 
reevaluated with 15,000 cycles for each simulation.   
 
Without any “willingness to pay” amount defined, choice of therapy with alendronate was 


























































Monte Carlo Simulation -
CEA 2 Yr Femoral Neck BMD
A - 0.318
C - 0.261
E - 0.211 R - 0.210
Monte Carlo Simulation -
























Figure 5.4 : Monte Carlo simulation for cost effectiveness model 
 
If a “willingness to pay” value is set at an arbitrary amount of $365.00 (representing a 
patient price of $1.00 per day), the percentage optimal would skew towards the least 
expensive drug, etidronate.  From the graphs below, etidronate had a very similar 
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Monte Carlo Simulation  - CEA 2 yr Lumbar BMD



















Monte Carlo Simulation - CEA 1 Yr Lumbar BMD



















Monte Carlo Simulation - CEA 3 Yr Lumbar BMD


















Monte Carlo Simulation -  CEA 1 Yr Femoral Neck BMD



















Monte Carlo Simulation  - CEA 2 Yr Femoral Neck BMD



















Monte Carlo Simulation  - CEA 3 Yr Femoral Neck BMD
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Hence, from this simulation, it is shown that when affordability was considered as an 
important issue, etidronate may have a role in therapy for patients who cannot afford the 
higher price of alendronate. 
 
Though useful in providing cost-effectiveness information on bisphosphonates, the model 
utilises BMD a surrogate marker for fracture rate, as the determinant of efficacy. A 
decision analytic model that could incorporate patient relevant outcomes of both hip and 
vertebral fracture reduction can therefore constructed to determine if similar conclusions 
would be derived as compared to the cost-effectiveness model.  Thus, the use of another 
approach (a model in this case) would offer the clinicians and decision makers a different 
perspective to look at the same problem. 
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5.4.4 Building a decision analytic model 
A model was created using Treeage DATA v3.5 for the 4 bisphosphonates alendronate, 
clodronate, etidronate and risedronate.  Similarly, Ibandronate, pamidronate and 
tiludronate were excluded as no oral preparations were available locally.  A “no 
treatment” arm was included in the model to test if prophylaxis with bisphosphonates 
could be implemented for all postmenopausal women.  The model is represented as a 
condensed version of the decision tree below showing one treatment arm (etidronate) in 















hf denotes hip fracture; vf denotes vertebral fracture  
chf denotes complications due to hip fracture; cvf denotes complications due to vertebral fractures 
 
P(age)  is the proportion of a patient being in a particular age group (as shown in Table 1.3).  The numbers following 
P(age) indicates age range ie. P(age) 70-74 is the proportion of the population between 70 to 74 years of age 
P(hf)  is the probability of sustaining a hip fracture 
P(vf)  is the probability of sustaining a vertebral fracture 
P(chf)  is the probability of hip fracture complications 
P(cvf)  is the probability of vertebral fracture complications 
 








Yes Complicated Vertebral & Hip Fracture
No Uncomplicated Vertebral & Complicated Hip Fracture
Yes
Yes Complicated Vertebral & Uncomplicated Hip Fracture
No Uncomplicated Vertebral & Uncomplicated Hip Fracture
NoYes
Yes Complicated Vertebral Fracture only
No Uncomplicated Vertebral Fracture only
No
Yes P(vf)
Yes Complicated Hip Fracture only
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A decision analytic model was chosen over a state transition Markov model as no local 
data existed as to the transition probability of patients from one state of BMD to another 
during a time cycle. 
 
Unlike other studies on drugs for osteoporosis utilising Markov models, 226, 227 death rate 
was not incorporated into the model, as the objective of the study was to look at the 
economics of bisphosphonates in fracture prevention.  
 
The following assumptions were made on the model: 
• Cost of a medical consult to obtain medication for osteoporosis was based on the 
range between a subsidised polyclinic rate and a private rate for a senior 
consultation in KK Hospital ($4 to $80) 
• Cost of a BMD test based on a range for a subsidised and a private patient in KK 
Hospital ($35 to $100) 
• Cost of management of gastrointestinal side effects was calculated based on 
incidence obtained from the meta-analyses data and TCBGG for gastrointestinal 
events (Table 5.72).  For clodronate and etidronate, it was assumed that there is a 
negligible incidence of severe GI adverse effect as no published literature reporting 
the frequency of such effects were found 
• Loss of income was taken as negligible as most of the patients were assumed to be 
housewives or have retired.  For housewives, the cost of loss of work would be 
accounted for under the cost of domestic help 
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• Cost of domestic help is calculated for a total of monthly salary of between $250- 
350, monthly government levy of $345, 228 and initial agency fees of $200-1000.  
Duration of domestic help is assumed to be on average, half of the duration of the 
model i.e. For a 2-year model, it is assumed that on average, patients sustain a 
fracture at one year and therefore, require domestic help for a duration of one year.   
• It is also assumed that only 50% of the maid’s time is utilised to look after the 
patient with fractures, but the other half of the time to contribute to domestic work 
previously performed by the patient.  This is inferred from the “Training Checklist 
for Employers of Foreign Domestic Workers”, where domestic maids hired may be 
expected to perform domestic tasks in addition to caring for the elderly patient. 229 
• Cost of transportation was calculated as 2 times per month of a 2-way taxi trip, 
taken as between $7.50 to $10.00 per trip 
• Benefit of preventing death was not taken into account in the model as the objective 
of this thesis was to look at fracture prevention due to osteoporosis 
• Probability of a patient being in particular age range is calculated based on estimated 
population data for women in 2001 30 
• Probability of complicated hip or vertebral fracture is calculated from the proportion 
of patients with such complications as compiled by the public DRG report 
• Fracture rate of each group was calculated based on BMD results in meta-analyses 
(Chapter 5.1.5) applied to the linear regression models derived from the correlation 
studies (Chapter 5.2) 
• Cost of hip and vertebral fractures were derived based on TCBGG as discussed in 
the next section. 
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5.4.5 Derivation of costs for a decision analytic model 
Local data on the average bill size (Total Charges Before Government Grant - TCBGG) of 
DRGs for hip and vertebral fractures was obtained from period of July 2000 to March 
2001 are shown in the table below.   The TCBGG was utilised as an estimate of the total 
healthcare costs required to treat an episode of a hip or vertebral fracture. 
DRG DRG Description TCBGG 
440 Fractures of Hip & Pelvis with complications $ 8,049 
441 Fractures of Hip & Pelvis Age > 74 without complications $ 5,126 
442 Fractures of Hip & Pelvis Age < 75 without complications $ 3,282 
453 Medical Back Problems Age > 74 with complications $ 4,687 
454 Medical Back Problems Age > 74 without complications or Age < 75 with complications $ 3,212 
455 Medical Back Problems Age < 75 without complications $ 1,747 
 
Table 5.69 : Total costs before government subsidy for Hip and Vertebral Fracture DRGs 
 
Derivation of costs of fractures for the one year model. 
 Min Max Average 
TCBGG for Hip Fracture - - $3,828.00 
TCBGG for Hip Fracture > 75 - - $5,126.00 
TCBGG for Complicated Hip Fracture - - $8,049.00 
Cost of Transportation $360.00 $480.00 $420.00 
Domestic Help 
- government levy per month - - $345.00 
- salary per month $250.00 $300.00 $275.00 
Loss of Income - - $0.00 
 
Table 5.70 : Derivation of costs of hip fracture in a one year model 
 
 
 Min Max Average 
TCBGG for Vertebral Fracture - - $1,747.00 
TCBGG for Uncomplicated Vertebral Fracture > 75 or Complicated < 75 - - $3,212.00 
TCBGG for Complicated Vertebral Fracture > 75 - - $4,687.00 
Cost of Transportation $360.00 $480.00 $420.00 
Salary of Domestic Help 
- government levy - - $345.00 
- salary $250.00 $300.00 $275.00 
Loss of Income - - $0.00 
 
Table 5.71 : Derivation of costs of vertebral fracture in a one year model 
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Similarly, the TCBGG for the appropriate DRGs was utilised as an estimate for the total 
costs for an episode of the relevant gastrointestinal side effect. 
DRG DRG Description TCBGG 
339 Complicated peptic ulcer with complications $ 3,342 
340 Complicated peptic ulcer without complications $ 1,891 
341 Uncomplicated peptic ulcer $ 1,211 
348 Oesophagitis, Gastroent & Misc Dig Dis Age > 74 or (age 10-74 with complications) $ 1,982 
349 Oesophagitis, Gastroent & Misc Dig Dis Age 10-74 without complications $ 991 
 
Table 5.72 : Total costs before government subsidy for gastrointestinal side effects DRGs 
 
Expected value of intervention was calculated as a summation of the following : Costs of 
drug + Medical consultation + BMD test + Gastrointestinal side effects + Cost of treating 
fractures + Transportation and domestic costs 
 Minimum Maximum Average 
Cost of Drug (cost per unit x total quantity per year) 
- alendronate $1,007.40 $1,173.20 $1,090.30 
- clodronate $1,788.50 $3,759.50 $2,774.00 
- etidronate $75.04 $180.32 $127.68 
- risedronate $912.50 $1,211.80 $1,062.15 
Cost of Medical Consult for Menopause $4.00 $80.00 $42.00 
Cost of Bone Mineral Density Test $35.00 $100.00 $67.50 
 
















Probability of GI side effect x TCBGG 
 
 
0.55/100 x 991 
0.06/100 x 2276 
 
6.62/100 x 991 
Nil 
 
0.7/100 x 991 
Nil 
 
0.07/100 x 991 
0.49/100 x 2276 
 
Cost of treating a fracture Relative risk of fracture x Baseline fracture rate x TCBGG 
Transportation Costs 
Domestic Costs Calculated as per assumptions 
  
Table 5.73 : Total costs of Intervention with Bisphosphonate, including side effects 
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For the two year model, discounting using 1/(1+r)n was factored into the 2nd and 
subsequent years costs of therapy, where r = 0.05 (representing a 5% discounting rate used 
in most health economic studies) 230 and n = 2 (i.e. for 2nd year of therapy) and so forth. 
 
The expected values of treatment for each of the treatment arms were then obtained using 
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5.4.6 Results from the decision analytic model 
Rankings for Interventions is as shown in the tables below.  
One-year decision analytic model for all postmenopausal women : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 41.80 NA 
2 Etidronate $ 272.83 $ 231.03 
3 Risedronate $ 1,211.07 $ 1,169.27  
4 Alendronate $ 1,233.46 $ 1,191.66  
5 Clodronate $ 2,981.09 $ 2,939.29  
 
Table 5.74 : Expected value of treatment with bisphosphonates in a one year decision analytic model 
 
Among the therapeutic interventions, the option with “no treatment” was optimal as 
compared to the various interventions.  Among the interventions, the etidronate treatment 
arm had the lowest expected value. 
 
Two-year decision analytic model for all postmenopausal women : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 118.32 NA 
2 Etidronate $ 566.49 $ 448.17 
3 Risedronate $ 2,442.50 $ 2,324.18  
4 Alendronate $ 2,482.99 $ 2,364.67  
5 Clodronate $ 5,981.05 $ 5,862.73  
 
Table 5.75 : Expected value of treatment with bisphosphonates in a two year decision analytic model 
 
Two-year decision analytic model for all postmenopausal women (with discounting) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 107.32  NA 
2 Etidronate $ 513.82 $ 406.50 
3 Risedronate $ 2,215.42  $ 2,108.10  
4 Alendronate $ 2,252.15  $ 2,144.83  
5 Clodronate $ 5,424.99  $ 5,317.67  
 
Table 5.76 : Expected value of treatment with bisphosphonates in a two year decision analytic model with discounting 
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Three-year decision analytic model for all postmenopausal women: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 234.11 NA 
2 Etidronate $ 890.49 $ 656.38 
3 Risedronate $ 3,704.41 $ 3,470.30  
4 Alendronate $ 3,768.02 $ 3,533.91  
 
Table 5.77 : Expected value of treatment with bisphosphonates in a three year decision analytic model 
 
Three-year decision analytic model for all postmenopausal women (with discounting): 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 202.23  NA 
2 Etidronate $ 769.24 $ 567.01 
3 Risedronate $ 3,200.01  $ 2,997.78  
4 Alendronate $ 3,254.96  $ 3,052.73  
 
Table 5.78 : Expected value of treatment with bisphosphonates in a three year decision analytic model with discounting 
 
Similar results on the ranking of the interventions were obtained for the 2 and 3 years 
model. 
 
In the decision analytic model, the “no treatment” arm resulted in the lowest expected 
value indicating that it is not cost effective for all postmenopausal women to be prescribed 
bisphosphonates for fracture prevention.  Among the treatment choices, etidronate had the 
lowest expected value of treatment for all the “1 year”, “2 years” and “3 years” models. 
 
Four sets of one-way sensitivity analyses were separately performed to explore the 
robustness of the results from the decision analytic models by  
- utilising the lowest cost for all bisphosphonates 
- utilising the highest costs for all bisphosphonates 
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- minimizing fracture rate in the bisphosphonates treatment arm by using the upper 
95% confidence interval of percent change in BMD 
- maximizing fracture rate in the bisphosphonates treatment arm by using the lower 
95% confidence interval of percent change in BMD 
 
Results of the sensitivity analyses did not indicate any significant change in rankings of 
the interventions (Appendix 9).  The “no-treatment” arm continued to return the lowest 
expected value, followed by the etidronate treatment arm.  The clodronate treatment arm 
also ranked last in all the sensitivity analyses, i.e. with the highest expected value for all 
the analyses done. 
 
Between risedronate and alendronate, alendronate was ranked higher than risedronate if 
the highest pricing for all drugs was utilised in the sensitivity analyses. 
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A simulation on the same model was also applied for geriatric women as defined by age of 
65 years old and above to determine if it would be cost effective for all geriatric women to 
take a bisphosphonate.  Results of this analysis are shown in the following tables. 
 
One-Year Decision Analytic Model for geriatric women: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 94.13 NA 
2 Etidronate $ 309.43 $ 215.30 
3 Risedronate $ 1,245.83 $ 1,151.70 
4 Alendronate $ 1,267.60 $ 1,173.47 
5 Clodronate $ 3,031.91 $ 2,937.78 
 
Table 5.79 : Expected value of treatment with bisphosphonates for geriatric women in a one year decision analytic model 
 
Two-year decision analytic model for geriatric women: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 266.87 NA 
2 Etidronate $ 666.02 $ 399.15 
3 Risedronate $ 2,538.07 $ 2,271.20 
4 Alendronate $ 2,571.72 $ 2,304.85 
5 Clodronate $ 6,106.24 $ 5,839.37 
 
Table 5.80 : Expected value of treatment with bisphosphonates for geriatric women in a two year decision analytic model 
 
Two-year decision analytic model for geriatric women (with discounting): 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 242.06 NA 
2 Etidronate $ 604.1 $ 362.04 
3 Risedronate $ 2,302.10 $ 2,060.05 
4 Alendronate $ 2,332.63 $ 2,090.57 
5 Clodronate $ 5,538.54 $ 5,296.48 
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Three-year decision analytic model for geriatric women: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 525.13 NA 
2 Etidronate $ 1089.55 $ 564.42 
3 Risedronate $ 3,897.05 $ 3,371.92 
4 Alendronate $ 3,954.34 $ 3,429.21 
  
Table 5.82 : Expected value of treatment with bisphosphonates for geriatric women in a three year decision analytic model 
 
Three-year decision analytic model for geriatric women (with discounting): 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 453.63 NA 
2 Etidronate $ 941.19  $ 487.57  
3 Risedronate $ 3,366.42 $ 2,912.79 
4 Alendronate $ 3,415.91 $ 2,962.28 
 
Table 5.83 : Expected value of treatment with bisphosphonates for geriatric women in a three year decision analytic model 
with discounting 
 
The subgroup analysis with geriatric women did not appear to affect the ranking of cost of 
the various interventions.  Sensitivity analyses were not performed as previous sensitivity 
analyses already showed that different drug acquisition costs and changes in fracture rates 
did not have a significant change in ranking between the “no treatment” arm and the 
bisphosphonate treatment arms.  
 
Since local women who are above 75 years of age had the highest rate of fractures (Table 
1.1), another subgroup analysis was performed to determine if it is cost effective to treat 
these women. 
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One-Year Decision Analytic Model for women above 75 years of age: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 164.59 NA 
2 Etidronate $ 361.18 $ 196.59 
3 Risedronate $ 1,293.22 $ 1,128.63  
4 Alendronate $ 1,315.58 $ 1,150.99  
5 Clodronate $ 3,120.87 $ 2,956.28  
 
Table 5.84 : Expected value of treatment with bisphosphonates for geriatric women in a one year decision analytic model 
 
Two-Year Decision Analytic Model for women above 75 years of age: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 468.77 NA 
2 Etidronate $ 806.11 $ 337.34 
3 Risedronate $ 2,669.42 $ 2,200.65  
4 Alendronate $ 2,696.32 $ 2,227.55  
5 Clodronate $ 6,316.43 $ 5,847.66  
 
Table 5.85 : Expected value of treatment with bisphosphonates for geriatric women in a two year decision analytic model 
 
Two-Year Decision Analytic Model for women above 75 years of age (with discounting): 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 425.19 NA 
2 Etidronate $ 731.17 $ 305.98 
3 Risedronate $ 2,421.24 $ 1,996.05  
4 Alendronate $ 2,445.64 $ 2,020.45  
5 Clodronate $ 5,729.19 $ 5,304.00  
 
Table 5.86 : Expected value of treatment with bisphosphonates for geriatric women in a two year decision analytic model 
with discounting 
 
Three-Year Decision Analytic Model for women above 75 years of age: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 912.56 NA 
2 Etidronate $ 1362.78 $ 450.22 
3 Risedronate $ 4,156.01 $ 3,243.45  
4 Alendronate $ 4,209.13 $ 3,296.57  
  
Table 5.87 : Expected value of treatment with bisphosphonates for geriatric women in a three year decision analytic model 
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Three-Year Decision Analytic Model for women above 75 years of age (with 
discounting): 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 788.30 NA 
2 Etidronate $ 1,177.22 $ 388.92 
3 Risedronate $ 3,590.12 $ 2,801.82  
4 Alendronate $ 3,636.00 $ 2,847.70  
 
Table 5.88 : Expected value of treatment with bisphosphonates for geriatric women in a three year decision analytic model 
with discounting 
 
Though the intervention with no treatment still rank first with the lowest expected value of 
treatment, there is a definite trend towards a reduction in the marginal value between “no 
treatment” and “etidronate” arms. 
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CHAPTER 6.  DISCUSSION 
6  
6.1 Discussion 
From the meta-analyses, alendronate consistently provided the highest improvement in 
both femoral neck and lumbar vertebral BMD.  It is congruent with the clinical 
observation that alendronate is more effective in improving BMD.  However, it is higher 
in acquisition cost (therefore, higher dispensing price to patients) as compared to other 
bisphosphonates such as etidronate and risedronate.  Hence, from the perspective of the 
patient, there may be an issue of “willingness-to-pay” and affordability for the higher 
improvement of BMD.  Therefore from the results obtained, for patients who cannot 
afford the relatively higher price of therapy with alendronate, etidronate may have a role 
as a more cost-effective alternative.  For patients who are willing and able to pay more for 
the incremental benefits and for those patients (eg. those with very low BMD) who would 
benefit from a higher increase of BMD, then alendronate would be an option to consider. 
 
The pharmacoeconomic evaluation provides more in-depth information of the relative 
cost-effectiveness of the available bisphosphonates in Singapore. From the modeling 
exercise, among the bisphosphonates studied, etidronate appears to be the most cost 
effective in both models.  One reason would be its significantly lower acquisition costs as 
compared to other bisphosphonates.  Another important cause would be the inherently low 
fracture rates among the general population.  This could have resulted in the benefit of 
fracture reduction not being able to outweigh cost of bisphosphonate therapy in the 
decision analytic model, and hence the lowest expected value with the “no treatment arm”.  
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From the perspective of public health, the results from the decision analytic model shows 
unambiguously that it is not cost-effective to treat all postmenopausal women as a 
preventive measure against osteoporotic fractures.  The model also indicates a trend of 
reduced marginal values when it was applied only to higher age-groups as compared to all 
postmenopausal women.  This indicates that if treatment was to be decided based on age 
without measurement of BMD, it would be more cost effective to treat only those within a 
higher age group.  Similarly , the 1998 guideline from the US National Osteoporosis 
Foundation also recommends the initiation of pharmacological therapy without BMD 
testing to reduce fracture risk for women over 70 years of age with multiple risk factors 
(especially for those with previous non-hip, non-spine fractures). 231 
 
Between alendronate and risedronate which are currently available at KK Hospital, the 
marginal analyses for both femoral neck and lumbar vertebrae exhibited a significant 
difference in terms of incremental cost effectiveness ratio when compared to etidronate, 
favoring alendronate over risedronate.  This is unlike the results from the decision analytic 
model, whereby both agents had a minimal difference in marginal value.  The main reason 
could be that the decision analytic model calculates costs based on the perspective of 
treating a population of patients, and since the cost of drugs was significant higher as 
compared to the cost of fractures (due to the low rate of fractures in the general 
population), the cost offset due to reduction in rate of fractures is diluted as a result.   
 
There are a number of potential limitations in the pharmacoeconomic models that may 
warrant discussion. 
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Firstly, femoral neck BMD may be argued as not being an accurate predictor of hip 
fractures and hence, may not be an ideal surrogate marker of efficacy in the models.  
However, in deciding whether to use femoral neck BMD or actual hip fracture rates (from 
clinical studies) as the efficacy markers, the decision was to use the surrogate markers 
because of the lack of large scale studies reporting fracture rates as the final outcomes, 
especially for the older agents such as clodronate, pamidronate and tiludronate.  On the 
contrary, studies reporting changes in BMD were available for most bisphosphonates 
evaluated in this thesis.  Pooling these studies would provide more accurate effect size 
estimates of the bisphosphonates as compared to placebo. 
 
Furthermore, due to the low incidence of such fractures in the general population,  some 
of the studies reporting fractures as the final outcomes may not have enough sample size 
or sufficient duration of follow-up.  Moreover, non-vertebral fractures are frequently the 
result of traumatic events.  A number of studies have reported a clear link between 
osteoporotic hip fractures and the frequency as well as type of falls. 232-234  Since traumatic 
events occur by chance, studies with insufficient population size or duration may suffer 
from baseline bias even though they may be randomised. 
 
Secondly, another limitation may be that the decision analytic model used in 
pharmacoeconomic evaluation did not take into consideration costs incurred with an 
increased risk of new fractures in patients with previous vertebral fractures.  Studies have 
reported significant increase in relative risk of new vertebral 235, 236 or hip 237-239 fractures 
in this group of patients (between 1.6 to 7.4 fold increase).  In addition, risk of death, 
which was 26% within the first year of hip fractures from a local study, 25 was also not 
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considered in the models studied.  However, due to the inherently low rate of hip and 
vertebral fractures in the population, both factors are not believed to have a significant 
impact on the results of the study.  This would be supported indirectly by the sensitivity 
analyses performed showing that by varying the fracture rates (hence the complication 
rates) produce minimal impact on the results. 
 
Finally, other types of fractures that may be reduced with improved BMD, such as wrist 
fractures, are also not considered in the model. 45, 240  This will confer additional benefit to 
patients treated with bisphosphonates.  Undeniably, the reduction of these types of 
fractures would affect the patients’ quality of life.  However, these again are not thought 
to significantly affect the outcome of the study due to their low incidences and are usually 
less debilitating as compared to vertebral or hip fractures.  In addition, the cost associated 
with treating these fractures are much lower. 
 
Another factor that could not be considered in the thesis is the intangible benefits and 
costs of preventing an osteoporotic fracture.  This deliberate omission is due to the non-
existence of local data.   From the patient’s perspective, significantly reduced health-
related quality of life after an episode of vertebral or hip fracture should also be taken into 
account when considering therapy for osteoporotic patients. 241, 242  The local study by 
Wong et al, 2002 25 reported 24% of patients to be wheelchair bound and 9% bedridden 
after an episode of a hip fracture.  Moreover, patients are known to suffer from chronic 
pain after an episode of hip or vertebral fracture.  Hence, postmenopausal women who 
know about the sequelae of osteoporotic fractures may be relatively willing to pay for 
prevention of such fractures.  One study reported that women in Israel were willing to pay 
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between 84% to 124% of price of drugs for osteoporosis, and that the amount increases 
significantly with an increased risk of hip fractures. 243 Although it would be difficult to 
extrapolate this “willingness to pay” into dollar terms in our local environment,  the 
undeniable fact is that for women with risk factor(s) of suffering from osteoporotic 
fracture are willing to pay a price for the benefit of treatment in our local environment. 
 
With these factors taken together into consideration, the model would most likely skew 
towards an increased benefit with drug therapy as compared to no treatment.   
 
Despite the fact that the main focus of the thesis is on bisphosphonates, the approach used 
could be applied to other drugs.  Future studies may be done to explore other 
pharmacological agents such as raloxifene and tibolone using the same models.  With such 
studies, an overall perspective of the cost effectiveness of all locally available drugs for 
management of postmenopausal osteoporosis could be obtained.  Similarly, the model 
may also be applied for more specific subgroup of patients with a high risk of fractures, 
such as for those with a previous wrist fracture, in order to identify whether such groups 
of patients would benefit from therapy with bisphosphonates. 
 
On the issue of the affordability of bisphosphonates to patients, the inclusion of an agent 
into the Standard Drug Listing (subsidised by the government) will improve accessibility 
of patients who require such therapy but cannot afford so.  Though there may be  
significant healthcare costs involved in the drug subsidy, it would partially be offset by the 
decrease in hospitalisation due to reduced rate of hip, vertebral and other fractures and 
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associated complications, if a bisphosphonate is being prescribed for the appropriate 
postmenopausal women who are osteoporotic by WHO definition. 1 
 
Another important factor to be taken into consideration in providing a greater access and 
affordability to bisphosphonates would be the prevention of the deterioration of health 
related quality of life (QOL) due to either vertebral or hip fractures.  Besides limitation in  
movement and chronic pain associated with both types of fractures, a significant 
proportion of postmenopausal women with hip fractures become immobile, hence 
requiring assistance to move or even perform simple daily tasks.   
 
From the results as presented in the thesis, if the Ministry of Health was considering the 
inclusion of only one bisphosphonate into the Standard Drug Listing, etidronate should be 
considered due to its lower acquisition cost and marginal lower efficacy as compared to 
alendronate.  On the other hand, there is a rationale for the inclusion of alendroante into 
the hospital formulary (assuming that MOH would subsidize etidronate) to provide an 
alternative for patients who may benefit from the extra improvement in BMD, and are 
willing to bear the higher costs.   
 
Finally, it should be highlighted that pharmacological therapy, though important, should 
not be the only emphasis when decisions are to be made on allocation of healthcare 
resources for prevention of osteoporotic fractures.  Other interventions such as increasing 
public awareness about osteoporosis, and education on various aspects of risk reduction, 
such as home safety, appropriate diet, medication compliance, lifestyle improvements and 
exercise are equally important to achieve the end-point of fracture prevention. 52  Only 
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with such a multi-prong approach can the risks of osteoporotic fractures in 
postmenopausal women be minimised. 
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CHAPTER 7 .  CONCLUSION 
7  
7.1 Conclusion 
From the results obtained from the studies carried out in this thesis, the following 
conclusions can be drawn. 
 
1. There appears to be a significant proportion of alendronate in KK Hospital 
prescribed not in accordance to the guidelines available.  Besides exerting extra financial 
burden to patients and therefore the healthcare system as a whole, such practice is not in 
accordance with the practice of evidence based medicine.  Educational interventions and a 
more specific guideline may improve the prescribing pattern. 
 
2. The results of the meta-analysis confirmed previous studies that alendronate is the 
most effective bisphosphonate with regard to improvement in either femoral neck or 
lumbar vertebral bone mineral density (BMD).  However, it is also one of the most 
expensive in terms of acquisition costs.  For patients who are willing to pay a higher price 
for this incremental benefit, alendronate would be the choice of bisphosphonate.  
Otherwise, etidronate with possibly lower effectiveness in improvement of BMD but 
significantly lower costs may be recommended as the choice of therapy for most patients. 
 
3. Based on the results of the decision analytic model, it would not be cost effective 
to treat all postmenopausal patients with bisphosphonates.  However, if treatment is to be 
instituted for the general population, etidronate may be the drug of choice.  For patients 
whom it is desirable to have a higher rate of increase in either vertebral or femoral neck 
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BMD and are able to afford a higher price therapy, alendronate may be recommended as 
the alternative based on results of the meta-analyses and cost effectiveness model. 
 
4. In consideration of inclusion of a bisphosphonate into the Standard Drug List for 
patients who may be financially challenged, etidronate would be a strong candidate based 
on its cost-effectiveness ratio as compared to the other bisphosphonates.    


















Bisphosphonates may be classified according to their antiresorptive potency (in ascending 
order) 244, 245 : 
• Etidronate 






MECHANISM OF ACTION : Bisphosphonates are postulated to treat osteoporosis by 
reducing the rate of bone turnover.  They are chelated to calcium hydroxyapatite on the 
surface of bones and released when osteoclasts resorb the bone.  The released 
bisphosphonates results in inhibition of bone resorption or mineralisation processes 
depending upon concentration. The chemical structures of bisphosphonates have been 





































Various mechanism of actions have been studied.  They include metabolism of the 
bisphosphonates to an active metabolite adenosine 5'-(β,γ-dichloromethylene) 
triphosphate (AppCCl2p) which increases osteoclasts apoptosis and reduces their rate of 
bone resorption. 248  Bisphosphonates with nitrogen containing side chains (pamidronate, 
alendronate and risedronate) are also postulated to inhibit GTP-binding proteins such as 
farnesyldiphosphate synthase, an enzyme in the mevalonate pathway which is essential for 
protein prenylation.  Prenylated proteins are required for essential cellular functions such 
as regulation of cytoskeletal organization and endocytosis. 249-253 
 
INDICATION : Among the various agents listed above, only etidronate, alendronate and 
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in Singapore. 254  Zoledronate is currently being studied as a potential parenteral agent for 
treatment of postmenopausal osteoporosis. 178 
 
SIDE EFFECTS : The more commonly reported clinically significant side effects of 
bisphosphonates are related to the gastrointestinal system.  They include diarrhea, gastritis 
as well as esophageal irritation and ulceration.  There is some evidence suggesting that all 
bisphosphonates may have direct irritant effects on gastrointestinal mucosa under acidic 
conditions.  Patients with Helicobacter Pylori and reduced gastric motility may also have 
an increased risk of gastrointestinal mucosal irritation and ulceration.  Besides, nitrogen-
containing bisphosphonates (pamidronate, alendronate and risedronate) have been 
postulated to induce apotosis of the gastrointestinal epithelial cells in a similar mechanism 
of action as explained above for inducing apotosis of bone osteoclasts. 
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APPENDIX TWO 
Optimally sensitive Medline search strategy for identifying randomised clinical trials 
 
Set No Term searched or sets combined 
 
1 RANDOMIZED CONTROLLED TRIAL in PT 
2 RANDOMIZED CONTROLLED TRIALS 
3 RANDOM ALLOCATION 
4  DOUBLE BLIND METHOD 
5  SINGLE BLIND METHOD 
6  1 or 2 or 3 or 4 or 5 
7  TG-ANIMAL not (TG=HUMAN and TG=ANIMAL) 
8  6 not 7 
 
9  CLINICAL-TRIAL in PT 
10  explode CLINICAL-TRIALS 
11  (clin* near trial*) in TI 
12  (clin* near trial*) in AB 
13  (single* or doubl* or trebl* or tripl*) near (blind* or mask*) 
14  (13 in TI) or (13 in AB) 
15  Placebos 
16  placebo* in TI 
17  placebo* in AB 
18  random* in TI 
19  random* in AB 
20  RESEARCH-DESIGN 
21  9 or 10 or 11 or 12 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22  TG=ANIMAL not (TG=HUMAN and TG=ANIMAL) 
23  21 not 22 
24  23 not 8 
 
25  TG=COMPARATIVE-STUDY 
26  explode EVALUATION-STUDIES 
27  FOLLOW-UP-STUDIES 
28  PROSPECTIVE-STUDIES 
29  control* or prospectiv* or volunteer* 
30  (29 in TI) or (29 in AB) 
31  25 or 26 or 27 or 28 or 30 
32  TG=ANIMAL not (TG=HUMAN and TG=ANIMAL) 
33  31 not 32 
34  33 not (8 or 24) 
 
Format shown is for SilverPlatter version 3.10. Upper case denotes controlled vocabulary; 
lower case denotes freetext terms. Those wishing to run this search strategy are 
recommended to seek the advice of a trained medical librarian. 
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Search Strategy modified for OVID MEDLINE by Author 
 
1 RANDOMIZED CONTROLLED TRIAL.pt. 
2 Randomized Controlled Trials/ 
3 Random Allocation/ 
4 Double-Blind Method/ 
5 Single-Blind Method/ 
6 1 or 2 or 3 or 4 or 5 
 
7 CLINICAL TRIAL.pt. 
8 exp CLINICAL TRIALS/ 
9 (clin$ adj trial$).ti 
10 (clin$ adj trial$).ab 






17 RESEARCH DESIGN/ 
18 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
 
19 COMPARATIVE STUDY/ 
20 exp Evaluation Studies/ 
21 FOLLOW-UP STUDIES/ 
22 PROSPECTIVE-STUDIES/ 
23 (control$ or prospectiv$ or volunteer$) 
24 19 or 20 or 21 or 22 or 23 
 
25 6 or 18 or 24 
26 exp OSTEOPOROSIS, POSTMENOPAUSAL/ 
27 (osteopo$ and menopau$).af 
28 26 or 27 
29 diphosphonat$ or bisphosphonat$ or Etidron$ or Tiludron$ or Clodron$ or 
Pamidron$ or Alendron$ or Risedron$ or Zoledron$ 
30 Bone Density/ 
31 FRACTURES/ 
32 30 or 31 
33 28 and 29 and 32 
34 25 and 33 
35 ..dedup 34 
36 35 not (Review or Letter or News or Meta-Analysis or Editorial).pt 
 
Number of records retrieved : 200 
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Search Strategy modified for Cochrane Controlled Trials Register by Author 
 
1 OSTEOPOROSIS, POSTMENOPAUSAL/ 
2 osteopo$ and menopau$ 
3 1 or 2 
4 diphosphonat$ or bisphosphonat$ or Etidron$ or Tiludron$ or Clodron$ or 
Pamidron$ or Alendron$ or Risedron$ or Zoledron$ 
5 bone mineral density or fracture 
6 3 and 4 and 5 
7 ..dedup 6 
 
Number of records retrieved : 122 
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Search Strategy for OVID Medline by KK Hospital Librarian 
 
1      exp RANDOMIZED CONTROLLED TRIALS/ or exp Clinical Trials/ or 
randomized.mp. or exp Random Allocation/ or exp Double-Blind Method/ or exp 
Prospective Studies/  
2      placebo.mp. or exp Double-Blind Method/ or exp Placebos/ or exp Clinical Trials/  
3      (comparative or follow-up).mp  
4      ((single or double or triple) and blind).mp 
5      exp Research Design/ or research design.mp 
6      exp Diphosphonates/ or bisphosphonates.mp 
7      (alendronate or clodronate or etidronate or tiludronate or risedronate or 
pamidronate or zoledronate or ibandronate).mp 
8      (1 or 2 or 3 or 4 or 5) and (6 or 7)  
 
9    exp Osteoporosis, Postmenopausal/ or postmenopausal osteoporosis.mp 
10 8 and 9  
11 exp Bone Density/ or bone mineral density.mp 
12 exp HIP FRACTURES/ or exp SPINAL FRACTURES/ or exp FEMORAL NECK 
FRACTURES/ or exp FRACTURES/ or exp FRACTURES, CLOSED/ or exp 
FRACTURES, COMMINUTED/ or exp FRACTURES, MALUNITED/ or exp 
FRACTURES, OPEN/ or exp FRACTURES, SPONTANEOUS/ or exp 
FRACTURES, STRESS/ or exp FRACTURES, UNUNITED/  
13 fractures.mp 
14 10 and (11 or 12 or 13)  
 
15 14 not (Review or Letter or News or Meta-Analysis or Editorial).pt 
16 remove duplicates from 15 
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Search Strategy for OVID Medline by OVID Australian Customer Support 
 
1 randomized controlled trial.pt. 
2 controlled clinical trial.pt. 
3 RANDOMIZED CONTROLLED TRIALS/ 
4 randomi#ed controlled trial?.mp. 
5 RANDOM ALLOCATION/ 
6 random allocation.mp. 
7 DOUBLE-BLIND METHOD/ 
8 Single-Blind Method/ 
9 or/1-8 
 
10 (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase 
iii or clinical trial phase iv).pt. 
11 exp CLINICAL TRIALS/ 
12 (clin$ adj5 trial$).ti,ab. 




17 Research Design/ 
18 or/10-17 
 
19 Comparative Study/ 
20 exp evaluation studies/ 
21 Follow-Up Studies/ 
22 PROSPECTIVE STUDIES/ 
23 (control$ or prospectiv$ or volunteer$).ti,ab. 
24 or/19-23 
25 animal/ not (human/ and animal/) 
26 9 not 25 
27 18 not 25 
28 24 not 25 
29 27 not 26 
30 28 not (26 or 27) 
31 or/26-28 
 
32 exp diphosphonates/ 
33 (diphosphonate? or bisphosphonate?).ti,ab. 
34 diphosphonic acid.ti,ab. 
35 alendronate/ 
36 alendronate.ti,ab. 
37 alendronic acid.ti,ab. 
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42 marvil.ti,ab. 
43 (oncalst or onclast).ti,ab. 
44 teiroc.ti,ab. 
45 risedronate.ti,ab. 
46 resedronic acid.ti,ab. 
47 actonel.ti,ab. 
48 ne 58095.ti,ab. 
49 clodronic acid/ 
50 clodronate.ti,ab. 
51 clodronic acid.ti,ab. 














66 ibandronic acid.ti,ab. 




71 tiludronic acid.ti,ab. 
72 me 3737.ti,ab. 
73 skelid.ti,ab. 
74 sr 41319.ti,de. 
75 sr 41319b.ti,de. 
76 etidronate.ti,de. 









86 hydroxyethylidenediphosphonic acid.ti,ab. 
87 dequest.ti,ab. 
88 difosfen.ti,ab. 
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89 etidron.ti,ab. 
90 pamidronate.ti,ab. 
91 pamidronic acid.ti,ab. 
92 aredia.ti,ab. 
93 cgp 23339.ti,ab. 




97 (post menopaus$ or postmenopaus$).ti,ab. 
98 exp OSTEOPOROSIS/ 
99 osteoporosis.ti,ab. 
100 bone loss.ti,ab. 
101 (96 or 97) and (98 or 99 or 100) 






107 101 and 106 
108 exp Spine/ 
109 Hip/ 
110 exp Fractures/ 
111 ((spine or spinal) adj2 fracture?).ti,ab. 
112 (hip adj2 fracture?).ti,ab. 
113 (108 or 109) and 110 
114 or/111-113 
 
115 Bone Density/ 
116 bone mineral density.ti,ab. 
117 or/115-116 
 
118 114 or 117 
119 31 and 95 and 107 and 118 
 
120 119 not (Review or Letter or News or Meta-Analysis or Editorial).pt 
121 remove duplicates from 120 
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Search Strategy for OVID Medline by General Hospital Drug Information Pharmacist 
 
1 RANDOM ALLOCATION/ or random$.mp 
2 Diphosphonates/ or bisphosphonate.mp 
3 ALENDRONATE/ or alendronate.mp 
4 Clodronic Acid/ or clodronate.mp 





10 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
11 1 and 10 
 
12 Spinal Fractures/ or spinal fracture.mp 
13 Hip Fractures/ or hip fracture.mp 
14 (spinal or vertebral or hip).mp. [mp=title, abstract, cas registry/ec number word, 
mesh subject heading] 
15 FRACTURES/ 
16 Bone Density/ or bone mineral density.mp 
17 14 and (15 or 16) 
18 12 or 13 or 17 
19 11 and 18 
 
20 19 not (Review or Letter or News or Meta-Analysis or Editorial).pt 
21 remove duplicates from 20 
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APPENDIX THREE 
 
EXAMPLE OF AN EMAIL NOTIFICATION FROM AN AUTOMATICALLY 
EXECUTED SEARCH FROM OVID MEDLINE 
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APPENDIX FOUR 
(ADAPTED FROM STATISTICAL METHODS PROGRAMMED IN METAVIEW VERSION 4) 
 
DerSimonian and Laird Random Effects Models 
 
Under the random effects model, the assumption of a common treatment effect is relaxed, and the effect 
sizes are assumed to have a distribution Θi ≈  N (Θ, τ2) 
 
The estimate of τ2 is given by 2τˆ = max {[Q  – (k – 1)] / [ iw – (
2
 iw )) /  iw ], 0} 
where the wi are the inverse variance weights (calculated as 1/se( iΘˆ )2 for log OR, log RR, RD, WMD and 
SMD, as appropriate. 
 
The estimate of the combined effect for the heterogeneity may be taken as either the Mantel-Haenszel or the 
inverse variance estimate. Again, for odds ratios and risk ratios, the effect size is taken as the natural 
logarithm of the OR and RR. Each study's effect size is given weight iw'  = 1 / (se ( iΘˆ )2 + 2τˆ ) 
 
The pooled effect size is given by DLΘˆ = ( Θiiw ˆ' ) / ( iw' )     and    se{ DLΘˆ } = 1/  iw'  
Note that in the case where the heterogeneity statistic Q is less than or equal to its degrees of freedom (k - 1), 
the estimate of the between trial variation, 2τˆ , is zero, and the weights reduce to the those as given by the 
inverse variance method. 
 
Confidence intervals 
The 100 (1-α)% confidence interval for Θˆ is given by Θˆ - se( Θˆ ) Φ (1 - α/2), to Θˆ + se( Θˆ ) Φ (1- α /2) 
where Θˆ is the log odds ratio, log relative risk, risk difference, mean difference or standardised mean  
difference, and Φ is the standard normal deviate. 
 
Test statistics 
In all cases, the test statistic is given by 
Z = Θˆ  / se( Θˆ ) 
where or risk ratio is again considered on the log scale. 
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APPENDIX FIVE 
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01 Etidronate vs Placebo
02 Percentage Change in Lumbar Vertebral BMD from Baseline
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Funnel plots for studies on efficacy variables (with appropriate regimen) con’t 




































01 Alendronate vs Placebo
02 Percentage Change in Femoral Neck BMD from Baseline
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Etidronate femoral neck BMD studies (3 years) - Not done as less than 6 studies  
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APPENDIX SIX 
RAW DATA OF EFFICACY VARIABLES USED FOR DATA POOLING 
 
 
Alendronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine BMD 




































































Braga de Castro Machado, 
A., 1999 16 / 7 6 + 2.77 No sd 0.05 No sd 
Chesnut, C. H et al, 1995 
32 / 30 / 


























































































Downs, R. W et al, 2000 105 / 51 12 5.28 0.4 0.27 0.58 
Dursun, N. et al, 2001 51 / 50 12 + 7.19 SD = 7.6 - 0.36 SD = 6.77 


























452 / 445 / 
461 



















Kung, 2000 28 / 28 12 + 5.86 0.68 + 1.68 0.39 
Lau, 2000 41 / 37 12 + 5.49 0.55 + 3.09 0.66 
Liberman, 1995 
185 / 180/ 
182 / 374 
 
179 / 174 
/176 / 347  
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Treatment Placebo 
Trial N Duration (months) 
Mean Spine BMD 













Lindsay, 1999 203 / 191 12 + 3.61 0.30 + 1.01 0.30 
Malavolta N, 1999 26 / 57 9 3.79 No SD 0.54 No SD 
McClung M, 1998 
88 / 84 / 

































Murphy, 2001  II :109 / IV 
: 36 12 + 4.56 0.34 + 0.55 0.47 




Pols, 1999 832 / 865 12 + 5.0 Sd = 3.2 + 0.1 Sd = 3.4 




0.50 - 1.30 0.26 
Rossini, 1994 15 / 15 6 + 3.68 0.50 - 0.23 0.68 




1.4 + 2.0 1.3 




0.93 - 1.34 0.70 
Yen, 2000 24 / 22 12 + 6.53 0.97 - 0.75 1.12 









Johnell, 2002 82 / 83 12 + 4.3 0.4 - 0.4 0.3 
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Trial N Duration (months) 
Mean Femoral 


































































Braga de Castro 
Machado, A., 1999 16 / 8 6 1.75 No sd - 0.14 No sd 































Cummings, S. R. et al, 
















Devogelaer, J. P. et al, 
1996 















































Downs, R. W et al, 2000 105 / 51 12 + 2.85 0.44 - 1.18 0.61 
Dursun, N. et al, 2001 51 / 50 12 + 3.75 SD = 6.16 + 2.33 SD = 4.32 
Hosking, 1998 396 / 409 24 + 1.3 0.2 - 1.6 0.2 
Kung, 2000 28 / 28 12 + 2.33 0.61 - 0.23 0.69 
Lau, 2000 29 / 27 12 + 3.98 0.61 + 0.12 0.73 
Liberman, 1995 
185 / 180 
/182 / 374 
 
179 / 174 
/176 / 347  
 
167 / 170 














































Lindsay, 1999 203 / 191 12 + 1.70 0.40 0.80 0.40 
Malavolta N, 1999 26 / 57 9 + 2.37 SD =  - 0.75 SD = 














































Murphy, 2001  II :109 / IV : 36 12 + 1.45 0.43 + 0.35 0.60 
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Treatment Placebo 
Trial N Duration (months) 
Mean Femoral 








Pols, 1999 832 / 865 12 + 2.3 SD = 4.5 - 0.2 SD = 4.5 
Rossini, 2000 41 / 42 / 41 12 + 1.60 
+ 1.51 
0.95 
0.88 - 0.69 0.41 
Rossini, 1994 15 / 15 6 + 0.46 1.08 - 0.33 1.00 
Sahota, 2000 31 / 32 / 33 12 + 2.6 
+ 1.6 
0.9 
0.8 + 0.4 0.6 
















Yen, 2000 24 / 22 12 + 6.86 1.39 + 1.20 1.26 









Johnell, 2002 82 / 83 12 + 2.7 0.5 + 0.2 0.4 
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Clodronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine 








Filipponi, P. et al, 
1995 










Giannini, S. et al, 1993 16 / 20 12 +3.88  0.65 - 2.34  0.49 
Giannini, S. et al, 1996 17# / 17@ / 14 12 +3.32  
+0.43  
 0.71 
 0.89 - 2.68   0.74 





SD = 3.40 
SD = 3.60 
- 0.12 
- 1.24 
SD = 3.52 
SD = 4.85 
Heikkinen, J. et al,  
1997 
21A / 22B / 











SD = 2.9 
SD = 3.0 
SD = 3.2 
SD = 3.7 
SD = 3.9 





SD = 4.2 
 
 
SD = 4.6 
Rossini, M. et al, 1999 
27 / 24 / 30 
 


















Saarto, T. et al, 1997 40 / 53 12 24 
- 0.7 
- 2.2  
CI = 0.99 
CI = 1.68 
- 3.7 
- 5.9 
CI = 1.10 
CI = 1.47 
Tsai, K. S. et al, 1999 29# / 25 12 - 0.95  0.9 - 2.2  0.9 
McCloskey, 2001 333 / 341 12 +3.2 0.3 +0.5 0.3 
 
# cyclical / intermittent 
@ continuous regimen 
 
 
Clodronate Mean Femoral Neck BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Femoral 








Giannini, S. et al, 1996 17# / 17@ / 14 12 12 
- 0.14  
1.24  
0.74 
0.99 - 1.84 0.75 





SD = 4.58 
SD = 3.97 
0.4 
-1.04 
SD = 3.50 
SD = 4.24 
Heikkinen, J. et al,  
1997 
21A / 22B / 











SD = 3.6 
SD = 3.0 
SD = 2.9 
SD = 3.8 
SD = 3.9 





SD = 2.8 
 
 
SD = 3.5 
Rossini, M. et al, 1999 27 / 16 / 30 24 + 0.07 
+ 0.62 
0.93 
1.01 - 1.29 0.97 
Saarto, T. et al, 1997 40 / 53 12 24 
- 0.4 
+ 0.9 
CI = 1.40 
CI = 1.68 
-1.5 
- 2.0 
CI = 0.85 
CI = 1.52 
Tsai, K. S. et al, 1999 29 / 25 12 - 0.78  0.83 - 2.13 0.61 
McCloskey, 2001 
(Total Hip BMD) 333 / 341 12 + 1.3 0.3 + 0.4 0.3 
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Etidronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine 




BMD % Change 
from baseline 
SEM (%) 


















Evans, R. A. et al, 1993 15 / 11 12 24 
+ 4.4 
+ 2.4 
SD = 6.6 
SD = 9.1 
- 6.0 
- 4.7 
SD = 5.8 
SD = 4.4 
Gurlek, A. et al, 1997 10 / 10 12 + 4.52 5.77 + 0.83 2.28 
Harris, S. T. et al, 1993 
92 / 90 
92 / 90 

























































Montessori, ML. et al, 1997 
40 / 34 
40 / 34 

























Sahota, 2000 36 / 34 12 + 4.9 1.5 + 2.0 1.3 
Shiota E et al, 2001 20 / 20 12 24 
+ 5.55 
+ 10.62 
SD = 3.72 
SD = 3.73 
- 2.17 
- 5.89 
SD = 3.74 
SD = 5.03 




















Wimalawansa, S. J. et al, 
1995 
12 / 11 











Wimalawansa, S. J. et al, 
1998 
16 / 16 
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Etidronate Mean Femoral Neck BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Femoral 




























Harris, S. T. et al, 1993 
92 / 90 
92 / 90 
















































Montessori, ML. et al, 
1997 
40 / 34 
40 / 34 

























Sahota 2000 36 / 34 12 + 2.0 1.1 + 0.4 0.6 
Watts, N. B. et al, 1990 92 / 89 24 + 3.66 1.03 + 0.51 0.86 
Wimalawansa, S. J. et al, 
1995 
12 / 11 











Wimalawansa, S. J. et al, 
1998 
16 / 16 * 
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Ibandronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine 








Ravn, P. et al, 1996  30# / 30 12 + 4.6 SD = 3.1 + 0.7  SD = 2.7 
Riis, BJ et al, 2001 81
#
 / 78@ / 




0.46 + 1.58   0.52 









+ 0.85   0.50 
 
# : 2.5mg daily 
@ : 20mg eod for 24 days, then 9 weeks no drug 
 
IV : 0.25mg, 0.5mg, 1.0mg, 1.5mg, 2mg, placebo 
 
 
Ibandronate Mean Femoral Neck BMD Efficacy Table  (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Femoral neck 








Ravn, P. et al, 1996  30# / 30 12 + 2.5 SD = 3.2 + 1.2  SD = 3.7 
Thiebaud, D. et al, 1997 
19 / 24 / 











+ 0.25   0.65 
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Pamidronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine BMD 




BMD % Change 
from baseline 
SEM (%) 
Lees, B. et al, 1996  22
@




SD = 2.1 
SD = 2.9 -1.6 SD = 3.1 









Ryan, P. J. et al, 2000  40 
#




















# 300mg per day for 4 weeks every 16 weeks 
@ 150mg per day for 4 weeks every 8 weeks 
 
 
Pamidronate Mean Femoral Neck BMD Efficacy Table  (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Femoral 





BMD % Change 
from baseline SEM (%) 
Lees, B. et al, 1996  22
@




SD = 2.3 
SD = 2.9 - 1.9 SD = 3.9 









Ryan, P. J. et al, 2000  40 
#
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Risedronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine 




Mean Spine BMD 




Clemmesen, B. et al, 1997 
(2.5mg study)  














































Harris, S. T. et al, 1999  
259 / 265 
480 / 495 



















































* 2.5mg daily oral 
# 2.5mg daily for 2 weeks, then 10 weeks placebo 
@ 30mg daily for 2 weeks, then 10 weeks placebo 
$ 5mg daily for 2 weeks, then 2 weeks placebo 
 
 
Risedronate Mean Femoral Neck BMD Efficacy Table (All randomised controlled trials) 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Femoral 










Clemmesen, B. et al, 1997 
(2.5mg study)  














































Harris, S. T. et al, 1999  
265 / 266 
504 / 509 
















Mortensen, L. et al, 1998 
32 / 32 / 
32 
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Tiludronate Mean Lumbar Spinal BMD Efficacy Table (All randomised controlled trials) 
 
Appropriate regimen - Average 50mg daily in a cyclical regimen 
 
Treatment Placebo 
Trial N Duration (months) 
Mean Spine 









Reginster, J. Y. et al, 1989  38 / 38 12 * + 1.33 0.8 - 2.1 0.8 
Reginster, J. Y. et al, 2001 
(non-fracture)  
139@ / 





























* 6 months daily, followed by 6 months placebo 
@ 50mg daily for 7 days per month 
# 200mg daily for 7 days per month 
 
 
No RCTs were found reporting on hip BMD changes of patients on Tiludronate. 
  159 
APPENDIX SEVEN 
 
CHARACTERISTICS OF STUDIES INCLUDED IN META-ANALYSES 
 
ALENDRONATE : Appropriate regimen - 10mg PO daily 
 
% of patients at baseline 
 Study Location 
BMD T-score Baseline BMD Baseline fractures 
1 Adami, 1995 Lumbar Less than 2 SD < 0.86g/cm2 5% with fractures 
 Black, 1996 Excluded, inappropriate dosing regimen 
 Bone, 1997 Excluded, inappropriate dosing regimen 
 
Braga de Castro 
Machado, 1999 Excluded, study is only 6 months duration 
2 Chesnut, 1995 Lumbar Less than -2 SD < 0.88g/cm2 0% with fractures 
 Cummings, 1998 Excluded, inappropriate dosing regimen 
3 Devogelaer, 1996 Lumbar Less than -2.5 SD < 0.80g/cm2 0% with fractures 
4 Downs, 2000 Lumbar or femoral neck Less than -2 SD Not stated 0% with fractures 
5 Dursun, 2001 Lumbar or femoral neck Less than -2 SD Not stated Yes, 77% with fractures 
6 Gonnelli, 1999 Lumbar Less than -2.5 SD Not stated Not mentioned 
 Hosking, 1998 Excluded, inappropriate dosing regimen 
7 Kung, 2000 Lumbar Less than -2.5 SD Not stated 37% with fractures 
8 Lau, 2000 Lumbar Less than -2.5 SD Not stated 
0% with hip fractures, 
6% with vertebral 
fractures 
9 Liberman, 1995 Lumbar Less than -2.5 SD Not stated Approx 20% vertebral fractures 
 Lindsay, 1999 Excluded, inappropriate dosing regimen 
 Malavolta N, 1999 Excluded, inappropriate dosing regimen, study is only 9 months duration 
10 McClung, 1998 * Lumbar More than -2 SD Not stated 0% with fractures 
11 Murphy, 2001 Femoral neck Less than -2 SD < 0.695g/cm2 0% with fractures 
 Passeri M, 1991 Excluded, inappropriate dosing regimen 
12 Pols, 1999 Lumbar Less than -2 SD <0.86g/cm2 Not excluded, but % not 
stated 
 Rossini, 2000 Excluded, inappropriate dosing regimen 
 Rossini, 1994 Excluded, inappropriate dosing regimen, study is only 6 months duration 
13 Sahota, 2000 Lumbar / Total hip Less than -2.5 SD Not stated 100% with one or more 
vertebral fractures 
14 Yen, 2000 Lumbar Less than -1 SD Not stated 100% without fractures 
 Greenspan, 1998 Excluded, inappropriate dosing regimen 
 Shiraki, 1998 Excluded, study is 8 months duration only 
15 Bone, 2000 Lumbar Less than -2.5 SD < 0.862g/cm2 Not mentioned 
16 Johnell 2002 Femoral neck Less than -2 SD Not stated Not excluded, but % not 
stated 
 
* study reported only results at 24 and 36 months duration 
  160 
CHARACTERISTICS OF STUDIES INCLUDED IN META-ANALYSES 
CLONDRONATE : Appropriate regimen – at least 800mg PO daily 
 % of patients at baseline 
 
Study Location 
BMD T-score Baseline BMD Baseline fractures 
 Filipponi, 1995 Excluded, inappropriate dosing regimen 
 Giannini, 1993 Excluded, inappropriate dosing regimen 
 Giannini, 1996 Excluded, inappropriate dosing regimen 
 Gnudi, 2001 Excluded, inappropriate dosing regimen 
 Heikkinen, 1997 Excluded, inappropriate dosing regimen 
 Rossini, 1999 Excluded, inappropriate dosing regimen 
1 Saarto, 1997 NA Not reported Not reported 100% no fractures 
 Tsai, 1999 Excluded, inappropriate dosing regimen 
2 McCloskey, 2001 Lumbar less than -2.5 SD Not reported 49% with vertebral fractures 
 
ETIDRONATE : Appropriate regimen - 400mg PO daily for 2 weeks every 12 weeks or 3 
months  
% of patients at baseline  
 Study Location 
BMD T-score Baseline BMD Baseline fractures Z- score * 
1 Adami, 2000 Lumbar Not stated Not stated No fragility fractures 
Between -2 to 2 SD of 
age match BMD 
2 Blake, 1996 Lumbar Not stated Not stated No fractures Between -2 to 0 SD of 
age match BMD 
3 Evans, 1993 NA Not stated Not stated Not stated  
 Gurlek, 1997 Excluded, inappropriate dosing regimen 
4 Harris, 1993 Not stated Not stated Not stated Not stated  
 Hasling, 1994 Excluded, inappropriate dosing regimen 
5 Heath, 2000 Not stated Not stated Not stated No fractures  
6 Herd, 1997 Lumbar Not stated Not stated No fragility fractures 
Between -2 to 0 SD of 
age match BMD 
 Lyritis, 1997 Excluded, inappropriate dosing regimen 
7 Meunier, 1997 Not stated Not stated Not stated Not stated Between -2 to 2 SD of 
age match BMD 
8 Montessori, 1997 Not stated Not stated Not stated Not stated 
Less than -1SD of age 
match BMD 
9 Pouilles Jm, 1997 Not stated Not stated Not stated Not stated 
Post bilateral 
oophectomy patients 
10 Sahota, 2000 Lumbar less than -2.5 SD Not stated 
100% with 
vertebral fractures  
 Shiota E, 2001 Excluded, inappropriate dosing regimen 
 Storm, 1990 Excluded, inappropriate dosing regimen 
11 Watts, 1990 Not stated Not stated Not stated 100% with 
vertebral fractures  
 
Wimalawansa, 
1995 Excluded, inappropriate dosing regimen 
 
Wimalawansa, 
1998 Excluded, inappropriate dosing regimen 
* A column for z-score as inclusion criteria is added 
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CHARACTERISTICS OF STUDIES INCLUDED IN META-ANALYSES 
 
IBANDRONATE : Appropriate regimen - 2.5mg daily 
% of patients at baseline 
 Study Location 
BMD T-score Baseline BMD Baseline fractures 
1 Ravn, 1996 Distal forearm less than -1.5 SD Not stated Not stated 
2 Riis, 2001 Lumbar or femoral neck less than -2.5 SD Not stated Not stated 
 Thiebaud, 1997 Excluded, inappropriate dosing regimen 
 
 
PAMIDRONATE : Appropriate regimen - 300mg for 4 weeks every 16 weeks / 4 months 
% of patients at baseline 
  Study Location 
BMD T-score Baseline BMD Baseline fractures 
1 Lees, 1996 * Not stated Not stated Not stated Not stated 
 Reid, 1994 Excluded, inappropriate dosing regimen 
2 Ryan, 2000 Not stated Not stated Not stated 100% vertebral fractures 
 
* study reported data at only 24 months duration 
 
RISEDRONATE : Appropriate regimen - 5mg PO daily 
% of patients at baseline  
 Study Location 
BMD T-score Baseline BMD Baseline fractures z- score 
 Clemmesen, 1997 Excluded, inappropriate dosing regimen 
 Delmas, 1997 Excluded, inappropriate dosing regimen 
1 Fogelman, 2000 Lumbar less than -2 SD Not stated 28.7% with vertebral fractures  
2 Harris, 1999 Lumbar less than -2 SD < 0.83g/cm2 100% with vertebral fractures  
3 Mortensen, 1998 Not stated Not stated Not stated Not stated 
Between -2 to 2 
SD of age 
match BMD 
4 Reginster, 2000 Not stated Not stated Not stated 100% with vertebral fractures  
 
TILUDRONATE : Appropriate regimen - 5mg PO daily  
% of patients at baseline 
 Study Location 
BMD T-score Baseline BMD Baseline fractures 
 Reginster, J. Y. et al, 1989  Excluded, inappropriate dosing regimen 
 
Reginster, J. Y. et al, 2001 






































































No - Hip Frac
#
Hip_Fractures_Complications=0





Vertebral_Fractures_Complica=0 cc_Hip + Etidronate_Cost
No
#
Vertebral_Fractures_Complica=0 ncc_Hip + Etidronate_Cost
Yes - Hip Frac
Probability of Hip Fracture





























(-0.0198 x vert_bmd_eti_1yr+0.702) x baseline_vert_frac_65
Probability of Vertebral Fracture =
Probability of Hip Fracture =
(-0.02807 x fem_bmd_eti_1yr+0.718) x baseline_hip_frac_65
  163 
Abbreviations : 
• “cc” = complicated 
• vert_frac = vertebral fracture 
• fem_bmd_ale = percentage change in femoral bone mineral density for alendronate 
• clo = clodronate, eti = etidronate, ris = risedronate 
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APPENDIX NINE 
 
Sensitivity Analyses (Miminum cost of drugs) 
One-year decision analytic model for all postmenopausal women (miminum cost of drugs) 
: 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 41.80 NA 
2 Etidronate $ 149.69 $ 107.89 
3 Risedronate $ 990.92 $ 949.12 
4 Alendronate $ 1,080.06 $ 1,038.26 
5 Clodronate $ 1,920.09 $ 1,878.29 
 
Table : Expected value of treatment with bisphosphonates in a one year decision analytic model (minimum costs) 
 
Two-year decision analytic model for all postmenopausal women (with discounting) 
(miminum cost of drugs) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 107.32 NA 
2 Etidronate $ 290.44 $ 183.12 
3 Risedronate $ 1,816.05 $ 1,708.73 
4 Alendronate $ 1,973.87 $ 1,866.55 
5 Clodronate $ 3,500.27 $ 3,392.95 
 
Table : Expected value of treatment with bisphosphonates in a two year decision analytic model with discounting 
 
Three-year decision analytic model for all postmenopausal women (with discounting) 
(miminum cost of drugs) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 202.23 NA 
2 Etidronate $ 450.12 $ 247.89 
3 Risedronate $ 2,629.49 $ 2,427.25 
4 Alendronate $ 2,857.42 $ 2,655.19 
 
Table : Expected value of treatment with bisphosphonates in a three year decision analytic model with discounting 
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Sensitivity Analyses (Maximum cost of drugs) 
One-year decision analytic model for all postmenopausal women (maximum cost of 
drugs) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 41.80 NA 
2 Etidronate $ 395.97 $ 354.17 
3 Risedronate $ 1,386.86 $ 1,345.06 
4 Alendronate $ 1,431.22 $ 1,389.42 
5 Risedronate $ 4,042.09 $ 4,000.29 
 
Table : Expected value of treatment with bisphosphonates in a one year decision analytic model (minimum costs) 
 
Two-year decision analytic model for all postmenopausal women (with discounting) 
(maximum cost of drugs) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 107.32 NA 
2 Etidronate $ 737.21 $ 629.89 
3 Risedronate $ 2,530.42 $ 2,423.10 
4 Alendronate $ 2,614.78 $ 2,507.46 
5 Risedronate $ 7,349.71 $ 7,242.39 
 
Table : Expected value of treatment with bisphosphonates in a two year decision analytic model with discounting 
 
Three-year decision analytic model for all postmenopausal women (with discounting) 
(maximum cost of drugs) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 202.23 NA 
2 Etidronate $ 1088.36 $ 886.12 
3 Alendronate $ 3,652.50 $ 3,450.26 
4 Risedronate $ 3,770.53 $ 3,568.30 
 
Table : Expected value of treatment with bisphosphonates in a three year decision analytic model with discounting 
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Sensitivity Analyses (Miminum rate of fractures) 
One-year decision analytic model for all postmenopausal women (minimum rate of 
fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 41.80 NA 
2 Etidronate $ 272.34 $ 230.54 
3 Risedronate $ 1,210.59 $ 1,168.79 
4 Alendronate $ 1,233.19 $ 1,191.39 
5 Clodronate $ 2,980.35 $ 2,938.55 
 
Table : Expected value of treatment with bisphosphonates in a one year decision analytic model (minimum costs) 
 
Two-year decision analytic model for all postmenopausal women (with discounting) 
(minimum rate of fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 107.32 NA 
2 Etidronate $ 512.23 $ 404.91 
3 Risedronate $ 2,214.25 $ 2,106.93 
4 Alendronate $ 2,250.84 $ 2,143.52 
5 Clodronate $ 5,419.17 $ 5,311.85 
 
Table : Expected value of treatment with bisphosphonates in a two year decision analytic model with discounting 
 
Three-year decision analytic model for all postmenopausal women (with discounting) 
(minimum rate of fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 202.23 NA 
2 Etidronate $ 753.95 $ 551.72 
3 Risedronate $ 3,190.32 $ 2,988.08 
4 Alendronate $ 3,236.00 $ 3,033.76 
 
Table : Expected value of treatment with bisphosphonates in a three year decision analytic model with discounting 
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Sensitivity Analyses (Maximum rate of fractures) 
One-year decision analytic model for all postmenopausal women (maximum rate of 
fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 41.80 NA 
2 Etidronate $ 272.34 $ 230.54 
3 Risedronate $ 1,211.55 $ 1,169.75 
4 Alendronate $ 1,233.73 $ 1,191.93 
5 Clodronate $ 2,981.83 $ 2,940.03 
 
Table : Expected value of treatment with bisphosphonates in a one year decision analytic model (minimum costs) 
 
Two-year decision analytic model for all postmenopausal women (with discounting) 
(maximum rate of fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 107.32 NA 
2 Etidronate $ 512.23 $ 404.91 
3 Risedronate $ 2214.25 $ 2106.93 
4 Alendronate $ 2250.84 $ 2143.52 
5 Clodronate $ 5419.17 $ 5311.85 
 
Table : Expected value of treatment with bisphosphonates in a two year decision analytic model with discounting 
 
Three-year decision analytic model for all postmenopausal women (with discounting) 
(maximum rate of fractures) : 
Rank Treatment Arm Expected Value of Treatment Arm Marginal Value 
1 No Treatment $ 202.23 NA 
2 Etidronate $ 753.95 $ 551.72 
3 Risedronate $ 3,190.32 $ 2,998.03 
4 Alendronate $ 3,236.00 $ 3,033.76 
 
Table : Expected value of treatment with bisphosphonates in a three year decision analytic model with discounting 
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